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Abstract
Human T-lymphotropic virus type-1 (HTLV-1) infects approximately 10-20 million people
worldwide. The virus persists within hosts via de novo infection and infected cell prolif-
eration, creating a population structure of multiple clones (infected cell populations with
identical genomic proviral integration sites). The number of clones in one host is unknown,
and is determined by the rate of de novo infection.
Our primary objectives are: i) to estimate HTLV-1 clonal diversity; and ii) to develop a
model of HTLV-1 dynamics that can estimate the relative contributions of de novo infection
and mitotic replication. We use a combination of mathematical modelling, computer
simulation and statistical methods to interpret experimental observation.
We develop an estimator (named DivE) to estimate the number of HTLV-1 clones. DivE
uses the ecological method of rarefaction, and includes novel model selection criteria. We
show that DivE is more accurate than widely-used estimators from population ecology,
and we demonstrated that this holds across many systems. Di↵erences between these
systems and ecological populations are investigated, and DivE is applied to patients with
a range of HTLV-associated diseases.
HTLV-1 clonal abundance varies by several orders of magnitude: quantifying within-
host HTLV-1 dynamics requires mathematical modelling at multiple scales. Stochastic
processes, important for modelling small populations, are introduced, and we explore
properties and approximations of a mass-action birth-death process for biologically realistic
species extinction scenarios. We combine ordinary di↵erential equations with stochastic
processes in a hybrid model and explore its consequences.
The estimated HTLV-1 clonal diversity is substantially higher than previously thought,
which strongly implies higher rates of de novo infection. The hybrid model captures known
behaviour of HTLV-1, and can be used to infer rates of viral persistence. DivE and the
hybrid model are applicable to other biological systems, in particular the study of T and
B cell receptor repertoires.
9
Contents
Copyright Declaration 2
Acknowledgements 3
Declaration of Originality 4
Statement of Collaboration 5
Dissemination 7
Abstract 9
List of Abbreviations 14
List of Figures 18
List of Tables 19
1. Introduction 20
1.1. HTLV-1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.1.1. Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.1.2. Associated Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.1.3. Within-Host Persistence . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.1.4. Virology and Immunology . . . . . . . . . . . . . . . . . . . . . . . . 23
1.1.5. Preferences of Viral Integration . . . . . . . . . . . . . . . . . . . . . 24
1.1.6. Integration Site Mapping and Quantification Protocol . . . . . . . . 25
1.1.7. Outline of Thesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2. Quantification of HTLV-1 Clonality and TCR Diversity 29
2.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.2. Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.2.1. Ethics Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.2.2. HTLV-1 Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.2.3. Microbial Data Collection . . . . . . . . . . . . . . . . . . . . . . . . 32
2.2.4. TCR Data Collection . . . . . . . . . . . . . . . . . . . . . . . . . . 32
10
2.2.5. Prochlorococcus Data Collection . . . . . . . . . . . . . . . . . . . . 32
2.2.6. DivE Species Richness Estimator . . . . . . . . . . . . . . . . . . . . 33
2.2.7. Choice of DivE Candidate Models . . . . . . . . . . . . . . . . . . . 35
2.2.8. Fitting of Models to Data . . . . . . . . . . . . . . . . . . . . . . . . 35
2.2.9. Estimation of HTLV-1 Population Sizes . . . . . . . . . . . . . . . . 36
2.2.10. Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.11. DivE Frequency Distribution Generation Algorithm . . . . . . . . . 37
2.3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.3.1. Comparison of Estimators: Relationship Between Sample Size and
Estimated Diversity . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.3.2. Comparison of DivE and Second Order Bias-Corrected Akaike In-
formation Criterion (AICc) . . . . . . . . . . . . . . . . . . . . . . . 41
2.3.3. Comparison of Estimators: Accuracy of Diversity Estimate . . . . . 45
2.3.4. Estimate Error as a Function of Data Curvature . . . . . . . . . . . 47
2.3.5. Example Application: Estimated Number of HTLV-1 Infected Cell
Clones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.3.6. DivE Uncertainty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.3.7. Distribution Generation Algorithm . . . . . . . . . . . . . . . . . . . 54
2.4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3. Applications of DivE 58
3.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.2. Clonal Diversity in Adult T Cell Leukaemia / Lymphoma . . . . . . . . . . 58
3.3. Clonal Diversity in Asymptomatic Carriers . . . . . . . . . . . . . . . . . . 60
3.4. Relationship Between HTLV-1 and HTLV-2 Clonal Diversity Mirrors Rela-
tionship Between Clonal Diversity of CD4+ and CD8+ T Cells in HTLV-1 . 63
3.5. HTLV-1 Clonality in Early Infection . . . . . . . . . . . . . . . . . . . . . . 65
3.6. Comparison of HTLV-1 Clonality in Blood and Skin . . . . . . . . . . . . . 66
3.7. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4. Stochastic Modelling: Birth-Death Processes 69
4.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.2. Master Equation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2.1. Example: Classical Model of Within-Host HIV Infection . . . . . . . 72
4.2.2. Relationship Between ODEs and Expected Value of Stochastic System 73
4.3. Master Equation: Mass-Action Rate Birth-Death Process . . . . . . . . . . 74
4.3.1. Transition Matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4.3.2. Initial Probability Distribution . . . . . . . . . . . . . . . . . . . . . 78
4.3.3. Matrix Exponential . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
11
4.4. Properties of Birth-Death Process Without Source Inflow . . . . . . . . . . 81
4.4.1. Evolution of Extinction Probability . . . . . . . . . . . . . . . . . . . 81
4.4.2. E↵ects of Truncated State Space . . . . . . . . . . . . . . . . . . . . 83
4.4.3. Shape of Probability Distribution P(X; t) for Large Starting Values
x0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.4.4. Shape of Probability Distribution P(X; t) for x0 = 1 . . . . . . . . . 87
4.5. Inclusion of Source Inflow Changes P(X; t) . . . . . . . . . . . . . . . . . . . 92
4.6. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5. Hybrid Model of HTLV-1 persistence 97
5.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.2. Hybrid model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.2.1. Deterministic Model of HTLV-1 Dynamics . . . . . . . . . . . . . . . 99
5.2.2. Stochastic Model of Within-Host HTLV-1 Dynamics . . . . . . . . . 101
5.2.3. Clone State Space and Interactions . . . . . . . . . . . . . . . . . . . 103
5.2.4. Hybrid Model Propagation: Strang Splitting . . . . . . . . . . . . . 105
5.2.5. Infectious Spread rI . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
5.2.6. Variance and Covariance of Clones . . . . . . . . . . . . . . . . . . . 107
5.2.7. Clone Movement Between Deterministic and Stochastic Compart-
ments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
5.2.8. Choice of Density Dependency Parameters H and K . . . . . . . . . 110
5.2.9. Choice of State Space Upper Limit ⌧ and Frequency F . . . . . . . . 112
5.2.10. Modelling the Proportion of Expressing Cells . . . . . . . . . . . . . 113
5.3. Parameter Inference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
5.3.1. Parameter Inference with Unseen Clones . . . . . . . . . . . . . . . . 116
5.3.2. Hybrid Model Propagation . . . . . . . . . . . . . . . . . . . . . . . 117
5.4. Preliminary Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
5.4.1. System Death with Zero Proliferation . . . . . . . . . . . . . . . . . 117
5.4.2. E↵ect of Proviral Expression on Clone . . . . . . . . . . . . . . . . . 118
5.4.3. “Equilibrium” in Hybrid Model . . . . . . . . . . . . . . . . . . . . . 118
5.4.4. E↵ect of Infectious Spread Parameter rI . . . . . . . . . . . . . . . . 120
5.4.5. E↵ect of Time Step Length . . . . . . . . . . . . . . . . . . . . . . . 121
5.5. Identifiability of Rate of Infectious Spread: Proof of Principle . . . . . . . . 122
5.6. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
5.6.1. Improvements to Hybrid Model . . . . . . . . . . . . . . . . . . . . . 126
6. Concluding remarks 128
A. Appendix A: DivE supporting information 153
A.1. List of DivE Candidate Models . . . . . . . . . . . . . . . . . . . . . . . . . 156
12
B. Appendix B: Derivation of Expectation, Variance, and Covariance Clone
ODEs 163
13
List of Abbreviations
1. ACs - Asymptomatic Carriers of HTLV-1
2. ART - Anti-Retroviral therapy
3. AIC - Akaike Information Criterion.
4. AICc - Second Order Bias-corrected Akaike Information Criterion.
5. AIDS - Acquired Immune Deficiency Syndrome
6. ATLL - Adult T Cell Leukaemia Lymphoma
7. CME - Chemical Master Equation
8. CTL - Cytotoxic T-Lymphocyte - CD8+ T cell
9. CTMC - Continuous-Time Markov Chain
10. Cp - Rarefaction/DivE Curvature Parameter
11. DivE - Diversity Estimator
12. DNA - Deoxyribonucleic Acid
13. FSP - Finite State Projection Method
14. HAM/TSP - HTLV-1-Associated Myelopathy / Tropical Spastic Paraparesis
15. HAART - Highly Active Anti-Retroviral Therapy
16. HBZ - HTLV-1 Basic Leucine Zipper Factor
17. HCV - Hepatitis C Virus
14
18. HIV - Human Immunodeficiency Virus
19. HLA - Human Leukocyte Antigen System
20. HTLV-1 - Human T-Lymphotropic Virus Type-1 (also known as the Human Leukaemia
Virus Type-1)
21. HTLV-2 - Human T-Lymphotropic Virus Type-2
22. IDH - Infective Dermatitis Associated with HTLV-1
23. KIR - Killer-cell Immunoglobulin-like Receptor
24. KL-Divergence - Kullback Leibler Divergence
25. LM-PCR - Linker-Mediated Polymerase Chain Reaction
26. LTR - Long Terminal Repeat
27. MHC - Major Histocompatibility Complex
28. MTC - Mother-to-Child Transmission
29. NK Cell - Natural Killer Cell
30. OCI - Oligoclonality Index
31. ODE - Ordinary Di↵erential Equation
32. OTU - Operational Taxonomic Unit
33. PBMC - Peripheral Blood Mononuclear Cell
34. PMF - Probability Mass Function
35. PDF - Probability Distribution Function
36. PCR - Polymerase Chain Reaction
37. PVL - Proviral Load
38. RACE - 5’ Rapid Amplification of cDNA Ends
15
39. SDE - Stochastic Di↵erential Equation
40. SSA - Stochastic Simulation Algorithm, also known as the Gillespie Algorithm
41. StSt - Strongyloides
42. TCR - T cell Receptor
43. UIS - Unique Integration Site
44. VS - Virological Synapse
16
List of Figures
1.1. HTLV-1 infectious and mitotic spread schematic . . . . . . . . . . . . . . . 22
1.2. HTLV-1 proviral integration site abundance quantification . . . . . . . . . . 26
2.1. Outline of DivE Species Richness Estimator . . . . . . . . . . . . . . . . . . 33
2.2. Gini coe cient and Oligoclonality Index (OCI) schematic . . . . . . . . . . 38
2.3. Outline of DivE distribution generation algorithm . . . . . . . . . . . . . . 39
2.4. Comparison of species richness estimators . . . . . . . . . . . . . . . . . . . 42
2.5. Comparison of estimators: e↵ect of sample size on estimated diversity. . . . 43
2.6. Estimator bias with sample size not due to small subsamples . . . . . . . . 44
2.7. Comparison of estimators: accuracy of diversity estimates using TCR data 46
2.8. Ecological estimators underestimate diversity in HTLV-1 infection . . . . . 48
2.9. Ecological estimators underestimate diversity in HTLV-1 infection . . . . . 49
2.10. Rarefaction curvature parameter Cp . . . . . . . . . . . . . . . . . . . . . . 50
2.11. Test of species richness estimators at di↵erent values of curvature parameter
Cp using TCR data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
2.12. Performance of species richness estimators in metagenomic data . . . . . . . 52
2.13. Diversity estimates in HTLV-1 infection by estimator . . . . . . . . . . . . . 53
2.14. Rarefaction plots from bootstrap samples of HTLV-1, TCR, and Microbial
data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.15. Validation of DivE distribution generation algorithm . . . . . . . . . . . . . 54
3.1. HTLV-1 proviral load in ACs, ATLL and HAM/TSP patients. . . . . . . . . 59
3.2. Number of observed clones in ACs, ATLL and HAM/TSP patients. . . . . . 59
3.3. Relationship between OCI and estimated diversity in ATLL patients. . . . . 60
3.4. Comparison of HTLV-1 clonal diversity between ACs and HAM/TSP pa-
tients in blood and body. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.5. Relationship between clonal diversity and proviral load in Japanese cohort
of ACs and HAM/TSP patients. . . . . . . . . . . . . . . . . . . . . . . . . 62
3.6. Comparison of HTLV-1 and HTLV-2 clonal diversity. . . . . . . . . . . . . . 63
3.7. HTLV-1 clonal diversity of infected CD4+ and CD8+ T cells. . . . . . . . . 64
3.8. DivE estimates in the blood and skin of patients with IDH. . . . . . . . . . 67
4.1. Example non-normal probability distribution function. . . . . . . . . . . . 70
17
4.2. Mass action birth-death process flow diagram . . . . . . . . . . . . . . . . . 75
4.3. Mass action birth-death process flow diagram: truncated state space . . . . 77
4.4. Evolution of Extinction Probabilities for range of parameters . . . . . . . . 82
4.5. E↵ect of Truncated State Space ⌦ . . . . . . . . . . . . . . . . . . . . . . . 84
4.6. Probability distribution evolution: growing species . . . . . . . . . . . . . . 85
4.7. Probability distribution evolution: shrinking species . . . . . . . . . . . . . 85
4.8. Evolution of probability distribution at “equilibrium” . . . . . . . . . . . . 86
4.9. Example PDF evolutions P(X; t |x0 = 1) . . . . . . . . . . . . . . . . . . . . 88
4.10. The exponential distribution approximates P(X; t |x0 = 1) . . . . . . . . . . 89
4.11. Discrepancy between exponential distribution rate parameters  ˆ1 and  ˆ2
over time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
4.12. Kullback-Leibler divergences between P(X; t|x0 = 1, ✓k) and exponential
distribution approximations . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.13. Mass action birth-death process flow diagram with inflow from source (trun-
cated state space) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.14. Evolution of Extinction Probabilities with source inflow . . . . . . . . . . . 93
4.15. Example PDF evolutions P(X; t |x0 = 1) with source inflow . . . . . . . . . 94
4.16. Kullback-Leibler divergences between P(X; t |x0 = 1) and normal and ex-
ponential distributions with source inflow . . . . . . . . . . . . . . . . . . . 95
5.1. Schematic of single clone dynamics . . . . . . . . . . . . . . . . . . . . . . . 100
5.2. Example clone state space and interactions . . . . . . . . . . . . . . . . . . 104
5.3. Schematic of strang splitting procedure . . . . . . . . . . . . . . . . . . . . 106
5.4. Schematic of clone promotion and demotion . . . . . . . . . . . . . . . . . . 111
5.5. Proportion of expressing cells over time . . . . . . . . . . . . . . . . . . . . 115
5.6. Example: expected number of cells and clones over time with zero proliferation118
5.7. Proviral expression can drive proliferation . . . . . . . . . . . . . . . . . . . 119
5.8. Silencing can e↵ect clone death . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.9. Example: Number of cells N(t) and clones S(t) at equilibrium, no new
infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
5.10. Example: E↵ect of rate of infectious spread parameter rI . . . . . . . . . . 121
5.11. E↵ect of Time Step Length. . . . . . . . . . . . . . . . . . . . . . . . . . . 122
5.12. Example Likelihood Function without unseen clones . . . . . . . . . . . . . 125
18
List of Tables
2.1. Comparison of estimates produced by DivE and by weighted, second order
Akaike’s Information Criterion (AICc) . . . . . . . . . . . . . . . . . . . . . 45
2.2. Comparison of estimator performance for TCR data . . . . . . . . . . . . . 46
2.3. Estimator error variation with curvature in TCR data . . . . . . . . . . . . 52
2.4. Performance of DivE frequency distribution generation algorithm . . . . . 55
3.1. Comparison of clonality of ATLL, HAM/TSP and AC patients . . . . . . . 60
4.1. KL-divergence between P(X; t|✓k) and reference normal distributions: large
x0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
A.1. Subsamples used in analysis of relationship between sample size and esti-
mated diversity, and in comparison of DivE with AICc . . . . . . . . . . . . 153
A.2. DivE species richness estimates for HTLV-1 data . . . . . . . . . . . . . . . 153
19
1. Introduction
1.1. HTLV-1 Background
1.1.1. Epidemiology
Human T-lymphotropic virus type-1 (HTLV-1) was identified in 1979, and was the first
human retrovirus to be discovered [1]. Today it infects an estimated 10 to 20 million people
worldwide [2]. The virus has a curious worldwide distribution: though not particularly
prevalent, it is endemic in parts of the tropics and subtropics. Southwestern Japan, the
Caribbean, sub-saharan Africa and South America are the areas with the highest HTLV-1
prevalence [3, 4], and prevalence increases with age in all of these of regions [4]. HTLV-1
spreads through mother-to-child (MTC) transmission, sexual intercourse and through the
use of contaminated blood products [4]. Male-to-female transmission is approximately
four times more common than female-to-male transmission [5].
1.1.2. Associated Diseases
While the majority of infected individuals remain lifelong asymptomatic carriers (ACs),
the virus is the aetiological agent of the inflammatory disease of the central nervous system
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and Adult T-cell
Leukaemia/Lymphoma (ATLL) [6], an aggressive malignancy of mature T-lymphocytes.
Symptoms of HAM/TSP can include pain, bladder disturbance, slow progressive spastic
paraparesis [7], and weakness of the lower extremities [8].
ATLL has symptoms in common with non-Hodgkin’s lymphoma. Patients typically present
heightened thirst, fever, drowsiness, weight loss, and are prone to opportunistic infections
[5]. HTLV-1 infected cells in patients with ATLL are known as “flower cells”, T cells where
the nucleus has multiple lobules [9]. Chemotherapy initially reduces viral burden, but is
usually only e↵ective for approximately six months [5], and patients are now treated with
zidovudine and interferon-alfa [10], which can extend life expectancy by as much as two
years.
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Collectively, these conditions are estimated to a↵ect approximately 5-10% of infected in-
dividuals [11]. The proviral load (PVL) is defined by the number of viral copies expressed
as a fraction of the number of peripheral blood mononuclear cells (PBMCs). PVL can
vary between patients by over four orders of magnitude, and is a known risk factor for the
development of HAM/TSP [12] and ATLL [13].
1.1.3. Within-Host Persistence
HTLV-1 persists within host through two primary pathways: de novo infection (infectious
spread) and proliferation of infected cells [14]. Unlike the human immunodeficiency virus
type-1 (HIV-1), HTLV-1 does not infect host cells reliably with cell-free virus (virions) [15].
Instead, infectious spread requires cell-to-cell contact between infected and uninfected
CD4+ T cells [16], and occurs via the formation of a virological synapse (VS) [17, 18],
whereupon the genetic material of the virus is reverse transcribed and integrated into the
host genome in a di↵erent location than that of the infecting cell. The integrated viral
DNA is referred to as the provirus.
Mitotic spread is the proliferation of a provirus carrying cell. Because mitotic spread
utilizes the host’s high-fidelity DNA-based DNA polymerase, which is substantially less
error-prone than reverse transcriptase, mitotic replication results in relatively little viral
genetic sequence variation. With respect to the genomic site of proviral integration (the
integration site (IS)), a mitotically replicating cell and its o↵spring are identical. We refer
to a collection of cells with the same IS as a clone (Figure 1.1).
HTLV-1 has substantially less genetic sequence variation when compared to other viruses
such as HIV-1 [14, 15]. The estimated reverse transcriptase error rate of HTLV-1, while
lower than that of HIV-1, is not low enough to fully explain the di↵erences in observed
sequence variation [19]. There is therefore a widespread view that mitotic spread accounts
for the majority of HTLV-1 proviral load [20], and that infectious spread is the predominant
mode of persistence during initial infection, before the host has mounted an e↵ective
immune response [17, 20, 21, 22]. Given that anti-retroviral therapy (ART) is currently
used as first-line treatment for HTLV-1 infection, and given further that this therapy
does not address mitotic spread, determining the ratio of infectious to mitotic spread and
investigating whether this value changes either between patients or over the course of
infection has significant implications for HTLV-1 treatment.
Because infectious spread integrates the provirus within a new location of the host genome,
infectious spread creates new clones. Therefore, an estimate of the number of clones is
paramount in quantifying the rate of infectious spread. Estimating clonal diversity has
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Infectious Spread Mitotic Spread 
Uninfected CD4+ T cell HTLV-1 infected cell 
Host genome 
HTLV-1 infected cell 
HTLV-1 provirus 
Figure 1.1.: HTLV-1 infectious and mitotic spread schematic. Infectious spread (left
column): An HTLV-1 infected cell contacts and infects an uninfected CD4+ T cell.
The HTLV-1 provirus (red) integrates in a di↵erent genomic location of the newly
infected cell. Mitotic spread (right column): An HTLV-1 infected cell divides, where-
upon the provirus resides in the same genomic location in each daughter cell, creating
a clone of HTLV-1 infected cells.
been a subject of longstanding interest in HTLV-1, in part due to the belief that the
amount of oligoclonal proliferation influences disease status. Estimates have increased
over time as experimental techniques have acquired greater precision and sensitivity [20,
22, 23, 24, 25, 26].
In 1992, Furukawa et al [23] used a genomic southern blot to measure the clonality of
HAM/TSP patients. In each patient, fewer than 10 clones were found from 10µg of DNA,
all of which were highly expanded. Thus it was inferred that there were of the order of 101
clones in the host. In 1995, Eric Wattel’s group used a low-throughput linker-mediated
polymerase chain reaction (LM-PCR) protocol to measure between 10 and 15 clones from
1-2µg of DNA [20, 24], and hypothesized the existence of approximately 102 clones in the
host.
In 2011, a high-throughput LM-PCR protocol was developed in Charles Bangham’s lab-
oratory (this protocol is summarised in Section 1.1.6). Using this protocol, between 100
and 5000 clones are observed from samples derived from 10µg of DNA in a typical AC or
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HAM/TSP patient. While ATLL patients have a substantially higher proviral load and far
fewer clones, even here there remains wide variation in observed clonal diversity, ranging
from a single malignantly infected clone that occupies close to 100% of a patient’s PVL, to
as many as 300 clones. It is important to emphasize that HTLV-1 patient data sets, even
when derived using a protocol that can reliably measure two orders of magnitude more
clones than previous approaches, still only catalogue approximately 1108 of all infected cells
in the body. Further, a substantial proportion of these data sets is occupied by singletons
(clones that are observed only once). Therefore current sampling depth does not allow for
a complete census, and so the number of clones in one host remains unknown, and must
be estimated through theoretical means.
The low sampling depth and high number of low occupancy species encountered in HTLV-1
data are also found in other microbiological and immunological data. T cell data sets often
contain several clonotypes that are observed only once. Data on the human microbiome
have a high number of low frequency operational taxonomic units (OTUs). Another feature
in common with HTLV-1 data is the presence of highly expanded clonotypes [27] and high
frequency OTUs [28].
It is therefore natural to investigate whether methods to estimate the clonal diversity of
HTLV-1 have a wider application in microbiology and immunology, particularly as the
number of “classes” is an important quantity in each of these disciplines. In B and T cell
immunology, the number of “clonotypes” is associated with the host’s ability to e↵ectively
respond to pathogens [27, 29, 30, 31, 32, 33], and studies of the human microbiome have
shown an association between bacterial diversity and disease [34, 35].
1.1.4. Virology and Immunology
HTLV-1 is a delta retrovirus with an RNA genome that is approximately 10kb long.
Like HIV-1, HTLV-1 encodes for gag, env and pol genes [15]. Though it was previously
believed that the virus experiences a long latent period [36], it is now recognized that
HTLV-1 establishes a persistent infection whereby the immune system is engaged in a
continuous battle with the virus [37]. There is substantial evidence of a strong, sustained,
and chronically activated cytotoxic T-lymphocyte (CTL) response to infection [14, 15, 38],
in particular a strong positive correlation between PVL and the abundance of HTLV-1-
specific CTLs [38]. The CTL response causes PVL to fluctuate and eventually reach a
stable equilibrium [14, 15, 39, 40].
Two genes are believed to strongly influence the outcome of infection of HTLV-1 patients.
The regulatory protein Tax drives proliferation of infected cells [14], and its expression is
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associated with an abundance of HTLV-1-specific CTLs [41]. Spontaneous Tax expression
is observed in overnight cell culture in vitro [42], and the presence of Tax-specific CTLs
suggests frequent expression in vivo, although Tax is not usually detected immediately ex
vivo. While the Tax protein is the immunodominant antigen [5, 41], it is the host response
to the protein HTLV-1-basic leucine zipper factor (HBZ) that has the greatest influence on
an individual’s risk of developing disease [43, 44]. HBZ is encoded on the complementary
strand of the HTLV-1 genome, and is continuously expressed in vivo [44]. In HAM/TSP
patients, the magnitude of HBZ expression in the host is positively correlated with PVL
and the severity of disease, but this association does not hold for the Tax expression [44].
The mechanism underlying the heterogeneity between patients in their PVL and levels of
HBZ expression can be explained by the host genotype. The human leukocyte antigen
(HLA) system is the major histocompatibility complex (MHC) in humans. HLAs present
antigen to the immune system, and fall into three classes. HLA-class I molecules transport
fragmented proteins (named peptides) from within the host cell to the cell surface; HLA-
class II molecules present peptides located in the surrounding vicinity the cell; and HLA-
class III genes encode part of the complement system [45]. Individuals di↵er in their HLA
genotype, and the alleles that an individual possesses directly contribute to the strength of
immune response that can be mounted to a given pathogen. In the case of HTLV-1, certain
HLA alleles di↵er in their ability to present HBZ peptides to the immune response, and this
ability predicts the level of a patient’s proviral load. In particular, possession of the alleles
HLA-A*02 and HLA-Cw*08 is positively associated with the probability of remaining
asymptomatic, whereas possession of the allele HLA-B*54 is associated with the risk of
inflammatory disease. Killer cell immunoglobulin-like receptor (KIR) genotype has been
shown to amplify the e↵ects of HLA genotype. Possession of the KIR2DL2 gene enhances
both the protective and detrimental HLA class I-restricted anti-viral T cell responses,
and predicts final disease status [46]. Further, it is believed that KIR2DL2 enhances T
cell-mediated immunity, rather than natural killer (NK) cell mediated immunity [46].
HLA genotype and KIR genotype are important determinants of “CTL quality”, which
is the notion that is is not merely the magnitude of the immune response that dictates
response to infection, but rather how e↵ective a given cytotoxic T-lymphocyte is in its
ability to recognize and destroy a target cell [14, 15, 39, 47, 48].
1.1.5. Preferences of Viral Integration
The proviral integration site for HTLV-1 is not random but instead shows a preference
for sites in close proximity (between 1kb and 25kb) to genes and transcriptionally active
regions of the host genome [22, 25]. Further, the increased frequency of integration sites
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close to transcription units observed in vitro is not apparent in vivo. After long-term
infection, only the most-abundant clones show a similar integration bias near transcription.
These observations imply two possibilities: either that there exist selection forces in vivo,
or that there exist specific features of the genome that favour the expansion and survival
of infected cells, or both. Additionally, integration of the provirus in gene-dense regions
was found to be associated with higher levels of proviral expression and a greater risk
of inflammatory disease [25]. More recently, HTLV-1 has been demonstrated to show a
preference for integrating near transcription factor and chromatin remodelling binding
sites, notably the cell-cycle regulator and tumor suppressor p53, and the gene expression
regulator STAT1 [42]. Patients with ATLL show a similar profile of proviral integration
site preference, albeit with some di↵erences [11].
1.1.6. Integration Site Mapping and Quantification Protocol
This thesis makes extensive use of data obtained using a high-throughput LM-PCR pro-
tocol, originally developed by Gillet et al [22]. The protocol maps the integration site of
HTLV-1 infected cells, and quantifies the number of cells in the sample that contain a
given integration site. The protocol is summarised here.
DNA is extracted from uncultured PBMCs of HTLV-1 infected patients, randomly frag-
mented by sonication, and ligated to a partly double-stranded DNA linker. The 3’ long-
terminal repeat (LTR) of the provirus, together with the surrounding host DNA, are
amplified by LM-PCR. A molecule generated by this process is referred to as an amplicon.
Since fragmentation by sonication is random, a particular combination of a given provi-
ral integration site and a given shear site will be unique. This allows us to distinguish
between genuine copies of identical cells, and amplicon duplicates produced by PCR. For
example, if there are two amplicons that have the same integration and shear sites, it can
be concluded that both amplicons have been derived from a single infected cell (Figure
1.2).
Fragmentation by sonication improves upon previous approaches that use restriction en-
zymes. The nucleotide sequences split by restriction enzymes are biased to particular
locations in the host genome. Because PCR amplification preferentially amplifies short
PCR products, proviral integration sites that lie in proximity to restriction enzyme frag-
mentation sites will be over amplified. Thus the use of restriction enzymes will fail to
accurately quantify the frequency of a given integration site. In contrast, shearing the
DNA via sonication fragments the DNA randomly, thus removing systematic biases to-
wards particular integration sites.
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Figure 1.2.: HTLV-1 proviral integration site abundance quantification. The com-
bination of a shear site and an integration site allows quantification of HTLV-1 clonal
abundance. After PCR amplification, Clone A has 4 amplicons, but only a single
shear site; Clone B has three amplicons, but each amplicon has a distinct shear site.
Therefore a single sister cell is observed in Clone A, whereas three sister cells are
observed in Clone B.
Hence the high-throughput data used derived using the above protocol has three key
properties that are essential to estimate and quantify the clonality of HTLV-1. First,
PCR duplicates and genuine copies of infected cells can be distinguished. Second, there
is no preferential identification of particular integration sites. Finally, the data obtained
comprise absolute, and not proportional, counts of infected cells. That is, the frequency
of each clone is known, and not merely its relative abundance when compared with other
clones. Absolute counts are essential in diversity estimation, where the observed frequency
of each clone is used to estimate total diversity.
1.1.7. Outline of Thesis
The aim of this thesis is to estimate the clonal diversity of HTLV-1 infection, and to
use this information to build a model of the within-host dynamics of HTLV-1 persistence
that can infer the ratio of infectious spread to mitotic spread. We interpret empirical
observation using statistical methods, computer simulation and mathematical modelling.
Chapter 2
Chapter 2 develops and applies our diversity estimator (named DivE) to HTLV-1 infection.
Considering an HTLV-1 clone as a species or class of infected cells, estimating the number
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of clones in one host is similar to the “unseen species problem”: given the number of
species observed in a sample of a population, how many species are there in the total
population?
DivE is based on the technique of rarefaction, originally developed in ecology, where the
expected number of species is plotted against the number of individuals. Many mathemat-
ical models are fitted to multiple subsets of rarefaction data, and we apply novel criteria
to assess model performance. We compare estimates of species richness produced with
these criteria to those produced using Akaike’s Information Criterion (AIC), an informa-
tion theoretical method for selection of models. Using observed data and a maximum
likelihood modelling approach, we outline an algorithm to estimate the frequency of each
species in the wider population, including unseen species.
We investigate the applicability and accuracy of our methods when applied to a range
of biological systems where the number of classes of individual is an important, but un-
known, population metric. Our methods were applied to virological (HTLV-1 clonality),
microbiological (gastrointestinal microbiota), immunological (T cell receptor (TCR) reper-
toires), and metagenomic (clades of Prochlorococci genes) systems. The accuracy of our
estimates in each system was compared to that of widely-used non-parametric estimators
originally developed in population ecology. We address di↵erences between ecological pop-
ulations and immunological and microbiological populations, both in the structure of the
populations themselves and in collecting data from them.
Chapter 3
Chapter 3 applies DivE to estimate the clonal diversity in a range of patient groups with
di↵erent manifestation in HTLV-1 associated disease.
We consider patients with clones that have undergone malignant transformation and have
progressed to ATLL. Asymptomatic carriers and HAM/TSP patients from two Japanese
cohorts are examined, and we compare the clonality of the circulation and the skin in
patients with infective dermatitis associated with HTLV-1 (IDH).
We also explore the clonality of human T-lymphotropic virus type-2 (HTLV-2), and con-
trast this with the clonality of HTLV-1 when restricted to CD4+ and CD8+ T cells.
Finally, we use time series data comprising three immune-suppressed patients who con-
tracted HTLV-1 from contaminated solid organ transplantation. This provides a rare
opportunity to examine the clonality of early HTLV-1 infection.
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Chapter 4
Chapter 4 introduces techniques in stochastic modelling that we will use to model the
dynamics of small HTLV-1 clones. We briefly review existing stochastic methods, originally
motivated in chemical kinetics, and which are increasingly applied in mathematical biology.
We formally define the master equation, and explicitly derive this quantity for a pure birth-
death process.
We explore the consequences of a birth-death process that does not contain inflow, and
then explore potential approximations that can be made to the probability distribution
that describes how a given species obtains a given frequency at a given time, under a
variety of parameter values and initial states of the system.
Chapter 5
Here the techniques discussed in Chapter 4 are used to develop a deterministic and stochas-
tic hybrid model of the within-host dynamics of HTLV-1 infection. We outline an ide-
alized model that is not subject to computational runtime and memory constraints. We
then discuss approximations that reduce the complexity of the model such that it can
be propagated and fitted to empirical data. We describe a maximum likelihood method
of parameter estimation that can account for unseen species, and which will ultimately
enable inference of the relative contributions of infectious spread and mitotic spread to
overall HTLV-1 persistence.
Chapter 6
Concluding remarks and discussion of future work.
28
2. Quantification of HTLV-1 Clonality
and TCR Diversity
2.1. Introduction
How can we estimate the diversity of a population from a sample of that population?
In viral infections, the number of viral variants and their population structure inform
our understanding of disease pathogenesis, and can suggest treatment strategies [49, 50].
In immunology, the repertoire and population structure of B cell and T cell receptor
clonotypes vary with age, and are intimately linked to antimicrobial protective e cacy
[30, 32, 33, 51, 52, 53]. In the human microbiome, decreased diversity of the gastrointestinal
microbiota is associated with atopy [54], Crohn’s disease and ulcerative colitis [34, 35].
A complete census is usually impossible and so estimators of the number of unseen
“species” are required. Here we use the word “species” to denote a class of individu-
als, such a T cell clonotype, bacterial operational taxonomic unit (OTU) or viral clone.
We use the word “individual” to refer to a single T cell sequence read, microbial sequence
read, or virus- infected cell. The term “species richness” denotes the number of species in
the population under consideration.
Immunological and microbiological data di↵er in important respects from ecological data.
First, in many immunological and microbiological populations, it may be reasonable to
assume that species are taxonomically similar, that the spatial distribution of individu-
als is homogeneous, and that individuals are sampled randomly, independently and with
equal probabilities. If made, these simplifying assumptions allow the extrapolation of
individual-based rarefaction curves, which depict the expected number of species against
the number of individuals sampled [55, 56, 57, 58]. However, the above assumptions are
frequently violated in ecological populations [58, 59, 60, 61, 62], where unobserved indi-
viduals may di↵er from observed individuals in their colour, physical size, geographical
distribution, movement, variety of habitats and relationship to other species [59], and
thus remain unobserved despite substantial subsequent sampling. Second, many common
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assumptions about population structure are inappropriate for immunological and micro-
biological populations, for example that all species have equal frequencies [63, 64, 65], or
that the functional form of the population distribution is known [66, 67, 68, 69, 70]. We
therefore consider non-parametric estimators.
Non-parametric estimators, such as Chao1 [71], and the abundance-based coverage esti-
mator (ACE) [72], have been proposed. ACE has been suggested to be the best current
approach [58, 66, 73] and is widely applied in microbiology and immunology; for example
to estimate the diversity of the human gastrointestinal flora [74], human gut metagenome
[75], mouse TCR repertoire [76, 77], fungi [78], and the number of HTLV-1 infected cell
clones [26]. Although they were originally intended as methods to estimate lower bounds,
the Chao1 estimator, and the modified, bias-corrected form Chao1bc [79], have been used
to make a point estimate of the number of TCR clonotypes [80, 81], the number of OTUs in
hepatitis C virus infection [49], parasite diversity in malaria infection [82] metagenome size
[83], the number of integration sites of therapeutic gene therapy vectors [84], soil diversity
[85], and again the number of HTLV-1 infected cell clones [22, 26]. In addition to the ACE
and the Chao estimator, we also consider two additional non-parametric estimators: the
Bootstrap [86] and Good-Turing estimators [87].
Most diversity estimators aim to estimate the species richness in one of two populations
of interest: either in the population from which the sample was drawn (e.g. number of
microbial species in the gut, given a sample from the gut) or the value where the rarefaction
curve saturates (e.g. number of species at the point when further sampling does not yield
any new species). These definitions of the population of interest lack flexibility and may
be inappropriate or poorly defined for the question in hand. Essentially, given a complete
census, either the rarefaction curve will saturate or it will not. If it does not, then an
estimate of population size is required to avoid an infinite diversity estimate. Indeed, if
some species are represented by a single individual, the rarefaction curve will not saturate.
For many microbiological and immunological questions, an estimator that allows the user
to specify the size of the population of interest is desirable. For instance, we may wish to
know the T cell repertoire diversity of both the blood and the whole body.
The aim of this study was to identify a suitable method for estimating species richness
in immunological and microbiological populations. We tested widely-used estimators on
samples of microbiological and immunological populations. We found these estimators
performed poorly. We therefore developed and validated a new method to estimate species
richness and species frequencies.
We used data from three independent sources: (i) viral populations from HTLV-1-infected
subjects; (ii) T cell antigen receptor (TCR) clonotype repertoires; and, (iii) infant faecal
microbial samples.
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Our HTLV-1 data sets consisted of high-throughput data on the abundance of HTLV-
1 infected cell clones in 14 HTLV-1 seropositive subjects obtained using the protocol
described in [22].
The human gastrointestinal tract contains a densely populated ecosystem of microbes that
performs a variety of functions [88]. We obtained high-throughput 16S rRNA sequence
data from infant faecal samples. In this study we used observed frequencies of di↵erent
bacterial operational taxonomic units (OTUs) [28].
T cells are vital to adaptive immunity. The T cell population comprises a diverse repertoire
of TCR clonotypes, each defined by the DNA sequence of the expressed TCR. In humans,
there are a potential 1015 - 1020 di↵erent TCR clonotypes [89], but the actual number of
clonotypes in one person is thought to be far less, and is estimated to be between 106 and
108 [90, 91]. In this study we used RACE-based data on TCR clonotype abundance. We
studied circulating central and e↵ector memory, na¨ıve and total CD4+ and CD8+ T cells.
2.2. Materials and Methods
2.2.1. Ethics Statement
Blood samples were donated by HTLV-1+ subjects attending the HTLV-1 clinic at the
National Centre for Human Retrovirology (Imperial College Healthcare NHS trust) at
St. Mary’s Hospital, London UK, with fully informed written consent. This study was
approved by the UK National Research Ethics Service (NRES reference 09/H0606/106).
Parents gave full written informed consent for infant faecal sample collection, and all pro-
tocols and procedures were approved by the National Research Ethics Service Committee,
U.K. (Southampton and South West Hampshire) (ref: 05/Q1702/119). For the TCR data,
leukaphereses were performed on healthy donors who provided written informed consent
at the National Institutes of Health, USA. The protocol and use of these samples for im-
munological investigation were approved by the National Institute of Allergy and Infectious
Diseases Institutional Review Board.
2.2.2. HTLV-1 Data Collection
Previously reported [22] and new high-throughput data on HTLV-1 clonality provided
by our collaborators were analysed. Each HTLV-1 dataset quantifies the abundance of
HTLV-1-infected T cell clones. There were 105 datasets, comprising 9 datasets from each
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of 10 subjects (three independent samples at each of three time points), and 15 datasets
from an additional 4 subjects (Table A.2). All subjects had either HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) or were asymptomatic carriers of
HTLV-1 (ACs).
2.2.3. Microbial Data Collection
The microbial data was obtained and kindly provided by Kathleen Sim in Simon Kroll’s
laboratory at Imperial College. The data were derived from faecal samples obtained from
10 infants. DNA was amplified with two sets of PCR primers, generating 20 datasets [28].
Amplicons of the V3-V5 regions of the 16S rRNA gene were generated by PCR using two
sets of universal primers. Sequencing data were generated using the Roche 454 GS Junior
platform. Analysis was performed using the QIIME pipeline as described previously [28].
2.2.4. TCR Data Collection
TCR repertoire data was generously provided by our collaborators at the National In-
stitutes of Health in Bethesda Maryland, USA. A total of 16 datasets were collected
from two subjects, comprising TCR sequences from four phenotypically defined subsets
of CD4+ and CD8+ T-cells: na¨ıve, central memory (CM), e↵ector memory (EM) and
total. After flow cytometric sorting and cell lysis, mRNA was extracted and subjected to
a non-nested, template-switch anchored RT-PCR using a 3’ TCRB constant region primer
as described previously [92]. This approach allows linear and unbiased amplification of all
TCRs irrespective of TRBV or TRBJ gene usage. Paired-end sequencing reactions (each
150bp) were performed using an Illumina HiSeq 2000 sequencer. Raw FASTQ files were
annotated using reference TCRB sequences from the ImMunoGeneTics (IMGT) website
(http://www.imgt.org) and a custom-written Java application. Following annotation, the
data were filtered to eliminate potential sequencing and PCR errors.
2.2.5. Prochlorococcus Data Collection
Prochlorococci are vital to energy and nutrient cycling in the oceanic ecosystem, and the
genus contains a highly diverse and abundant population of clades. We analysed publicly
available metagenomic data describing clades Prochlorococcus. The data were obtained
by the Global Ocean Sampling Expedition and contains the frequency of distinct sequence
reads of genes of Prochlorococcus clades [93]. Sampling sites, sample collection, library
construction, fragment recruitment, and determination of Prochlorococcus abundances are
detailed in [93, 94].
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2.2.6. DivE Species Richness Estimator
We developed a heuristic approach to estimate species richness, which we named DivE
(Diversity Estimator) (Figure 2.1). To calculate the DivE estimator, many models (i.e.
functions of the form y = f(x)) are fitted to multiple nested subsamples of individual-
based rarefaction curves. Each function is fitted to all nested subsamples, and is scored
on a set of four criteria. The five best-performing functions are extrapolated and their
respective estimates are aggregated to produce the DivE species richness estimate. DivE
requires an estimate of population size. If the species richness of a wider population is
desired, the same functions are used but extrapolated to a di↵erent population size; this is
only justified if the two populations are similar in their spatial distribution of individuals.
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Figure 2.1.: Outline of DivE Species Richness Estimator. DivE fits many functions
to rarefaction curves (black) and subsamples thereof (orange). Data is denoted
by circles; fits by solid lines. Models are scored according to DivE criteria (see
Section 2.2.6). The best performing functions are aggregated and extrapolated
to estimate species richness. Model A performs poorly as Accuracy and
Similarity criteria are not satisfied. Model B performs well as all criteria are
satisfied.
The criteria against which each function fit is scored are:
1. Discrepancy: the mean percentage error between data points and prediction of the
function.
2. Accuracy: the percentage error between the full sample species richness, and the
estimate of full sample species richness from a given subsample.
3. Similarity: the area between the curve fitted to a subsample and the curve fitted
to the full sample, normalized to the area under the curve from the full data, on the
interval [0, Nobs] where Nobs is the size of the full data.
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4. Plausibility: the predicted number of species must either increase monotonically
or plateau and the predicted rate of species accumulation must either decrease or
plateau (i.e. for f(x) and x   1, where x is the number of individuals, f 0(x)   0,
and f 00(x)  0).
The rationale behind each criterion is as follows:
1. Discrepancy: the function must describe the data to which it was fitted.
2. Accuracy: from a subsample, the function should predict the full sample species
richness.
3. Similarity: an ideal function will produce identical fits from all subsamples. The
smaller the area between the function fits, the better the function (Figure 2.1).
4. Plausibility: this criterion requires that, as the observed number of individuals
increases, the observed number of species does not decrease and the rate of species-
accumulation does not increase; the former is biologically impossible and the latter
is highly implausible.
Criteria 2., 3. and 4. are independent of the fitting process. That is, they are not constraints
by which functions are fitted; instead they are tests of function performance. Note we do
not penalise functions for their complexity, for example by using Akaike’s Information
Criterion (AIC). Usually, functions with more parameters can be more easily made to
fit data, and thus have a natural advantage that does not correspond to their ability to
predict or describe data. However, DivE explicitly tests each function’s ability to predict
additional data with criteria 2., 3. and 4. and further there is no a priori reason why
more complicated functions should have an advantage in predicting additional data which
played no part in inferring parameter values. In any case, we compare DivE to AIC in
section 2.3.2.
Each function fit is scored on all four criteria. For criteria 1 to 3, we scored a fit in multiples
of empirically chosen precision levels. The precision level for criterion 1 was 0.01%: a score
of 1 denotes a function fit where the mean percentage error of the residuals, ✏, was less
than 0.01%; a score of 2 denotes 0.01%  ✏  0.02% and so on. Criteria 2 and 3 were
similarly scored in multiples of 0.5%. Criterion 4 was implemented by giving a score of
500 to function fits that violated either of its conditions; this value was chosen to exceed
the score of any function fit that satisfied this criterion.
The final score for each function is an aggregate of the scores of all function fits across
subsamples and criteria, and is calculated as follows. First, the score for each criterion is
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defined as the mean of the scores of all subsample fits for that criterion. The final score for
each function is the mean of all criteria scores. That is, for a given function, for criterion
i (where the criteria are numbered as above) and subsample j, each function has a score
Dij . A function’s final score D is given by
D =
1
4
4X
i=1
Pn
j=1Dij
n
=
1
4n
4X
i=1
nX
j=1
Dij (2.1)
where n is the number of subsamples (see Table A.1). The DivE species richness estimate
is the geometric mean of the estimates provided by the five best-performing,lowest-scoring
functions (see section 2.4).
2.2.7. Choice of DivE Candidate Models
A list of 58 candidate functions (see Appendix Section A.1) was chosen from an online
repository [95]. Many of these (e.g. logistic, logarithmic, hyperbolic) are widely used in
population ecology [55, 96]. Models were fitted by least squares regression using R version
2.14.2 [97] with the package FME [98]. Global fitting was performed using Price’s psuedo-
random search algorithm [99] followed by local fitting using the Levenberg-Marquardt
algorithm [100].
2.2.8. Fitting of Models to Data
The pseudo-random model fitting algorithm [99] requires that parameter ranges and initial
guesses be entered. The runtime incurred in model fitting increases with the size of the
parameter space. The need for parameter ranges small enough to yield precise parameter
estimates in acceptably short runtimes must be balanced against the need for parameter
ranges that adequately encompass appropriate parameter values for data of di↵erent scales.
The performance of the “modFit” and “pseudoOptim” functions from the R package
“FME”, which are used to estimate model parameters, is sensitive to the choice of initial
parameter guesses. Initial guesses were chosen as the midpoint of each parameter range.
To obtain better parameter fits, the fitting process was repeated, taking advantage of the
fact that data between subsamples (but within patients) is similar. Fitted parameters
from a single subsample often provided better initial guesses for a subsequent subsample
than the seeds originally given. This iterative process allowed for faster optimization of
parameters while keeping parameter ranges relatively large, ultimately improving function
fits.
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2.2.9. Estimation of HTLV-1 Population Sizes
Population size is a necessary input for species richness estimation when a given subpop-
ulation must be specified, or when a saturating relationship between population size and
species richness cannot be assumed. We estimate the number of HTLV-1 infected cells i)
in the circulation (Nblood), and ii) in the whole body (Nbody). For the former, we assumed
a circulating blood volume of 5L and a peripheral blood mononuclear cell (PBMC) count
of 3⇥109L 1 [45]. HTLV-1 proviral load PV L is defined as the number of viral copies per
100 PBMCs. We assumed that each infected T cell carries a single copy of the HTLV-1
provirus [101]. Thus, we estimated that
Nblood = 5⇥ 3⇥ PV L100 ⇥ 10
9 (2.2)
To estimate Nbody, we assumed that 40% of PBMCs are CD4+ T cells, and that 95% of
HTLV-1+ cells are CD4+ T cells [102]. We therefore multiplied the PVL by 10040 to obtain
the proportion of infected cells that are CD4+ T cells that are infected, i.e. PV LCD4 =
no. copies per 100 CD4+ T cells = PV L ⇥ 10040 . The total number of lymphocytes in the
body is approximately 2⇥ 1012, and 50% of lymphocytes are CD4+ T cells. Thus
Nbody =
PV L
100
⇥ 100
40
⇥ 1
0.95
⇥ 1012 (2.3)
2.2.10. Study Design
We evaluated DivE and five widely-used non-parametric estimators: the Chao1 bias-
corrected estimator (Chao1bc) [79], the abundance-based coverage estimator (ACE) [72],
the Bootstrap estimator [86], the Good-Turing estimator [87, 103, 104] and the widely-
used negative exponential model [55, 56, 79, 105, 106]. ACE and Chao1 [71], have been
suggested as best practice [56, 58, 66, 73, 107] and are widely applied in microbiology and
immunology [22, 26, 49, 74, 76, 78, 80, 82, 83, 84, 85]. For ACE, “abundant” species were
defined as those with an observed frequency of greater than 10, as recommended in [107].
Due to di↵erences between estimators and between datasets, we conducted multiple, dis-
tinct evaluations and validations. We first evaluated, for each estimator, the relationship
between estimated diversity and sample size, using the estimates produced from a series
of successively smaller, randomly generated in silico subsamples of observed data. For the
microbial and TCR data respectively, five and six equidistant subsample sizes were chosen
from each observed dataset. For the HTLV-1 data, subsample sizes were chosen to be
approximately equidistant; however some were removed due to runtime constraints. See
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Table A.1 for further details. Second, we measured the accuracy of DivE by comparing the
estimated species richness Sˆobs at the size of the full dataset Nobs from each subsample to
the (known) species richness Sobs in the full data. Using the same method, we compared
DivE to the second order bias-corrected Akaike Information Criterion (AICc) [108, 109].
Third, the TCR data have rarefaction curves which plateau. Using smaller subsamples of
this data and making the assumption that the species richness of the full data is equal
to that of the entire population, we were able to evaluate the accuracies of all estimators
together. Finally for 11 of the 14 HTLV-1 patients detailed in Table A.1, three samples
were taken at a single time point. For each time point, the three samples were pooled and
used as a practical test of DivE’s ability to predict species richness in larger samples.
2.2.11. DivE Frequency Distribution Generation Algorithm
In addition to species richness, we estimated the population frequency distribution. Be-
cause of the considerable structural variation between and within immunological and mi-
crobiological populations, we developed a general method which does not assume the
analytical form of the population structure. This algorithm uses the DivE estimator com-
bined with observed abundances (Figure 2.3). The algorithm was applied to multiple
random subsamples of observed data. The estimated distributions were then compared to
the full data frequency distribution using two measurements: (i) error, defined as the sum
of discrepancies in species frequencies between estimated and observed (full) distributions,
divided by the number of individuals in the observed distribution, i.e.
error =
PSˆobs
i=1 |Esti  Obsi|PSˆobs
i=1 Obsi
(2.4)
and (ii) percentage error between the Gini coe cients of the estimated and observed
distributions. The Gini coe cient is an index of dispersion used widely in epidemiology,
sociology, biology, and ecology [22, 110] (Figure 2.2).
Consider an observed species frequency distribution where x individuals are dispersed
among species 1, ..., y, each with observed relative frequencies p(x,1), p(x,2), ..., p(x,y). We
define
yX
i=1
p(x,i) = 1 (2.5)
That is, all x cells belong to the observed clones 1, ..., y, and so 100% of the x cells belong
to observed clones.
Now consider the observed frequency distribution’s corresponding species accumulation
curve. The final point of this species accumulation data would be (x, y) (Figure 2.3). After
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Figure 2.2.: Gini coe cient and Oligoclonality Index (OCI) schematic. Blue line
shows the cumulative proportion of PVL plotted as a function of the descending rank
order of the clone abundunce. Red diagonal line (line of equality) denotes that all
clones have an equal share of the PVL. The OCI or Gini coe cient is given by AA+B .
(Note that the Gini coe cient is often defined with clones in ascending order, in
which case the cumulative proportion of PVL will sit below the line of equality.)
fitting the functions returned by DivE to the species accumulation curve, we extrapolate
to the point (x + a, y + 1), i.e. until another, unobserved, species is encountered. We
determine the proportion of the x + a individuals occupied by the previously observed y
species. That is, we wish to calculate
pmax =
yX
i=1
p(x+a,i) (2.6)
Using this quantity, we can calculate the relative frequency of the newly observed species
y + 1,
p(x+a,y+1) = (1  pmax) (2.7)
We estimate the most likely number of individuals in the wider population that belong to
the species in the observed sample i.e. to species 1, ..., y.
Let N be the size of the wider population from which all individuals are drawn without
replacement, and let r be the number of individuals in the wider population that belong
to species 1, ..., y. Let dj be the number of individuals from any of species 1, ..., y drawn
on the jth trial. dj can take values 0 or 1. Then P(d1 = 1) = r/N , and
P(d2 = 1 | d1 = 1) = r   1
N   1 (2.8)
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Figure 2.3.: Outline of DivE distribution generation algorithm. A Truncated species fre-
quency distribution with x individuals distributed among y species. The frequency
of species Si after sampling x individuals is denoted Fx(Si). B Species accumulation
data generated from frequency distribution. C An aggregate of the best performing
functions as returned by DivE is used to extrapolate to point (x+a, y+1), where the
next species is predicted. D Species Sy+1 is assigned a frequency of (1 pmax)(x+a),
where pmax is the maximum likelihood proportion of individuals occupied by the y
previously observed species. The remaining pmax(x + a) individuals are distributed
among species S1, ..., Sy in proportion to their observed relative frequencies at x.
Steps C and D are repeated until the predicted species richness is reached. See
Section 2.2.11 for further details.
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More generally,
P(dj = 1 | dj 1 = 1 | ... | d1 = 1) = r   (j   1)
N   (j   1) (2.9)
The likelihood L of observing (x+ a  1) individuals from species 1, ..., y, followed by an
individual belonging to a new species is thus
L(r) = r(r   1)(r   2)...(r   (x+ a  2))
N(N   1)(N   2)...(N   (x+ a  2)) ⇥
N   r
N   (x+ a  1) (2.10)
N r
N (x+a 1) is the probability of drawing an individual that does not belong to species 1, ..., y
on the (x + a)th draw (i.e. where N   (x + a   1) individuals remain) when all previous
draws have produced individuals belonging to species 1, ..., y. Note we assume that the
new species y + 1 is observed only once in draws x+ 1, ..., x+ a. We obtain
Py
i=1 p(x+a,i)
by numerically optimizing rmax (using the method of Nelder and Mead [111]) such that
L(rmax) is maximal. We compute pmax =
Py
i=1 p(x+a,i) =
rmax
N Then for i = 1, ..., y,
p(x+a,i) = p(x,i) ⇥ pmax = p(x,i) ⇥ rmaxN (2.11)
and
p(x+a,y+1) = 1  pmax (2.12)
We now have estimates of the frequencies of species 1, ..., y + 1 in x + a individuals. We
repeat the above process for species y+2 (i.e. by extrapolation to the point (x+a+b, y+2))
and so on until the predicted number of species in the population is reached (Figure 2.3).
2.3. Results
2.3.1. Comparison of Estimators: Relationship Between Sample Size
and Estimated Diversity
Each species richness estimator (Chao1bc [79], Bootstrap [86], ACE [72], Good-Turing [87],
the negative-exponential model [55, 56] and DivE) was applied to random subsamples of
observed data. We used linear regression to calculate the average proportional increase
in estimated diversity as a function of the proportional increase in sample size. Sample
size and diversity were normalized respectively to the smallest sample and the estimated
diversity at the smallest sample. For example, a “normalized gradient” of 0.5 would
mean that, on average, an increase of 10% in sample size would produce a 5% increase in
estimated diversity. A value of zero would signify no bias with sample size.
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The existing estimators performed poorly when applied to the HTLV-1 and microbial
data: estimates systematically increased with sample size. In contrast, DivE produced
consistent estimates that showed no obvious relationship with sample size (Figures 2.4
and 2.5). Across subjects and for all methods except DivE, estimates showed significant
positive normalized gradients (p < 0.01 for every estimator, n = 14; two-tailed binomial
test) ranging between 0.17 and 0.52 for the HTLV-1 data and 0.3 to 0.45 for the micro-
bial data (Figure 2.5). Conversely, the normalized gradients produced by DivE did not
di↵er significantly from zero (p = 0.18, n = 14; two-tailed binomial test), and were much
smaller (0.0081 and 0.022 for the HTLV-1 and microbial data respectively) (Figure ref-
fig:SlopeBeeSwarm). In any specified population there is only one value of species richness,
and an accurate estimator will arrive at this value regardless of sample size. An increase
in estimate magnitude with sample size implies that estimates of a population’s species
richness would increase if e.g. greater blood volumes were drawn or technique sensitivity
was improved.
The existing estimators were less biased when applied to the TCR data, and estimates were
largely consistent. Although the normalized gradients were still significantly positive (p <
0.0001 for each estimator except DivE, n = 16), their magnitudes were substantially lower
than for the HTLV-1 and microbial data. However, existing estimators again increased
with sample size for the e↵ector memory (EM) CD8+ T cell population from the same
subject. These observations can be explained with reference to the TCR rarefaction curves
(Figure 2.4). With the exception of the CD8+ EM dataset (for which the subsample sizes
were considerably smaller), each TCR rarefaction curve reached a plateau, implying that
the vast majority of observed clonotypes were encountered early. In contrast, the CD8+
EM rarefaction curve did not plateau, suggesting that further sampling would reveal more
CD8+ EM clonotypes. In common with the microbial and the HTLV-1 datasets, DivE
performed well for all TCR datasets, producing consistent results from all subsample sizes.
To make sure that the smallest subsamples did not disproportionately contribute to the
observed gradients, we repeated the above analysis using only estimates from the largest
three subsamples in each patient dataset, which showed almost identical results (Figure
2.6).
2.3.2. Comparison of DivE and Second Order Bias-Corrected Akaike
Information Criterion (AICc)
The best-performing functions were largely consistent within patients and between sub-
samples for the microbial and TCR data, although less so for the HTLV-1 data. Ideally,
function selection would be consistent across all subsamples. Deviation from this will result
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Figure 2.4.: Comparison of species richness estimators. A - D The Chao1bc (blue),
ACE (grey), Bootstrap (green), Good-Turing (black), and negative-exponential esti-
mators (orange) are applied to in silico random subsamples of observed data. Ex-
amples for HTLV-1, microbial, and TCR data are shown. Estimates systematically
increase with sample size in datasets where rarefaction curves do not plateau (e.g. in
I, J, K). Where rarefaction curves do plateau (e.g. in L), estimates are consistent. E
- H DivE (red) is applied to same subsamples as the other estimators. Performance of
DivE was evaluated by comparing the error of estimates (Sˆobs), to the (known) num-
ber of species Sobs in the full observed data (purple line), i.e. error = |Sobs Sˆobs|/Sobs.
In all datasets, DivE accurately estimates the species richness of the full observed data
from subsamples of that data. I - L Corresponding HTLV-1, microbial and TCR rar-
efaction curves: arrows denote the size of the subsample to which each estimator was
applied.
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Figure 2.5.: Comparison of estimators: e↵ect of sample size on estimated diver-
sity. Normalized gradients measuring proportional increase in estimated diversity
against proportional increase in sample size. Normalized gradients (shown for each
estimator and each patient data set in Table A.1) were calculated by linear regression.
For the HTLV-1 and microbial data, all estimators except DivE show large normal-
ized gradients that are significantly positive. The TCR normalized gradients, though
significantly positive, are small and do not show a substantial bias with sample size.
*, **, and *** signify p < 0.01, p < 0.001, and p < 0.0001 respectively; two-tailed
binomial test (n = 14, 16, 20 for the HTLV-1, TCR and microbial data respectively).
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Figure 2.6.: Estimator bias with sample size not due to small subsamples. As
for Figure 2.5, except that normalized gradients calculated using only largest three
subsamples. For the HTLV-1 and microbial data, all estimators except DivE again
show large normalized gradients that are significantly positive. The TCR normalized
gradients, show no bias with sample size. *, **, and *** signify p < 0.05, p < 0.01,
and p < 0.001 respectively; two-tailed binomial test (n = 14, 16, 20 for the HTLV-1,
TCR and microbial data respectively).
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in a discrepancy between Sobs and Sˆobs. This discrepancy is quantified in Figure 2.4 (mid-
dle column) and in Table 2.1. To ensure the four criteria provide a useful metric of model
performance, we compared DivE to the second order bias-corrected Akaike Information
Criterion (AICc) [108, 109]. DivE’s mean errors (between the species richness of the full
data Sobs and Sˆobs) were 3.3%, 1.0%, and 4.0% for the HTLV-1, TCR and microbial data
respectively. These were lower than the corresponding errors of 6.7%, 1.1%, and 7.5%,
produced when functions were scored by the AICc. This e↵ect was more marked when
we considered estimates from small subsamples, defined as those comprising at most 50%
of the observed data (Table 2.1). However, the di↵erences between errors were smaller for
the TCR data, perhaps also due to the saturating rarefaction curves in these samples.
Table 2.1.: Comparison of estimates produced by DivE and by weighted, second order
Akaike’s Information Criterion (AICc)
Data source Method Small Error1 Large sub error2 Overall3
Collated AICc 11.3 1.9 5.0
DivE 5.5 1.4 2.7
HTLV-1 AICc 13.1 0.5 6.7
DivE 6.2 0.5 3.3
TCR AICc 2.4 0.5 1.1
DivE 1.8 0.6 1.0
Microbial AICc 23.0 3.7 7.5
DivE 10.4 2.4 4.0
1 Average percentage error between Sˆobs and Sobs for small subsamples for each data source. Small
subsamples were defined as those  50% of the size of each patient data set.
2 Large subsamples defined as those > 50% of the size of each patient data set.
3 Average percentage error between Sˆobs and Sobs across all patient datasets and subsamples for each
data source
2.3.3. Comparison of Estimators: Accuracy of Diversity Estimate
When rarefaction curves reach a plateau, we can assume that the value of the plateau is
approximately equal to the species richness of the entire population, which the ecological
estimators aim to estimate. Thus it is appropriate to evaluate DivE and the existing
estimators together using those TCR rarefaction curves which plateau. We took random
subsamples of 0.5%, 1%, 2%, 5%, and 10% of the total CD4+ and CD8+ cells for subjects C
and E. We then applied each estimator to each subsample and measured its error, defined
by
error =
|Sobs   Sˆobs|
Sobs
(2.13)
DivE’s median error was 6.7%, substantially lower than respective median errors of 43.8%,
42.8%, 65.3%, 61.7%, and 50.7% for the Chao1bc, ACE, Bootstrap, Good-Turing and
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Figure 2.7.: Comparison of estimators: accuracy of diversity estimates using
TCR data. Random subsamples of 0.5%, 1%, 2%, 5%, and 10% of the total
CD4+ and CD8+ cells for subjects C and E were taken, and each estimator was
applied to each subsample. These populations have rarefaction curves that plateau,
so making the assumption that the value of the plateau Sobs is the diversity of the
whole population, the distribution of errors for each estimator error = |Sobs Sˆobs|Sobs is
shown.
negative exponential estimators (p < 0.0005 for each estimator comparison with DivE,
n = 20; two-tailed binomial test) (Table 2.2, Figure 2.7).
Table 2.2.: Comparison of estimator performance for TCR data.
Estimator Median Error1 (%) p-value2
Chao1bc 43.8 0.0004
ACE 42.8 0.0004
Bootstrap 65.3 < 0.0001
Negative-exponential 50.7 < 0.0001
Good-Turing 61.7 < 0.0001
DivE 6.7 NA
1 Median absolute percentage error between Sˆobs and Sobs
2 p-value of the significance of the di↵erences between the errors of each estimator and DivE (n = 24;
two-tailed binomial test)
As neither the HTLV-1 nor the microbial data exhibit rarefaction curves that plateau, we
cannot apply the same analysis to these datasets. Instead we took advantage of the fact
that, for 11 of the 14 HTLV-1 subjects, the data comprised three time points, with three
samples drawn at each time point in immediate succession from the subject. For a given
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subject and a single time point, the three samples were combined in silico to produce a
single pooled sample. We compared the observed species richness of the pooled sample
to each estimator’s estimates from a subsample (Figure 2.8, Figure 2.9). The total blood
diversity must be at least as great as that observed by pooling the samples. However, all
existing estimators estimate the total diversity to be less than that observed. Based on a
single subsample, the Chao1bc, ACE, Bootstrap, Good-Turing and negative exponential
estimators respectively estimate medians of 27.0%, 12.7%, 71.1%, 65.5%, and 47.6% fewer
clones than observed in the pooled samples (n = 11). Since the pooled samples do not
saturate, and since the blood contains approximately 105 times more infected cells than
the pooled sample, the diversity observed in the pooled sample is likely to be a small
fraction of the total diversity. Since the existing estimators produce estimates lower than
the pooled sample diversity, let alone total blood diversity, this represents a considerable
error. We used DivE to produce two estimates: the pooled sample diversity and blood
diversity. From the subsamples DivE estimated a median of 2.6⇥ 103 clones in the pooled
samples, a median error of 2.5% (n = 11) (Figure 2.8, Figure 2.9). Additionally, DivE
estimated 2.8 ⇥ 104 clones in the blood, approximately one log higher than the observed
pooled sample diversity. Whilst we cannot determine whether or not this is accurate it is
at least plausible, considering that it is not less than the diversity of the pooled sample,
that the sampling fraction is very small, and that the rarefaction curve has not reached a
plateau.
2.3.4. Estimate Error as a Function of Data Curvature
Next we sought to identify conditions under which DivE would be prone to error and
should not be applied. When the observed rarefaction curve is linear, the data imply a
constant rate of species accumulation, and so provide little information on how quickly
the rate of species accumulation will decrease. This is usually indicative of severe under-
sampling. We predicted that DivE will fail to give accurate estimates given such a near
linear rarefaction curve. We tested this prediction by calculating the error in the DivE
estimates as a function of rarefaction data curvature.
The curvature parameter Cp was quantified by the area between the observed rarefaction
curve and a linear rarefaction curve, as a fraction of the maximum possible area, which
occurs when the rarefaction curve saturates immediately. Cp can take values between 0 and
1, where 1 reflects perfect saturation and 0 reflects a constant rate of species accumulation
(Figure 2.10). We took additional samples of 0.1% of the total CD4+ and CD8+ cells for
subjects C and E to obtain lower curvature values.
As expected, at very low curvatures (0.016  Cp  0.101), DivE was prone to over-
estimation and performed poorly (Figure 2.11), with median error 0.23. However, for
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Figure 2.8.: Ecological estimators underestimate diversity in HTLV-1 infection.
For HTLV-1 Patient D, three samples are pooled. Rarefaction curves from the pooled
sample (black circles) and a subsample (red circles) are shown. Chao1bc, ACE,
Bootstrap, Good-Turing and negative exponential estimates (blue, grey, green, black,
and orange lines respectively) from the subsample, and DivE estimates (red cross)
from the same subsample are plotted. Existing estimators produce a single estimate
of diversity, and so their estimates are shown as lines. The diversity in the blood
must be at least as great as that observed by pooling the samples. All existing
estimators estimate the total diversity to be less than that observed. Given that the
observed diversity is likely to be a small fraction of the total diversity this represents
a considerable error. We used DivE to produce two estimates: the diversity in the
pooled sample (i.e. in 15000 cells, red cross) and the total diversity of the blood.
DivE accurately estimates the pooled sample species richness from the subsample,
but also predicts higher values of species richness in the blood, consistent with the
unseen clones implied by the pooled rarefaction curve. See Figure 2.9 for further
examples.
under-sampled populations of intermediate curvature (0.11  Cp  0.62) DivE improved
markedly (median error = 0.06), and typically outperformed the other estimators (Figure
2.11, Table 2.3). Finally, all estimators perform well when the curvature is high and most
of the diversity has been observed (Figure 2.4, panels D, H and L).
We next tested DivE using the Prochlorococcus data [93], with multiple subsamples of
increasing curvature (as for the TCR data). At low curvatures DivE again performed
poorly, but it became more accurate as the curvature increased. For under-sampled popu-
48
●●
●
●
●
●
●
●
●
●
●
●●
●●
●●
0 4000 8000
0
10
00
20
00
Patient 1
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
0 1000 3000
0
40
0
80
0
12
00
Patient 2
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
0 2000 5000
0
50
0
15
00
Patient 3
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
0 4000 8000
0
10
00
20
00
Patient 4
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
0 2000 4000
0
40
0
80
0
12
00
Patient 5
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
0 1000 3000
0
40
0
80
0
12
00
Patient 6
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
0 10000 25000
0
40
00
80
00
Patient 7
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●●
0 5000 15000
0
10
00
30
00
Patient 8
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
0 10000 20000
0
10
00
25
00
Patient 9
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
0 4000 10000
0
10
00
25
00
Patient 10
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
0 5000 15000
0
10
00
30
00
Patient 11
(E
sti
m
at
ed
) N
o. 
Cl
on
es
No. infected cells
●●
●●
●
●
Chao1bc
ACE
Bootstrap
Good−Turing
Neg−exp
DivE
subsample
pooled sample
Figure 2.9.: Ecological estimators underestimate diversity in HTLV-1 infection.
As for Figure 2.8. Ecological estimators typically estimate fewer clones than
observed in pooled sample. In contrast, DivE accurately estimates the pooled
sample species richness from a subsample.
lations of intermediate curvature, DivE again outperformed the other estimators, although
the di↵erences between the estimator errors were not as dramatic as with the TCR data
(Figure 2.12).
Very low curvatures suggest severe under-sampling and researchers should exercise caution
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Figure 2.10.: Rarefaction curvature parameter Cp. Rarefaction curves (dashed) and
lines of constant rate of species-accumulation and perfect saturation (solid)
are shown. Areas between the line of constant rate of species-accumulation
and the rarefaction curve (A), and between the rarefaction curve and the line
of perfect saturation (B) are indicated. Note Cp = 0 when the rarefaction
curve is linear.
with such data. It is unlikely that any species richness estimator will be accurate or
informative in such cases.
2.3.5. Example Application: Estimated Number of HTLV-1 Infected
Cell Clones
In both HTLV-1 infection and infection with the related bovine leukaemia virus (BLV),
accurate determination of the number of infected cell clones in the host is critical to
understanding retroviral dynamics and pathogenesis [25, 112, 113, 114]. As we have seen in
Chapter 1, estimates of the number of clones have risen steadily in line with the sensitivity
of the methods used. Charles Bangham’s laboratory has observed as many as 5000 clones
in samples derived from 10µg of DNA [11, 22, 115]. Here we make two di↵erent estimates
of the number of HTLV-1 infected cell clones: (i) in the circulation; and, (ii) in the whole
body. See Section 2.2.9 for details of HTLV-1 population size estimation.
The mean estimated number of clones in the circulation in a single host was 2.9⇥ 104. It
is unknown whether the population structure of HTLV-1 clones in the blood reflects that
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Figure 2.11.: Test of species richness estimators at di↵erent values of curvature
parameter Cp using TCR data. The curvature parameter Cp is plotted
against the relative error = |Sobs Sˆobs|Sobs of each estimator. Four patient data sets are
shown: A total CD4+ from patient C; B total CD4+ from patient E; C total CD8+
from patient C; D total CD8+ from patient E. Each point represents an estimate
from a subsample of data. Note the plots have di↵erent y-axis scales and the y-
axes in C and D are segmented. Broadly, the accuracy of all estimators improves
as Cp increases, and this increase is more pronounced for DivE. From Cp > 0.1,
DivE generally outperforms the existing estimators, but is prone to error at very
low values of Cp, when the rarefaction curve implies a near-constant rate of species
accumulation.
in solid lymphoid tissue and the spleen. If we assume that these two populations have
similar structures, and thus that it is justified to extrapolate to the whole body, we obtain
an average of 6.2 ⇥ 104 clones, i.e. approximately only twice as many clones, although
there are more than 300 times as many infected cells in the body as the blood. These new
estimates in the blood and body are approximately 1 and 1.3 logs higher respectively than
those calculated using ACE and Chao1bc (p < 0.0001, two-tailed paired Mann-Whitney
U-test), and more than 2 logs higher than previously published estimates (Figure 2.13)
[22, 24, 25, 26].
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Table 2.3.: Estimator error variation with curvature in TCR data
Estimator low1 Cp2 p3 intermediate Cp p overall p
Chao1bc 56.9 0.45 42.3 0.002 46.8 0.0015
ACE 55.0 0.45 44.2 0.002 46.6 0.0015
Bootstrap 91.4 0.45 53.0 <0.0001 72.1 <0.0001
Neg-exp 60.2 0.45 51.4 0.0002 53.9 0.0003
Good-Turing 90.0 0.45 51.4 <0.0001 69 < 0.0001
DivE 23.1 NA 6.5 7.9 NA
1 Low curvatures Cp in range 0.016  Cp  0.101, intermediate curvatures in range 0.11  Cp  0.62.
2 Median absolute percentage error between Sˆobs and Sobs.
3 p-value of the significance of the di↵erences between the errors of DivE and each other estimator, for
each curvature range.
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Figure 2.12.: Performance of species richness estimators in metagenomic data.
The curvature parameter Cp is plotted against the error of each estimator. Each
point represents an estimate from a sample from the Prochlorococcus data. As with
the TCR data, DivE typically outperforms the other estimators from Cp ⇡ 0.1
onwards. As predicted, DivE is prone to error at lower values of Cp, but becomes
more accurate as Cp increases.
2.3.6. DivE Uncertainty
Because of its heuristic nature, DivE lacks formal statistical confidence intervals. Un-
certainty in the estimates produced by DivE has two sources: parameter values in each
respective function (within-model variation), and the choice of function (between-model
variation). Using standard errors of parameter estimates to calculate confidence inter-
vals ignores uncertainty from function selection. Information theoretic approaches that
take account of model selection uncertainty have become increasingly common in ecol-
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Figure 2.13.: Diversity estimates in HTLV-1 infection by estimator. Each estima-
tor was applied to 105 patient datasets, from 14 di↵erent HTLV-1+ subjects. All
subjects either had HAM/TSP or were ACs. *** signifies p < 0.0001 respectively;
two-tailed Mann-Whitney test.
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Figure 2.14.: Rarefaction plots from bootstrap samples of HTLV-1, TCR, and
Microbial data. Rarefaction plots from 100 bootstrap samples (grey) for each of
A HTLV-1, B TCR, and C microbial data. The species richness of the bootstrap
samples is at most the species richness of the original data (black), and is substan-
tially less in the majority of cases, although this e↵ect is less noticeable with the
TCR data.
ogy [116, 117, 118] and elsewhere. There are broadly two approaches: i) computing AIC
weights, and ii) repeated resampling and model ranking to determine bootstrap model
selection probabilities [109]. However, neither approach is appropriate in our case. We
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Figure 2.15.: Validation of DivE distribution generation algorithm. The DivE dis-
tribution generation algorithm (Figure 2.3) was applied to random samples (red
dashed) of observed data (black solid). Accuracy was evaluated by comparing the
estimated distribution (orange dashed) to the true distribution of the full observed
data (black). Examples for HTLV-1 (A), TCR (B) and microbial datasets (C) are
shown.
do not rank functions using AIC since this produces less accurate estimates than DivE
(Table 2.1), and so we cannot use AIC weights to derive confidence intervals. Further,
since there is a systematic bias towards lower species richness in bootstrap samples (Fig-
ure 2.14), a similar bias may be introduced in the estimation of bootstrap model selection
probabilities, leading in turn to a bias in species richness estimation. Systematic under-
estimation in bootstrap samples is particular to species richness estimation: this does not
highlight a general problem with resampling to quantify model selection uncertainty. As
a pragmatic indicator of estimate variability, we use the range of estimates produced by
the five best-performing functions; the geometric mean of these five functions is taken as
the point estimate (Table A.2).
2.3.7. Distribution Generation Algorithm
The distribution generation algorithm was reasonably accurate for the HTLV-1 data, and
considerably more accurate for the TCR and microbial data. The mean error between the
estimated and true distributions was 32.1%, 3.7%, and 6.0% for the HTLV-1, TCR and
microbial data respectively. The mean error between the estimated and true Gini coe -
cients was 7.5%, 1.2%, and 1.1% for the HTLV-1, TCR and microbial data respectively
(Table 2.4). For the HTLV-1 data, the algorithm underestimated the abundance of the
largest clones, but we did not observe this e↵ect in the TCR and microbial data (Figure
2.15).
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Table 2.4.: Performance of DivE frequency distribution generation algorithm
Data Source Mean Error (%)1 Mean Gini Error (%)2
HTLV-1 32.1 7.5
TCR 3.7 1.2
Microbial 6.0 1.1
1 Mean error across all subjects and all small subsamples, for each data source. Small subsamples were
defined as those  50% of the size of the observed each patient data set. Error defined as the sum of
absolute discrepancies between true and estimated frequency distributions, divided by area under true
distribution.
2 Mean percentage error across all subjects and all small subsamples in the Gini coe cients of the true
and estimated distributions.
2.4. Discussion
We wished to estimate species richness in three microbiological and immunological datasets.
Initially we used estimators that are reported to perform well in ecology [56, 78, 79, 103,
104, 119]. In the datasets with rarefaction curves that did not plateau, these estimators
were biased by sample size. For datasets with rarefaction curves that did plateau, esti-
mates were consistent, but in such cases estimators contribute little information because
approximate species richness is already known. Comparable results have been reported
elsewhere [56, 60, 105]. By combining data from multiple independent HTLV-1 samples,
we showed that these estimators substantially underestimated species richness.
We then developed a new approach, DivE, to estimate species richness and frequency
distribution. In our first validation, DivE consistently and accurately estimated the di-
versity of the observed data from incomplete subsamples of that data. We subsequently
determined conditions where DivE would fail and should not be applied. When the rar-
efaction curvature was low and the data implied a near-constant species-accumulation
rate, DivE was prone to overestimation. However, in under-sampled populations of in-
termediate curvature, DivE substantially improved. The DivE distribution generation
algorithm performed with reasonable accuracy (Table 2.4, Figure 2.15). We believe there
are two principal reasons why DivE is more accurate than the other estimators. First,
functions are selected on their ability to consistently predict additional data. The addi-
tional data (i.e. the full sample) has no influence on fitted parameter values, and so DivE
not only assesses goodness of fit, but also evaluates the accuracy of the function. Second,
DivE does not require a priori assumptions regarding the form of the clonotype frequency
distribution.
We argue that biologically meaningful and useful estimators should be able to estimate
species richness in a specified population. This is not the case with the existing estimators
we tested. Any estimator that does not take population size into account e↵ectively
55
assumes saturation, i.e. that after a certain undefined point, the number of additional
individuals does not a↵ect the number of species. However, many populations do not
plateau in this way. This is particularly true of immunological populations, where many
TCR clonotypes or microbial OTUs are likely to be represented by a single individual.
Therefore, while it would be convenient not to require an estimate of population size, any
such estimator would lead to false confidence. In contrast, DivE can estimate diversity in
any given population size. However, population size estimation can be nontrivial [120, 121,
122]. In spatially homogeneous populations with equiprobable detection of individuals,
estimating population size through scaling by area or volume is justifiable e.g. scaling from
cells in 50ml of blood to cells in the total blood volume. When population size estimates
are unavailable, it is still usually possible to provide meaningful diversity estimates, e.g.
the number of microbes per gram of faeces. DivE may also be useful in deciding the depth
of sampling required for an adequate census. Deeper sampling may require more DNA
sequencing or a larger tissue sample from a patient, and so minimizing sampling depth has
financial and ethical benefits. This is not possible with the other estimators we tested.
The HTLV-1 data consisted of absolute species counts, and so we could estimate HTLV-
1 diversity. Microbial and TCR datasets were used only for validation as these data
consisted of sequence reads and not absolute counts. To the extent that read abundances
di↵er from absolute counts, such data cannot be used to estimate species richness with
any abundance-based estimator (e.g. DivE, Chao1bc, and ACE). Over-amplification by
PCR may generate a saturating rarefaction curve that is not due to sampling depth,
falsely implying that the majority of species have been observed. This can be seen in our
TCR data: plateaus were far lower than previously reported diversity estimates [90, 123].
However, absolute counts can often be obtained (e.g. by spiking a sample with a known
quantity of identifiable individuals or by barcoding to identify PCR duplicates).
It is unlikely that sequencing error influenced our HTLV-1 diversity estimates, because
sequencing error cannot systematically alter proviral integration site mapping. However,
species richness estimates from TCR or microbial data are likely to be susceptible to
sequencing error. Sequencing error can falsely increase diversity, and this will influence
species richness estimates using any estimator; researchers must therefore exercise caution
when analysing such data; ideally by preprocessing the data to remove error prior to further
analysis. Caution must also be exercised when assuming that the spatial distribution of
individuals is uniform. We believe that these assumptions are reasonable for the blood,
but skin tissue for example may be more clustered.
DivE is conceptually simple but can be computationally intensive to implement. When ap-
plying DivE to a new type of data it is necessary to ascertain which functions perform best.
This requires that many functions be fitted to multiple subsamples. If, for a particular
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data type, a given set of functions performs consistently well, application becomes much
quicker because only these functions need to be fitted, and it is no longer necessary to fit all
functions to all subsamples. In our analysis we found that the best performing functions
di↵ered between data types. In the HTLV-1 analysis, functions 8, 10, 20, 25, and 45 per-
formed best, contrasting with functions 10, 17, 20, 55, and 56 in the microbial analysis and
functions 8, 12, 16, 22, and 23 in the TCR analysis (see A.1 for function analytical forms).
Perhaps unsurprisingly, all of the best-performing functions in the TCR analysis saturated.
In contrast, in both the HTLV-1 and microbial analysis, some of the best performing func-
tions did not. These results make sense in light of the rarefaction curves displayed in Figure
2.4. In the HTLV-1 analysis, five functions performed consistently well, and we adopted
this number of functions as the basis for the DivE estimate. However, since the optimal
functions di↵er between data types, we advocate careful analysis of function scores to
decide how many functions should be aggregated. The DivE estimator has been provided
as an R package, available at http://cran.r-project.org/web/packages/DivE/index.html .
In summary, we have developed and validated a new approach to estimate species richness
and distribution that significantly outperformed existing estimators of biodiversity in the
datasets we examined.
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3. Applications of DivE
3.1. Introduction
In this chapter we present a comparison of the number of clones, as estimated by DivE, in
patients with a range of clinical manifestations of HTLV-1 infection. Many of these results
have been published in [7, 11, 124, 125]. All data were obtained by our collaborators using
the high-throughput protocol outlined in [22], summarised in Section 1.1.6.
3.2. Clonal Diversity in Adult T Cell Leukaemia /
Lymphoma
Approximately 5% of HTLV-1 infected individuals develop Adult T cell Leukaemia /
Lymphoma (ATLL) [11], an agressive malignancy of post-thymic T lymphocytes [115, 126].
There is a relatively high incidence of HTLV-1 in mothers of ATLL patients compared with
mothers of other diseases caused by HTLV-1 [127], and childhood infection is believed
to predispose HTLV-1-infected patients to develop ATLL [126]. Under the Shimoyama
classification, ATLL can be subdivided into acute, lymphoma, chronic and smouldering
subtypes [9], which di↵er in their response to treatment and associated prognosis [115].
ATLL patients have a much higher proviral load (PVL) than ACs and HAM/TSP patients
(Figure 3.1), but fewer clones are typically observed (Figure 3.2). There is usually a single
clone that has undergone malignant transformation and which consequently occupies a
large proportion of total PVL. Thus the oligoclonality index (OCI) is substantially higher
in a typical ATLL patient than for ACs and HAM/TSPs [22, 11].
We estimated the diversity of 196 patients with ATLL. Population sizes were estimated
according to equation (2.2). Samples where Cp < 0.1, or where the number of sisters was
less than 150 were excluded from the analysis (below 150 sisters renders the subsamples
required for DivE unfeasibly small), as were 100% monoclonal samples with only a single
clone (a rarefaction curve is useless in the latter case). The mean estimated number
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Figure 3.1.: HTLV-1 proviral load in ACs, ATLL and HAM/TSP patients. PVL
is greater in ATLL patients than it is in HAM/TSP patients, who have higher
PVL than ACs (p < 0.0001 for all pairwise comparisons, two-tailed Mann-
Whitney test). Three ACs with undetectable proviral loads were omitted
from plot due to log scale.
Figure 3.2.: Number of observed clones in ACs, ATLL and HAM/TSP patients.
The are fewer observed clones in ATLL patients than in HAM/TSP patients,
who have higher PVL than ACs (p < 0.0001 for all pairwise comparisons,
two-tailed Mann-Whitney test)
of clones was 3084, substantially fewer than for ACs and HAM/TSP patients, which is
unsurprising given the higher number of observed clones, higher curvature parameter Cp,
and OCI (Table 3.1).
ATLL is known to exhibit highly expanded clones and correspondingly high proviral loads.
Because highly expanded clones increase the OCI, we would expect that a high OCI would
be correlated with a low diversity, as small clones are out-competed by malignant clones.
However, it is interesting to note that, within ATLL patients, we see a positive correlation
(p < 0.0001, two-tailed paired Mann-Whitney test) between estimated diversity and OCI
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Figure 3.3.: Relationship between OCI and estimated diversity in ATLL pa-
tients. Estimated diversity (log) strongly positively correlated with OCI
(p < 0.0001, two-tailed paired Mann-Whitney test)
(Figure 3.3). A high OCI can occur through reduced diversity, but also through the
reduced share of PVL among existing clones. We conclude that highly expanded clones
suppress the abundance of smaller clones to undetectable levels, thus increasing the OCI.
Table 3.1.: Comparison of clonality of ATLL, HAM/TSP and AC patients
Disease Status PVL (%) Observed Clones Cp OCI DivE
ATLL 87.6 32 0.218 0.849 3084
HAM/TSP 8.6 1039 0.152 0.467 30272
AC 2.1 209 0.123 0.501 20679
Mean values of PVL, number of clones observed in sample, Curvature Cp, OCI and DivE given for
ATLL, HAM/TSP and AC patients. All di↵erences between groups significant: p < 0.0001 for each
pairwise comparison of each variable, except HAM/TSP vs. ATLL curvature (p = 0.004) and HAM/TSP
vs. AC OCI (p = 0.023), two-tailed Mann-Whitney test
3.3. Clonal Diversity in Asymptomatic Carriers
Approximately 90% of HTLV-1-infected patients are able to control the virus for decades
without developing disease. The mechanisms by which they are able to do so have major
implications for the development of treatment. A high proviral load (PVL) is a known
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Figure 3.4.: Comparison of HTLV-1 clonal diversity between ACs and
HAM/TSP patients in blood and body. In both the circulation and the
whole body, ACs had significantly fewer clones than patients with HAM/TSP
(p = 0.0001 and p = 0.001 for blood and body respectively; two-tailed Mann-
Whitney test)
risk factor of inflammatory disease [22], and PVL in asymptomatic carriers (ACs) is often
undetectable.
Undetectable proviral loads can inhibit or preclude a detailed analysis of the clonality of
ACs, creating a paradoxical situation whereby the patients who are the most di cult to
study are the patients who have the greatest potential to enhance our understanding of
HTLV-1 pathogenesis.
We compared the HTLV-1 clonal diversities between ACs and HAM/TSP using data from
two cohorts (Figure 3.4). The first cohort consisted of 95 HAM/TSP patients and 68 ACs
from Kagoshima, Japan, and the second consisted of 75 ACs from Kumamoto, Japan [7].
Population sizes for blood and body were estimated according to equations (2.2) and (2.3)
respectively. Samples where Cp < 0.1, or where there were less than 150 infected cells
were excluded from the analysis. Therefore the following analysis, as with all analyses of
ACs, is biased towards ACs with relatively high proviral loads.
In both the blood and the body, the estimated number of clones was significantly lower in
ACs than HAM/TSP patients (p = 0.0001 and p = 0.001 for blood and body respectively;
two-tailed Mann-Whitney test). In ACs, the median number of clones in the blood and
body were 7.3⇥ 103 and 1.7⇥ 104 respectively, whereas in HAM/TSP patients, the corre-
sponding values were 1.5⇥ 104 and 3.2⇥ 104. In both cases, estimates of clonal diversity
showed a strong correlation with PVL (Figure 3.5).
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Figure 3.5.: Relationship between clonal diversity and proviral load in Japanese
cohort of ACs and HAM/TSP patients. Estimated diversity strongly
positively correlated with proviral load (R2 = 0.247, p = 0.0002 for HAM/TSP
and R2 = 0.392, p < 0.0001 for AC, linear regression on log scale)
The estimated number of clones in these Japanese cohorts is less than the number of
clones estimated in Figure 2.13, and the di↵erence is likely due to the smaller PVL of the
Japanese cohort. The mean proviral loads of ACs and HAM/TSP patients in the Japanese
cohort was 2.0% and 7.7% respectively, compared to 4.3% and 9.6% in the cohort analysed
in Figure 2.13 and Chapter 2.
Fewer clones in ACs strongly implies less infectious spread, which in turn raises questions
about the role of infectious spread in disease progression. More precise estimation of the
ratio of infectious to mitotic spread in di↵erent patients is ongoing (see Chapter 5).
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Figure 3.6.: Comparison of HTLV-1 and HTLV-2 clonal diversity. DivE estimates
are plotted on log scale.
3.4. Relationship Between HTLV-1 and HTLV-2 Clonal
Diversity Mirrors Relationship Between Clonal
Diversity of CD4+ and CD8+ T Cells in HTLV-1
Human T-lymphotropic virus type-2 (HTLV-2) is a retrovirus that is not known to cause
inflammatory disease or malignancy of T cells, unlike the closely related retrovirus HTLV-
1. Both viruses establish a persistent lifelong infection, and are transmitted through the
sharing of contaminated needles, sexual intercourse and blood transfusion [128]. HTLV-2
does not exhibit the same endemic prevalence of Japanese islands or the Caribbean, but
instead is endemic in indigenous populations in Africa [124] and North and South America
[129]. The viruses are similar in their genomic structure [130], but they crucially di↵er in
their preferred target host cell [124]. Approximately 95% of HTLV-1 PVL is comprised of
CD4+ T cells, with the remaining 5% in CD8+ T cells. Interestingly, this ratio of infected
CD4+ T cells to CD8+ T cells is reversed in HTLV-2, where almost 100% of infected cells
are CD8+ but infected CD4+ are detected [124].
Here we compare the clonal diversity in the circulation of HTLV-1 and HTLV-2 in 16
HTLV-1+ patients (9 ACs, 7 HAM/TSP patients) and 28 HTLV-2+ patients. HTLV-2
proviral load is defined in the same way as for HTLV-1, i.e. by the number of viral copies
as a fraction of PBMCs, and so population size estimates were again performed using
equation (2.2), as for HTLV-1. We then show that the relationship between HTLV-1 and
HTLV-2 clonal diversities is similar to the relationship between the clonalities of HTLV-1-
infected CD4+ and CD8+ T cells, using another cohort of 6 HAM/TSP patients 6 HTLV-1
ACs.
Figure 3.6 shows DivE estimates of clonal diversity for HTLV-1 and HTLV-2. The mean
number of clones for the HTLV-1 patients was 2.0 ⇥ 104, substantially higher than for
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Figure 3.7.: HTLV-1 clonal diversity of infected CD4+ and CD8+ T cells. DivE
estimates are plotted on log scale. Estimates are from samples where HTLV-
1+ cells were sorted for CD4+ phenotype (red), CD8+ phenotype (blue), the
sum of estimates from these samples (purple), and estimates from samples
that were not sorted by T cell phenotype (green). There is broad agreement
between the sum of estimates from CD4+ and CD8+ samples, and the esti-
mates of clonal diversity form the unsorted samples.
the mean diversity of HTLV-2 patients at 1253 clones. The di↵erence does not appear to
be attributable to the number of infected cells, because the mean values of PVL in this
cohort are 6.1% and 9.3% for HTLV-1 and HTLV-2 respectively. Indeed the di↵erence in
diversity and the similarity in PVL strongly suggests that mitotic spread makes a greater
contribution to HTLV-2 persistence than it does to that of HTLV-1. Since HTLV-2 is
not associated with disease, it is therefore possible that the level of infectious spread is a
determinant of disease status. If true, a potential mechanism would be that fewer instances
of infectious spread will decrease the probability of proviral integration in regions of the
genome that are vital to the host, for example in cell-cycle maintenance and replication.
In the second cohort, we estimated the diversity of HTLV-1 clones in CD4+ and CD8+
T cells, as well as total diversity from unsorted samples, using data generously provided
by our collaborators Melamed et al (manuscript in preparation). CD4+ and CD8+ T
cells were magnetically sorted using MACS (Miltenyi), whereupon HTLV-1 integration
site data for each population was obtained using the high-throughput protocol described
in Section 1.1.6. The data includes the proportions (pCD4 and pCD8) of HTLV-1-infected
cells that were CD4+ and CD8+ respectively, and so population sizes NCD4 and NCD8
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were estimated by
NCD4 = 5⇥ 3⇥ PV L
100
⇥ 109 ⇥ pCD4 = Nblood ⇥ pCD4 (3.1a)
NCD8 = 5⇥ 3⇥ PV L
100
⇥ 109 ⇥ pCD8 = Nblood ⇥ pCD8 (3.1b)
The mean estimated number of clones was 2.7⇥104 in CD4+ T cells and 1.7⇥103 in CD8+
T cells (Figure 3.7). Remarkably, these estimates strongly resemble the clonal diversities of
HTLV-1 and HTLV-2. There is also a reasonable agreement between the sum of estimated
diversities of CD4+ and CD8+ T cells (mean 2.8⇥ 104) and the estimated diversity from
samples that were not sorted for T cell phenotype (mean 2.4⇥ 104 clones) (Figure 3.7).
These estimates suggest that the preferred target cell, in addition to the genomic loca-
tion of the proviral integration site, influences the proviral population structure and the
pathogenesis of infection. There may be a quality intrinsic to CD8+ T cells that renders
their infection less harmful to the host than infection of their CD4+ counterparts.
3.5. HTLV-1 Clonality in Early Infection
HTLV-1 infection has a long clinical latency period in patients who go on to develop
malignancy or inflammatory disease [113]. Patients do not typically present symptoms
until a stable population structure of HTLV-1 clones has already been established, and
thus comparatively little is known about early infection. Here we present DivE estimates
for three immune-suppressed patients who contracted HTLV-1 after exposure to solid
organ transplantation. The circumstances of these patients’ infection is highly unusual,
and so the following diversity estimates must be considered as a proxy for the clonality of
early normal HTLV-1 infection.
Integration site abundance data were available for three timepoints for patient A, four
timepoints for patient B, and five timepoints for patient C. It was hoped that these data
would enable estimates of clonal diversity over time and inform how the viral population
structure is established, but unfortunately after excluding data points where either the
number of cells was less than 150, or where Cp < 0.1, few data points remained. Population
sizes were estimated using Equation (2.2). The date of infection was taken to be the date
of transplantation.
We were able to estimate the clonal diversity for all three data points for patient A. The
number of clones was 2.3 ⇥ 105 at 38 days post infection, which decreased by half to
1.1⇥ 105 clones at 93 days post infection, and then increased slightly to 1.3⇥ 105 clones
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at 133 days post infection. The dramatic decrease can be attributed to the patient’s PVL,
which decreased by more than an order of magnitude in between the first two timepoints.
In patient B, only two timepoints were feasible. Between 50 and 77 days post infection,
the number of clones increased from 9.4 ⇥ 104 to 1.7 ⇥ 105, again in line with their PVL
which increased by a factor of four. For patient C, DivE estimates were only possible for
a single time point at 182 days post infection, where the number of clones was 7.1⇥ 103.
The mean number of clones over all patients and time points was 1.2⇥ 105, substantially
higher than for HAM/TSP patients and ACs. The relatively low curvature of the sample
may be responsible for overestimating the patients’ clonal diversity. However it is not
straightforward how best to reconcile high diversity in the presence of low curvature.
Highly diverse populations would indeed produce a rarefaction curve with a lower curvature
than would a low diversity population. It may also be true that the number of clones is
greater in these patients because of immune suppression as a result of transplantation.
3.6. Comparison of HTLV-1 Clonality in Blood and Skin
Infective dermatitis associated with HTLV-1 (IDH) is the most common manifestation of
disease in HTLV-1-infected children [131, 132]. It is a chronic eczema, and there is some
evidence that presentation of IDH in patients without neurological symptoms predicts later
progression to HAM/TSP [133, 134]. We compare the number of clones in the circulation
and in the skin, using a data set with 10 blood samples and 10 skin samples from 6 patients
with IDH.
We cannot estimate the clonal diversity of the skin as we can for the blood, because
there are complicating factors in population size estimation and in the extent to which
samples are reflective of the total skin tissue. Because the distribution of infected cells in
the skin is non-uniform, we cannot utilise two important simplifying assumptions. First,
that the population is homogeneous (i.e. that samples taken from one location do not
systematically di↵er from samples taken from another). Second, that infected cells are
sampled independently, randomly, and with an equal probability of detection. On the
contrary, di↵erent areas of skin have di↵erent concentrations of infected cells, and tissue
samples are purposefully chosen from visible skin lesions and thus are highly non-random.
Further, while it is safe to assume the random mixing of infected cells in the blood, this
assumption is less tenable for the skin. Because there will be a higher concentration of
HTLV-1-infected cells in our skin samples than the rest of the skin, we also cannot estimate
the population size via scaling as we do in equations (2.2) and (2.3).
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Figure 3.8.: DivE estimates in the blood and skin of patients with IDH.
Nevertheless, the clonality of the skin remains of interest, as does its relationship to the
clonality of the circulation. Cautioning that the skin estimates are taken from a population
where homogeneity cannot be assumed, we estimated the diversity of the blood and skin
at a standardised population size of 105 infected cells to facilitate comparison. As before,
samples where Cp < 0.1 or where the number of sisters was less than 150 were excluded
from the analysis. The median number of clones was 1458 and 7904 in the skin and blood
populations respectively (p = 0.0006; two-tailed Mann-Whitney test).
The greater diversity of the blood is perhaps surprising in light of the fact that there is
no significant di↵erence between the clonality index or curvatures of the two populations.
Further, the di↵erence cannot be attributed to PVL, since an standardised population size
that does not depend on PVL was used. It is also revealing that these diversity estimates,
while lower than those of ACs and HAM/TSP patients, are based on a substantially
smaller population size (105 rather than ⇠ 1011 infected cells), suggesting that the bulk
of diversity is contained in a relatively small proportion of PVL. This implies that a near
complete census could be obtained with blood samples that are large but still feasible.
3.7. Discussion
A di culty of using DivE is in deciding whether to fit all candidate functions to the data,
or whether to use functions that have previously performed well on data that is similar to
the population that is to be examined. While the former will produce estimates that are
more data-specific, the estimates are rendered less suitable for comparison. That is, are
the diversity estimates between two populations di↵erent because of the populations, or
because of the function chosen?
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Using functions that have performed well previously avoids this issue, but is not a vi-
able option where the data sources are markedly di↵erent, or where there are strong a
priori reasons to believe the relationship between population size and diversity may be
qualitatively di↵erent. Ultimately, because DivE is a heuristic estimator, deciding which
approach is most appropriate will depend on the problem at hand.
Two lines of evidence point to infectious spread as a driving determinant of inflammatory
disease and malignancy. First, the number of clones is substantially lower in ACs than in
HAM/TSP patients, and this has been observed across multiple cohorts. Second, HTLV-2
is much less clonally diverse, but has not been associated with disease or malignancy.
At first, however, the hypothesis that infectious spread correlates with disease status
appears di cult to reconcile with the fewer observed and estimated clonal diversities of
leukaemic patients. Still, it is highly plausible that greater infectious spread increases the
probability of proviral integration in (and disruption of) essential cell-maintenance regions
of the host genome. If a malignant clone is established, a polyclonal background (i.e. a
population of clones with a low OCI) will eventually change to a monoclonal background
as the malignant clone out-competes the other clones. That is, leukaemic patients may
initially have a higher diversity that vanishes upon malignant transformation of a single
clone.
Alternatively, it may be that it is simply high PVL that causes more clones, and that the
per-capita rates of infectious spread do not di↵er between patients with di↵erent diseases.
If so, this implies that infectious spread does not play a role in determining disease status.
However, this explanation would not account for the di↵erences in observed and estimated
clonal diversities of HTLV-1 and HTLV-2, where the proviral loads are similar, and so this
explanation is less likely.
In Chapter 5, we develop a model of within-host HTLV-1 dynamics that will infer rates
of infectious and mitotic spread. In the next chapter, we outline and develop stochastic
mathematical methods required by our within-host model.
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4. Stochastic Modelling: Birth-Death
Processes
In this chapter, we introduce the concepts and techniques we will use to model the within-
host dynamics of HTLV-1 persistence. We define the master equation, and provide an
explicit derivation of this quantity for a mass-action birth-death process. In particular, we
explore approximations that avoid expensive numerical computation of the solution to the
master equation. The concepts explored in this chapter will form the basis of the eventual
model that is developed and applied in Chapter 5.
4.1. Introduction
Ordinary di↵erential equations (ODEs) are ubiquitous in mathematical modelling. They
are used in a wide variety of biological contexts, for example viral infections [38, 135, 136,
137], epidemiology [138, 139, 140], microbiology [141, 142], immunology [136, 143, 144,
145, 146], and genetics [147]. ODEs, often referred to as “reaction rate equations” [148],
are deterministic: given a set of initial conditions and details of the ODEs, the state of
the system at any time t can be computed, at least numerically.
In many situations, however, deterministic models do not adequately encompass all that
we need to know about a system [149, 150, 151], in particular its inherent uncertainty
[152]. Broadly, we can view the outcome of a deterministic model as the expected value of
the system [153]. This is usually appropriate where the number of particles in the system
is large and where random e↵ects can be neglected. However, when there are small particle
numbers [154, 155] or when the system is highly variable, we may be interested in a range
of possible outcomes, as here the signal to noise ratio is low and random e↵ects have a
larger relative e↵ect on the system [156, 157]. In addition, the expected value of the system
can actually be misleading. First, the expected value may not be an integer (i.e. ODEs are
continuous), and most biological applications of interacting individuals and species require
a discrete state space [153]. Rounding will represent a greater error in small values than
in large values. Second, and more subtly, the expected value may be highly improbable
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Figure 4.1.: Example non-normal probability distribution function. In this bi-
modal distribution (black), the expected value, which approximately equals
the value predicted by an ordinary di↵erential equation, does not correspond
to a state or frequency (x) that is actually likely. Here a deterministic model
is inappropriate, as is an assumption of normality about the mean (normal
distribution given in orange).
when the probability distribution is non-normal, in which case it will no longer correspond
to a “typical” value (Figure 4.1).
Stochastic modelling is used to answer the questions: i) how probable is each possible
outcome and ii) how do these probabilities change with time? Deterministic modelling
can be used to answer these questions, but additional assumptions must be made about
the form of the probability distribution, for example that deviations from the predicted
value follow a normal distribution [158, 159]. This assumption is not always appropriate,
and stochastic modelling is becoming more common in mathematical biology [156, 157].
For example, branching processes have been used to study early HIV infection [160], HIV
latency [161], HIV epidemiology [162], and the MMR outbreak [163]. Random walks have
been used to model tumour angiogenesis [164], animal movement [165], and chemotaxis
[166]. Stochastic di↵erential equations (SDEs) are employed in modelling gene regulatory
networks [167], and systems biology [152]. Perhaps the most commonly used stochastic
modelling approach is the Stochastic Simulation Algorithm (SSA) of Gillespie [153], which
has been used in cell physiology [168], HIV [137, 161], biotechnology [154] gene regulation
[155], as well as in its original motivation in chemical kinetics [151, 169]. The Gillespie
algorithm is an implicit solution of the Chemical Master Equation (CME), which will
be the main focus of this chapter. The CME o↵ers an elegant and complete description
[151] of many biological systems (e.g. HIV [161], gene expression [170], intracellular virus
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dynamics [156], E. Coli [149, 171], and cell division [157, 172]), but it is rarely solved
explicitly because it is usually prohibitively large [168, 173, 174]. Branching processes,
random walks, the Gillespie algorithm and the master equation provide a description of
the inherent uncertainty of the system under examination, albeit with the consequence
that their use usually requires substantial computational time [137, 152, 161].
4.2. Master Equation
The following has been described previously [173] and is presented here for completeness.
Consider a system with a discrete number of individuals, where each individual belongs
to exactly one species or type. Assume that there are S 2 N species (S1,S2, ...,SS),
and that species Si has a frequency Xi(t) 2 N0 = N [ {0} at time t. Assume further
that all individuals of the same species are identical, and that the position or location of
any one individual of any species may be regarded as uniformly distributed (i.e. spatial
homogeneity is assumed). Then the vector X(t) = (X1(t), X2(t), , XS(t))T 2 NS0 is a
random variable that describes the population of the system at time t. Suppose that
there are R reactions R1, ...,RR that can happen in the system, where a reaction Rr
(r 2 {1, ..., R}) is given by
Rr : NS0 cr ! NS0 (4.1a)
Rr :
SX
i=1
INri Si cr7 !
SX
i=1
OUTri Si (4.1b)
Rr : INr1S1 + ...+ INrSSS cr7 ! OUTr1 S1 + ...+ OUTrS SS (4.1c)
where INri 2 N0 is the number of particles of the ith species required for the rth reaction,
OUTri 2 N is the number of particles of the ith species present after the rth reaction, and
cr > 0 is the reaction constant. cr is closely related to the reaction rate constant, and
represents the average probability that a particular combination of
PS
i=1 
IN
ri Si individuals
will react according to reaction Rr in an infinitesimal time interval dt [151, 153]. We define
the stoichiometric vector ⌫r as the di↵erence to the state vector X(t) made by reaction r
⌫r =
 
OUTr1   INr1 , ..., OUTrS   INrS
 T 2 ZS (4.2)
The propensity function ↵r of reaction Rr is the reaction constant cr multiplied by the
number of di↵erent combinations of individuals required for reaction Rr, and is given by
↵r(x) = cr
SY
i=1
xiCINri = cr
SY
i=1
 
xi
INri
!
= cr
SY
i=1
xi!
(xi   INri )!(INri )!
(4.3)
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for a potential state of the system x = (x1, x2, ..., xS)T 2 NS0 (i.e. xi is the number of
particles of species Si). The evolution of the state vector X(t) is given by
X(t) = x0 +
RX
r=1
Pr
✓Z t
0
↵r(X(s))ds
◆
⌫r (4.4)
for x0 2 NS0 . Equation (4.4) states that the population X(t) at time t is equal to the
initial population x0 plus the sum over all reactions r of the change ⌫r to the population
induced by each reaction, multiplied by the (random) number of times the reaction has
occurred. The number of times each reaction occurs is given by a Poisson distribution
in the time interval [0, t] with expected value of
R t
0 ↵r(X(s))ds, i.e a Poisson distribution
Pr
⇣R t
0 ↵r(X(s))ds
⌘
⌫r.
4.2.1. Example: Classical Model of Within-Host HIV Infection
It is helpful to provide an example to make the preceding section less abstract. We
consider a simple model of the within-host dynamics of HIV infection, originally proposed
in [40]. Consider populations of uninfected cells x, infected cells y, and cell free virus
particles (virions) v. Uninfected cells are created at a constant rate  , and die at a rate
hx. Infected cells are produced at a rate  xv when uninfected cells and virions meet, and
die at a rate ay. Finally, virions are produced from infected cells at a rate ky and die at
a rate uv. This leads to the following system of ODEs.
x˙ =    hx   xv (4.5a)
y˙ =  xv   ay (4.5b)
v˙ = ky   uv (4.5c)
In this model, there are three “species” (S1 = X ,S2 = Y, and S3 = V) and six reactions,
so S = 3 and R = 6. The reactions are as follows (c.f. Equation (4.1c))
R1 : ⇤   ! X (4.6a)
R2 :X h ! ⇤ (4.6b)
R3 :X + V   ! Y + V (4.6c)
R4 :Y a ! ⇤ (4.6d)
R5 :Y k ! Y + V (4.6e)
R6 :V u ! ⇤ (4.6f)
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where ⇤ is defined to mean “no species” (i.e. reaction R1 creates species X from source
and reactions R4 and R6 are destructive). Letting X(t) = (x(t), y(t), v(t))T , the reactions
have the following stoichiometric vectors and propensities (c.f. equations (4.2) and (4.3)):
⌫1 =
0B@10
0
1CA , ⌫2 =
0B@ 10
0
1CA , ⌫3 =
0B@ 11
0
1CA , ⌫4 =
0B@ 0 1
0
1CA , ⌫5 =
0B@00
1
1CA , ⌫6 =
0B@ 00
 1
1CA ,
↵1(X(t)) =  ⇥ (xC0 ⇥ yC0 ⇥ vC0) =   , ↵2(X(t)) = h (xC1 ⇥ yC0 ⇥ vC0) = hx,
↵3(X(t)) =   ⇥ (xC1 ⇥ yC0 ⇥ vC1) =  xv , ↵4(X(t)) = a⇥ (xC0 ⇥ yC1 ⇥ vC0) = ay,
↵5(X(t)) = k ⇥ (xC0 ⇥ yC1 ⇥ vC0) = ky, ↵6(X(t)) = u⇥ (xC0 ⇥ yC0 ⇥ vC1) = uv
So a stochastic description of the deterministic system (4.5) is given by the random variable
X(t) = (x(t), y(t), z(t))T , where
X(t) =
0B@x0y0
v0
1CA+ P1✓Z t
0
 ds
◆0B@10
0
1CA+ P2✓Z t
0
hxds
◆0B@ 10
0
1CA+ P3✓Z t
0
 xyds
◆0B@ 11
0
1CA
+ P4
✓Z t
0
ayds
◆0B@ 0 1
0
1CA+ P5✓Z t
0
kyds
◆0B@00
1
1CA+ P6✓Z t
0
uvds
◆0B@ 00
 1
1CA (4.7)
4.2.2. Relationship Between ODEs and Expected Value of Stochastic
System
The stochastic process and the deterministic ODE model are related in the following way.
If stochastic e↵ects can be ignored, the population can be described with a deterministic
process z(t) 2 NS0 given by [175, 176]
z(t) = z0 +
RX
r=1
✓Z t
0
↵r(z(s))ds
◆
⌫r (4.8)
and we derive
d
dt
[z(t)] =
d
dt
"
z0 +
RX
r=1
✓Z t
0
↵r(z(s))ds
◆
⌫r
#
=
RX
r=1
↵r(z(s))⌫r (4.9)
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Note the similarity between Equation (4.8) and Equation (4.4). Taking the time-derivative
of the expected value of Equation (4.7) in the above HIV infection example, we have
˙z(t) =
0B@x˙y˙
v˙
1CA =  
0B@10
0
1CA+ hx
0B@ 10
0
1CA+  xy
0B@ 11
0
1CA+ ay
0B@ 0 1
0
1CA+ ky
0B@00
1
1CA+ uv
0B@ 00
 1
1CA
(4.10)
which is equal to the original system of ODEs in (4.5)
4.3. Master Equation: Mass-Action Rate Birth-Death
Process
The probability distribution associated to the random variable X(t) 2 NS0 in (4.4) is given
by P(X; t) = P(X(t) = x|X(0) = x0). Here P(X; t) is a column vector where each entry
is a probability associated to a potential state of the random variable. It can be shown
[177, 178, 179] that P(X; t) the solution to the Chemical Master Equation (CME)
@P(X = x ; t)
@t
=
RX
r=1
(↵r(x  ⌫r)P(X = x  ⌫r; t)  ↵r(x)P(X = x; t)) (4.11)
We can interpret Equation (4.11) as follows: the rate of change in the probability of the
state taking value X(t) = x is the sum over all reactions r of the probability of arriving
at state X(t) = x via reaction r (having previously been in state X(t) = x   ⌫r) minus
the probability of leaving state X(t) = x via reaction r. We explicitly derive the master
equation for a mass-action birth-death process of a single species, the properties of which
we will explore later in this chapter.
Consider a species X that can take values x 2 N0, and where individuals of the species can
proliferate and die respectively with per-capita rates ⇡ and  . In this case the state vector
is X(t) 2 N0, and a “state” of the system corresponds to a “frequency” of the species (we
use both terms interchangeably). We assume that proliferation and death occur without
contact between individuals, so we have mass-action propensities ↵1(X(t) = x) = ⇡x and
↵2(X(t) = x) =  x, where X(t) is the random variable associated with the frequency of
species X at time t. We have the following reactions
R1 :X ⇡ ! X + X (4.12a)
R2 :X   ! ⇤ (4.12b)
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Figure 4.2.: Mass action birth-death process flow diagram. The potential states (in
this case frequencies) the species can take are shown, along with the propensity of
each reaction at each state. Note that there is no upper bound of species frequency,
and there is no source inflow from 0 to 1 .
The dynamics of this birth-death process are summarised in Figure 4.2. What is the
probability P(X(t) = x) that species X takes frequency x at time t?
Consider a time interval  t, small enough such that at most a single reaction can take
place in the interval [t, t + t]. Species X can thus take frequency x 2 N at time t + t
only when it was in one of three states at time t: i) X(t) = x; ii) X(t) = x   1; iii)
X(t) = x+ 1, that is: i) if nothing happened; ii) if an individual proliferated; or iii) if an
individual died. Hence
P (X = x; t+ t) = P (X = x; t+ t |X = x; t) ⇥ P(X = x; t)
+ P (X = x; t+ t |X = x  1; t)⇥ P(X = x  1; t)
+ P (X = x; t+ t |X = x+ 1; t)⇥ P(X = x+ 1; t)
(4.13)
We can rewrite Equation (4.13) informally as
P (X = x; t+ t) = P
 
NOTHING from x
 ⇥ P(X = x; t)
+ P
⇣
BIRTH from x  1
⌘
⇥ P(X = x  1; t)
+ P
⇣
DEATH from x+ 1
⌘
⇥ P(X = x+ 1; t)
(4.14)
We make use of the following property,
P (X = y; t+ t |X = x; t) = P (X = y; t |X = x; 0) (4.15)
for any x, y 2 N0. This property states that the probability of an event is constant
over time. Consider the probability mass function fPois of the Poisson distribution. The
probability fPois(k; ) of k events occurring at an average rate of   is given by
fPois(k; ) =
e   k
k!
(4.16)
The expected number of births from state x in the interval [0, t] is given by
R  t
0 ⇡xdt =
⇡x t (note that here x is a constant). Hence our Poisson process describing k births from
75
state x in time interval  t becomes
fPois(k; t|⇡x) = e
 ⇡x t(⇡x t)k
k!
(4.17)
So the probability of there being zero births from state x in [t, t+ t] is given by
P(No births from x ) = e
 ⇡x t(⇡x t)0
0!
= e ⇡x t = 1  ⇡x t+O(( t)2) (4.18)
Similarly we have,
P(No deaths from x ) = 1   x t+O(( t)2) (4.19)
P(1 birth from x  1 ) = (x  1)⇡ t+O(( t)2) (4.20)
P(1 death from x+ 1 ) = (x+ 1)  t+O(( t)2) (4.21)
Combining equations equations (4.18) and (4.19), we obtain
P
 
NOTHING from x
 
= P(No births from x )⇥ P(No deaths from x )
= 1  (⇡ +  )x t+O(( t)2)
(4.22)
so Equation (4.13) becomes
P (X = x; t+ t) = [1  (⇡ +  )x t]⇥ P(X = x; t)
+ [(x  1)⇡ t] ⇥ P(X = x  1; t)
+ [(x+ 1)  t] ⇥ P(X = x+ 1; t)
+O(( t)2)
(4.23)
Hence
P (X = x; t+ t)  P(X = x; t)
 t
=   x(⇡ +  )⇥ P(X = x; t)
+ (x  1)⇡ ⇥ P(X = x  1; t)
+ (x+ 1)  ⇥ P(X = x+ 1; t)
+O(( t))
(4.24)
Letting  t! 0, we obtain the master equation of our birth-death process
@ (P(X = x; t))
@t
=   x(⇡ +  )⇥ P(X = x; t)
+ (x  1)⇡ ⇥ P(X = x  1; t)
+ (x+ 1)  ⇥ P(X = x+ 1; t)
(4.25)
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Figure 4.3.: Mass action birth-death process flow diagram: truncated state
space. As for Figure 4.2, except for the imposition of an upper bound ⌧ of species
frequency.
for x > 1. Similarly, for x = 1, we have
@ (P(X = 1; t))
@t
=   (⇡ +  )⇥ P(X = 1; t)
+ 2  ⇥ P(X = 2; t)
(4.26)
and for x = 0,
@ (P(X = 0; t))
@t
=   ⇥ P(X = 1; t) (4.27)
4.3.1. Transition Matrix
If there is no upper limit on the frequency a given species can take, the state space is
given by ⌦ = N0. If however a species can only reach a maximum frequency of ⌧ 2 N,
then our state space is given by ⌦⌧ = {0, ..., ⌧}, shown in Figure 4.3. We refer to ⌦⌧ as a
“truncated state space”. Using ⌦⌧ , we can summarise Equation (4.25) by [150, 180]
dP(X; t)
dt
= AP(X; t) (4.28)
where A is a ⌧ ⇥ ⌧ transition matrix, given by
A =
0BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB@
0 1 2 · · · · · · · · · x · · · · · · · · · ⌧   1 ⌧
0 0   0 · · · · · · · · · 0 · · · · · · · · · 0 0
1 0  (⇡ +  ) 2  · · · · · · · · · 0 · · · · · · · · · 0 0
2 0 ⇡  2(⇡ +  ) . . . 0 0 0
3 0 0 2⇡
. . .
. . . 0 0 0
...
...
...
...
. . .
. . .
. . .
...
...
...
...
...
...
...
. . .
. . . x 
...
...
...
...
...
...
. . .  x(⇡ +  ) . . .
...
...
...
...
...
... x⇡
. . .
. . .
...
...
...
...
...
...
...
. . .
. . .
. . .
...
...
...
...
...
. . .
. . . (⌧   1)  0
...
...
...
...
...
. . .  (⌧   1)(⇡ +  ) ⌧ 
⌧ 0 0 0 · · · · · · · · · 0 · · · · · · · · · (⌧   1)⇡  ⌧ 
1CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCA
(4.29)
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The following hold:
1.
P
iAij = 0 8j
2. Aij   0 8i 6= j
3. Aij  0 8i = j and
4. Aii =  
P
j 6=iAij
Note that the species can “bounce” from the upper bound ⌧ back to ⌧   1 , but cannot
escape from 0 to 1 . The transition matrix (sometimes named a stochastic matrix,
the “state companion matrix” in control theory [181], or the “infinitesimal generator of
a continuous-time Markov chain (CTMC)” [182]) gives the reaction rates that can occur
between all states of the system in a single infinitesimal step  t. For example, if reaction
R2 occurs when the system is at state 3 , the systems will move to state 2 , and so
A32 = 3 . For i 6= j, the propensity of a transition from state j to state i in k infinitesimal
steps is given by (Ak)ij . For i = j, Aij can be interpreted as the rate of change of
probability from a given state i to any other state j.
In our system above, A does not have any time-dependent factors, and so Equation (4.28)
has solution
P(X; t) = eAtP0 (4.30)
where P0 = P(X; 0) is the initial probability distribution and eAt is the matrix exponential
[182].
4.3.2. Initial Probability Distribution
The initial probability distribution P0 2 R⌧ [182] can be used to enter a fixed initial value,
in which case we have for initial value X(0) = x0 and x 2 {0, ..., ⌧}
P0 =  x,x0 (4.31)
where  x,x0 [183] is the Kronecker delta such that [183]
 x,x0 =
8<:1, if x = x00, if x 6= x0 (4.32)
However, P0 does not have to be restricted to a fixed (deterministic) initial value in a
stochastic system. Any discrete probability distribution on the state space (in our case
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{0, ..., ⌧}) is acceptable, and can be used to model the uncertainty of the initial state of
the system. For example, in the fixed case where x0 = 2, or when we are uncertain over
the input, we may have respectively
P0 =
0BBBBBBBBB@
0 0
1 0
2 1
3 0
...
...
⌧ 0
1CCCCCCCCCA
and P0 =
0BBBBBBBBB@
1 0.3
2 0.5
3 0.1
4 0.05
...
...
⌧ 0.00001
1CCCCCCCCCA
(4.33)
4.3.3. Matrix Exponential
The matrix exponential is defined as follows. If M 2 C is an m⇥m square matrix m 2 N,
then the matrix exponential is given by
exp(M) = eM =
1X
k=0
1
k!
Mk (4.34)
The quantity Mk is always defined since M is finite and square. Intuitively, eAt denotes
the probability of starting at state j and finishing at state i in the time interval [0, t], and
so we have
⌧X
i
(eAt)ij = 1 8j 2 {1, ..., ⌧} (4.35a)
0  (eAt)ij  1 8i, j 2 {1, ..., ⌧} (4.35b)
For a, b 2 C, we have
e0 = Im (4.36a)
eaM+bM = eaMebM (4.36b)
where Im is the m⇥m identity matrix defined as
(Im)ij =  ij =
8<:1 if i = j0 if i 6= j (4.37)
Equation (4.36a) can be reconciled with the intuitive interpretation of eAt. If t = 0, then
eAt = e0 = I⌧+1 =  ij . That is, after zero time has elapsed, the probability of starting at
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state i and remaining at state i is 1, and the probability of moving to any other state j 6= i
is 0. In our example (Figure 4.3), indexing state 1 as the state 0 , we have (eAt)11 = 1
and (eAt)i1 = 0 8i 6= 1 because a species cannot proliferate once it is extinct and we do
not have a source or inflow, i.e. there is no flow out of state 0 to any other state.
Computing the matrix exponential is straightforward in principle, but considerably more
di cult in practice when the dimension of the M is large [184]. Because of the role of
the matrix exponential in solving linear di↵erential equations, finding reliable and e cient
approximations of the calculation is an ongoing area of research [181, 184, 185, 186].
Compounding this problem, the probability distribution is often desired for multiple time
points (i.e. to obtain the evolution of the probability distribution). Fortunately however,
the probability distribution for a series of time points can be calculated recursively using
a single matrix exponential. More precisely, if the propensities do not change with time,
for a given time step s, we can compute the matrix exponential eAs, and then recursively
calculate the probability distribution at any time that is a multiple of s. Using Equation
(4.36b), for k 2 N0, we have the following recurrence relation:
P(X = x ; t = s) = eAsP0 (4.38a)
P(X = x ; t = ks) = eAsP(X = x ; t = (k   1)s) (4.38b)
In long form, we have
P(X = x ; t = ks) = eAksP0 =
 
eAs
 k
P0 = e
AsP(X = x ; t = (k   1)s) (4.39)
This is important in that it means the computationally expensive [184] matrix exponential
eAs only needs to be calculated once, and then recursively multiplied k times to P0. While
k may be large, for our purposes matrix multiplication k times incurs significantly less
runtime than calculating the matrix exponential k times.
In the following section we explore novel consequences of the birth-death process described
in Figure 4.3 for a range of proliferation and death parameters. We examine potential
approximations to P(X = x ; t) that can save substantial runtime without distorting the
probability distribution. It is important to note that, in contrast to other birth-death
processes examined [173, 174, 187, 188] there is no source inflow from 0 to 1 in our
birth-death process. That is, we do not have a reaction Rj such that
Rj : ⇤   ! X (4.40)
like there is in, for example, reaction R1 (4.6a) of the HIV example. In many situations,
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it does not make biological sense for there to be a constant inflow into the species. For
example a species cannot proliferate once it has become extinct.
In our simulations, we use the expm function in the R package matrix [97, 189] to calculate
the matrix exponential, which uses the Pade´ approximation.
4.4. Properties of Birth-Death Process Without Source
Inflow
4.4.1. Evolution of Extinction Probability
The master equation can explicitly model the probability that a given species takes fre-
quency or state 0 at time t. That is, we can calculate the probability of extinction as a
function of time. This would not be possible using an ODE to model a birth-death process
described in Figure 4.3. If a given species has a higher death rate than proliferation rate,
we would intuitively expect the species to eventually become extinct. In such an ODE
model, the predicted frequency of the species will decrease to an asymptote of 0, but will
never actually reach this value. We model the evolution of the extinction probability using
a range of values of proliferation ⇡, death   and starting frequency x0 (Figure 4.4).
Four parameter sets ✓k = {⇡k,  k}, k 2 {1, 2, 3, 4} were randomly chosen from a uniform
distribution U(0, 1). For each parameter set, two starting frequencies x0 were randomly
chosen from a uniform distribution U(1, ⌧/3), where ⌧ = 500 and ⌧/3 was chosen so that
the boundary ⌧ would not adversely a↵ect results (see Section 4.4.2). In all cases, the
extinction probability at time t, P(X = 0 ; t) = P(Ext; t) was strictly increasing and
approached an asymptote (Figure 4.4). We define P(Ext)⇤ to be the asymptote of the
extinction probability, and this value is determined by the interplay between the values of
⇡,   and x0. By inspection, based on our numerical simulations, the value of the asymptote
appears to be given by the function
P(Ext)⇤ = h(⇡,  , x0) = min
⇢✓
 
⇡
◆x0
, 1
 
(4.41)
We tested this prediction using the randomly chosen parameters and starting values above.
In all cases, h(⇡,  , x0) correctly predicted the value of the asymptote (Figure 4.4).
Because there is no flow from state 0 to any other state, the probability of extinction must
increase over time. While this makes sense, it can be counterintuitive in certain situations.
If we consider a growing species (i.e. ⇡ >  ) that starts from a relatively high frequency
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Figure 4.4.: Evolution of Extinction Probabilities for range of parameters. All
plots show a strictly increasing extinction probability over time, eventually
approaching an asymptote (red line), given in Equation (4.41). The vertical
blue line denotes the minimum time text such that (P(X = 0; text)   P(X =
0; text   1)/P(X = 0; text   1) < 1/1000.
x0, a deterministic formulation would suggest that as the species frequency increases, the
probability of extinction decreases. However, when we consider the stochasticity of the
system, it is simply that the expected frequency increases.
If we again index state 0 as state number 1, we have for x 2 ⌦, P(X = 0; t) = P(X =
x; t)11, i.e. the first value in the m⇥ 1 state probability vector. Then by Equation (4.38),
P(X = x; t+ t)11 =
⌧X
j=1
 
eA t
 
1j
⇥ P(X = x; t)j1 (4.42)
P(X = x; t+ t)11 =
  
eA t
 
11
⇥ P(X = x; t)11
!
+
0@ ⌧X
j=2
 
eA t
 
1j
⇥ P(X = x; t)j1
1A
(4.43)
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Since
 
eA t
 
11
= 1, (i.e. remaining at state 0 having started at state 0 is certain for all
t   0), and since  eA t 
1j
  0 and P(X = x; t)j1   0, we have
P(X = x; t+ t)11  
 
P(X = x; t)11
!
(4.44)
Subtracting P(X = x; t)11 from both sides and dividing by  t > 0, we have
P(X = x; t+ t)11   P(X = x; t)11
 t
  0 (4.45)
Letting  t! 0 gives
dP(Ext; t)
dt
  0 (4.46)
This does not hold for birth-death processes where there is a non-zero source flow from
0 to 1 , as then
 
eA t
 
11
6= 1.
4.4.2. E↵ects of Truncated State Space
Under the birth-death process model given in Figure 4.2, given a set of growing parameters
(i.e. ⇡ >  ), there is no upper limit on the frequency that a species can take. However, to
make the problem computationally tractable (and to make the master equation solvable
using the matrix exponential), we must impose an upper limit ⌧ and truncate the infinite
state space ⌦ = N0 to the reduced state space ⌦⌧ = {0, ..., ⌧} as in Figure 4.3. Ideally ⌧ is
chosen so that the probability of the species taking frequency greater than ⌧ is negligible
[150], i.e. so that P(X   ⌧ ; t) ⇡ 0. For example, if x0 = ⌧   1 and ⇡ >  , a significant
amount of probability mass will build up at X = ⌧ . Clearly this is the result of truncating
the state space, and not because of any underlying biological behaviour we wish to examine
(Figure 4.5).
4.4.3. Shape of Probability Distribution P(X; t) for Large Starting
Values x0
Figures 4.6, 4.7, and 4.8 show the the probability distribution evolution for growing (⇡ >
 ), shrinking (⇡ <  ), and “equilibrium” (⇡ =  ) parameters. In order to examine the
form of P(X; t) when it is not distorted by the use of a truncated state space, large values
of ⌧ were chosen with starting frequencies x0 = ⌧/2. In the growing and shrinking cases,
⌧ = 104, and in the equilibrium case ⌧ = 1.5⇥104. Both of these values require substantial
computational time to calculate a single matrix exponential (approximately 7 and 24 hours
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Figure 4.5.: E↵ect of Truncated State Space ⌦. A growing species (i.e. ⇡ >  ) is
shown. In the first row, ⌧ = 50 is not large enough to prevent the probability
distribution being distorted in the time frame t 2 {1, 2}. In the second row,
⌧ = 100 appears large enough so that P(X; t) not significantly distorted. In
each case, ✓k = {⇡ = 1,   = 0.5, x0 = 10}. In first row, value of boundary ⌧
shown in red.
for ⌧ = 104 for ⌧ = 1.5⇥ 104 respectively) making them impractical for parameter fitting
where many parameters must be tested and many matrix exponentials calculated.
In all cases, the form of each distribution P(X; t |✓k) strongly resembled a Gaussian dis-
tribution, and we assessed their similarity using the Kullback-Leibler divergence. For two
discrete probability distributions P and Q, the Kullback-Leibler (KL) divergence of Q
from P is defined by
DKL(P ||Q) =
X
i
P (i) log
✓
P (i)
Q(i)
◆
(4.47)
The KL-divergence is a measure of the loss of information when P is approximated by
Q [109, 118]. DKL(P ||Q) = 0 if and only if P = Q, i.e. zero information is lost if P is
approximated by itself. Note that in general, DKL(P ||Q) 6= DKL(Q||P ).
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Figure 4.6.: Evolution of probability distribution given “growth” parameters
2 = ⇡ <   = 1.98. P(X; t) is plotted for multiple values of t (circles). Later
timepoints are represented by lighter colours. In all timepoints, the mean (dashed
vertical lines) is greater than the mode (dotted vertical lines), and the discrepancy
between these two values increases over time, as does the variance of each PDF. A
normal distribution (solid lines) N (µ(t), (t)2) is plotted, and is an excellent fit to
each P(X; t).
Figure 4.7.: Evolution of probability distribution given “shrinking” parameters
1.98 = ⇡ <   = 2. As for Figure 4.6.
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Figure 4.8.: Evolution of probability distribution given “equilibrium” parame-
ters ⇡ =   = 2. As for Figures 4.6 and 4.7. Though proliferation and death rates
are equal, the distribution moves left over time. This is most visible for the mode,
but the mean also moves left to a small extent. This is unlikely to be due to the
choice of ⌧ = 15000, as the x0 = 7500 is suitably far away.
Table 4.1.: KL-divergence between P(X; t|✓k) and reference normal distributions: large x0
✓k DKL(P(X; t)||N (µ(t), (t)2))†
Growing (⇡ >  , ⌧ = 104) 0.0002
Shrinking (⇡ <  , ⌧ = 104) 0.0003
Equilibrium (⇡ =  , ⌧ = 1.5⇥ 104) 0.0003
† Highest Kullback-Leibler divergence between P(X; t) and reference normal distributions
N (µ(t), (t)2)) for all time points.
DKL(P(X; t)||N (µ(t), (t)2)) was calculated to compare each P(X; t) to its corresponding
reference normal distribution N (µ(t), (t)2). Reference normal distributions were calcu-
lated using expectations µ(t) = E[P(X; t)] and variances  (t)2 = Var[P(X; t)]. Figures
4.6, 4.7, and 4.8 show P(X; t | ✓k), together with each N (µ(t), (t)2) for multiple t values.
The reference normal distributions are an excellent fit to each P(X; t), and the values of
DKL(P ||Q) 6= DKL(Q||P ) are low (see Figures 4.6, 4.7, and 4.8 and Table 4.1).
For each parameter set, the variance of P(X; t) increases over time, reflecting the increased
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uncertainty that arises as the system is propagated. Further, for each parameter set tested,
the mode is less than the expected value, indicating that the Gaussian characterisation of
P(X; t) remains an approximation, albeit an acceptable one. This e↵ect has been observed
previously [148], and is particularly curious when we consider the “equilibrium case” when
⇡ =   = 2. Under a deterministic framework, equal proliferation and death rates would
result in zero change to the system. If a set of ordinary di↵erential equations are used to
approximate the expected value of the system (or indeed the entire system), as in Section
4.2.2, this will overestimate the expected value as the “sinkhole” e↵ect of the absorbing
state 0 will not be considered. While this does not result in large practical di↵erences
in our system within the time-frame we have modelled, it does change our view of the
system: the stochastic formulation of equilibrium will eventually result in extinction; the
deterministic formulation will not.
The strictly increasing extinction probability accounts for the decreasing value of the
expectation. Clearly, as P(X = 0; t) increases, P(X 6= 0; t) decreases, and so when ⇡ =  
there is less probability mass contributing to non-zero values of the expectation summation.
However this decrease is very small, and it remains the case that approximating stochastic
systems with ODEs renders the modelling of many biological systems tractable. The fact
that the entire probability distribution, and not just the expected value moves to the left
(Figure 4.8) is an interesting feature of the stochastic system.
4.4.4. Shape of Probability Distribution P(X; t) for x0 = 1
The Gaussian-like distributions we observe when given large starting values x0 do not
appear when x0 = 1. Instead, the plots closely resemble exponential distributions (Figure
4.9). We now examine the extent to which P(X; t |x0 = 1) can be approximated by an
exponential distribution. Because the exponential distribution can be fully described by
a single parameter  , such an approximation could save substantial computational time.
The exponential distribution has probability density function given by
f(x; ) =
8<: e  x if x   00 if x < 0 (4.48)
Taking the natural logarithm gives for x   0,
F (x; ) = log(f(x; )) = log( e  x)
= log( ) + log(e  x)
= log( )   x
(4.49)
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Figure 4.9.: Example PDF evolutions P(X; t |x0 = 1). For example parameter sets ✓1
and ✓2 P(X; t |x0 = 1), P(X; t |x0 = 1) resembles an exponential distribution
for all time points. Note that the extinction probability P(X = 0; t |x0 = 1)
is not shown.
Because F (x; ) is linear with intercept log( ) and slope   , we can take the natural log of
P(X; t |x0 = 1), and use linear regression to determine whether an exponential distribution
with rate   (and expectation 1/ ) is an acceptable approximation of P(X; t |x0 = 1). That
is, we regress using the function
Y = aX + b (4.50)
where Y = log(P(X; t |x0 = 1)).
Figure 4.10 shows a series of probability distributions P(X; t |x0 = 1) for parameter sets
✓1 = {⇡1 = 2,  1 = 1.98} and ✓2 = {⇡2 = 1.98,  2 = 2}, both when plotted on a logarithmic
scale and not. When plotted on the log scale, P(X; t |x0 = 1) is strikingly linear. Running
a linear regression on log(P(X; t |x0 = 1)) for t 2 {0.5, 1, 1.5, ..., 19.5, 20}, the minimum
value of the coe cient of determination R2 was greater than 0.9999 for each ✓k, indicating
that the log-linear model proposed in Equation (4.50) is an excellent fit to P(X; t |x0 =
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Figure 4.10.: The exponential distribution approximates P(X; t |x0 = 1). PDF
progressions for two example parameter sets ✓1 (leftmost two columns) and
✓2 (rightmost two columns) and four time points t 2 {0.5, 2.5, 7.5, 15} (rows)
are shown (black dots). For each time point and ✓k, the PDF is plotted on
di↵erent scales: one magnified to the non-negligible probability mass for all
states except 0 (first and third column); and one plotted on the log scale
(second and fourth columns). In each plot, four exponential distributions
with di↵erent rate parameters ( i)4i=1 are plotted:  ˆ1 =  a (red);  ˆ2 = eb
(blue);  ˆ3 = 1/E[P(X; t |x0 = 1)] (green);  ˆ4 = 1/E(P'(X; t |x0 = 1))
(purple). Purple distributions give best fit to P(X; t |x0 = 1). See Section
4.4.4 for further details.
1 | ✓k), k = {1, 2}.
However, simply because a distribution is log-linear does not mean that it is exponential.
If each P(X; t |x0 = 1) was a perfect exponential distribution, then Equation (4.49) implies
that both the intercept and the slope of the line fitted to the natural log of P(X; t |x0 = 1)
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Figure 4.11.: Discrepancy between exponential distribution rate parameters  ˆ1
and  ˆ2 over time.  ˆ1 =  a, the slope of log(P(X; t |x0 = 1)) and  ˆ2 =
eb, derived from the intercept of log(P(X; t |x0 = 1)) (Equation (4.50)) are
initially similar, but diverge over time.
could be used to give an equivalent estimate of the rate   and expectation 1/ . That is,
 ˆ1 =  a should be equal to  ˆ2 = eb. As is shown in Figure 4.11, while  ˆ1 is approximately
equal to  ˆ2 at early time points, they diverge substantially thereafter. Indeed, while  ˆ1 is
an excellent fit to the distribution on the log scale, it does not approximate the distribution
well on the left-hand side of the plots. Since this is where the bulk of the probability mass
lies, neither Exp( ˆ1) nor Exp( ˆ2) are acceptable approximations of P(X; t |x0 = 1).
It is possible that the discrepancy between  ˆ1 and  ˆ2 and the inadequacy of Exp( ˆ1) and
Exp( ˆ2) is due to the distorting e↵ects of the absorbing state 0 and extinction proba-
bility. From Figure 4.10, we can see that the log-linearity breaks down at the extinction
probability in later time points. Thus the value of the intercept (log( ˆ2)) systematically
increases the magnitude of the slope ( ˆ1). This has the e↵ect of underestimating the
extinction probability while overestimating the probability of every other state.
It is therefore natural to consider how to approximate the probability distribution of non-
zero states. We make use of the conditional distribution [190] PN (X; t) as
PN (X; t) = '(t)⇥ P(X = x; t) (4.51)
for x   1, where
'(t) =
1
1  P(X = 0; t) (4.52)
PN (X; t) is simply the probability distribution P(X; t) without the extinction probability
but which is then normalised so that it sums to 1. The expectation µN (t) of the conditional
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distribution is given by by
µN (t) =
⌧X
i=1
i⇥ PN (X = i; t)
=
⌧X
i=1
i⇥ ('(t)⇥ P(X = i; t))
=
⌧X
i=0
i⇥ ('(t)⇥ P(X = i; t))
= '(t)⇥ µ(t)
(4.53)
because the extinction probability adds zero to the expectation µ(t).
The purple lines in Figure 4.10 are given by PD(X; t), given by
PD(X; t) =
8<: 1'(t) ⇥ Exp( 1µN (t)) if x   1P(X = 0; t) if x = 0 (4.54)
That is, PD(X; t) is an exponential distribution with expectation µN (t) that includes
P(X = 0; t), and so must be scaled down by a factor of (1   P(X = 0; t)) or 1'N (t) .
PD(X; t) provides an excellent fit to the distributions P(X; t), particularly at later time
points. The fit is less impressive at earlier time points towards the right of the distribution,
but since this represents an absolute discrepancy of less than 10 100, this is an acceptable
error.
Exponential distributions with rate 1/µ(t) were also used to estimate P(X; t) (Figure
4.10, green lines), but these did not provide an acceptable fit. Figure 4.12 show Kullback-
Leibler divergences over time between P(X; t|x0 = 1, ✓k) and each proposed exponential
distribution approximation. All approximations become less accurate over time, except
for PD(X; t), which eventually reaches a divergence of less than 10 9, again indicating an
excellent approximation.
While it is interesting that P(X; t |x0 = 1) can be closely approximated by an exponential
distribution for the parameters we have chosen, this is of dubious value if P(X; t |x0 = 1)
must be calculated explicitly in order to parameterise that distribution. Fortunately, our
simulations indicate that the extinction probability P(Ext; t) can be calculated accurately
using a much smaller value of ⌧ and state space, since if only the extinction probability
is desired, other values of the PDF can be distorted. Further, the expected value can
be approximately estimated using ODEs, and so P(X; t) and PN (X; t) can be calculated
using only the P(Ext; t) and the ODEs. Finally, at later time points, our repeated nu-
merical simulations suggest we need only use Equation (4.41) to calculate the extinction
probability.
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Figure 4.12.: Kullback-Leibler divergences between P(X; t|x0 = 1, ✓k) and expo-
nential distribution approximations. Kullback-Leibler divergences be-
tween P(X; t|x0 = 1, ✓k) and Exp( ˆl), l 2 {1, ..., 4} are plotted over time for
growing (✓1 = {⇡ = 2,   = 1.98}), shrinking (✓2 = {⇡ = 1.98,   = 2}), and
equilibrium (✓3 = {⇡ = 2,   = 2}) parameters. Definitions of each  ˆl are as
for Figure 4.11, i.e.  ˆ1 =  a (red);  ˆ2 = eb (blue);  ˆ3 = 1/E[P(X; t |x0 = 1)]
(green);  ˆ4 = 1/E(P'(X; t |x0 = 1)) (purple). Consistent with Figure 4.11,
purple distributions give best fit to P(X; t |x0 = 1). See Section 4.4.4 for
further details on each exponential distribution.
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Figure 4.13.: Mass action birth-death process flow diagram with inflow from
source (truncated state space). As for Figure 4.3, but with inclusion of
constant rate   of inflow from source.
4.5. Inclusion of Source Inflow Changes P(X; t)
Many biological systems consider inflow from a source, or a reaction R : ⇤  ! X that takes
a species of frequency 0 to 1 . For example, considering the two “species” of mRNA and
protein, source inflow would come from DNA transcription. Or considering a population of
T cells, source inflow comes from the thymus. However, this formulation is inappropriate
for many systems, for example the extinction of animal species. Indeed at the level of a
TCR clonotype, we cannot assume a constant rate of creation for that particular clonotype.
The inclusion of the source inflow fundamentally changes the probability distribution
P(X; t). Figure 4.14 shows the evolution of the extinction probability for a range of
randomly chosen parameters ⇡ and   and with source  . In contrast to Figure 4.4, the
extinction probability is no longer strictly increasing. Further, the form of P(X; t |x0 = 1)
can no longer be approximated by an exponential distribution, but under certain scenarios
can be approximated by a Gaussian distribution.
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Figure 4.14.: Evolution of Extinction Probabilities with source inflow. Inclusion
of source inflow from 0 to 1 results in di↵erent properties of P(X; t). The
extinction probability is no longer increasing.
We again used the Kullback-Leibler divergence to compare P(X; t |x0 = 1) to refer-
ence Gaussian distributions N (µ(t), (t)2), and to exponential distributions Exp(1/µ(t)).
For two sets of parameters ✓1 = {⇡1 = 0.02,  1 = 0.015, 1 = 2} and ✓2 = {⇡2 =
0.015,  2 = 0.02, 2 = 1}, Figure 4.16 shows DKL(P(X; t |x0 = 1) || N (µ(t), (t)2)) and
DKL(P(X; t |x0 = 1) ||Exp(1/µ(t))), i.e. the information lost by approximating P(X; t |x0 =
1) by normal and exponential distributions, and how the information loss varies over
time. For both parameter sets, P(X; t |x0 = 1), was better approximated by a normal
distribution than an exponential distribution, and this approximation improved (i.e. the
KL-divergence decreased) over time.
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Figure 4.15.: Example PDF evolutions P(X; t |x0 = 1) with source inflow. Inclu-
sion of source inflow changes P(X; t |x0 = 1) so that it closely resembles a
Gaussian distribution (plotted in green lines).
4.6. Discussion
In this chapter, we gave a brief overview of stochastic processes and their increased use
in modelling biological systems. We discussed the master equation and gave its explicit
derivation of a simple mass-action birth-death process of one species. We explored con-
sequences of this process without a source inflow, and found that for high starting fre-
quencies, the probability distribution could be accurately approximated using a Gaussian
distribution. We further explored how the probability distribution evolves when the species
is modelled from a starting frequency x0 = 1. In this case, a Gaussian distribution no
longer gave an accurate description of P(X ; t), which was instead well approximated by a
simple manipulation of an exponential distribution. This is useful because of the amount
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Figure 4.16.: Kullback-Leibler divergences between P(X; t |x0 = 1) and normal
and exponential distributions with source inflow. Kullback-Leibler
divergences plotted for between P(X; t |x0 = 1) and normal distribution
N (µ(t), (t)2) (top row) and between P(X; t |x0 = 1) and exponential dis-
tributions Exp(1/µ(t)) (bottom row). Over time, the normal distributions
become more similar and exponential distributions become less similar to
P(X; t |x0 = 1), for parameter sets ✓1 where ⇡ >   (left column) and ✓2
where ⇡ <  . At all times, exponential distributions give poor approxima-
tion to P(X; t |x0 = 1).
of computational power that can be saved. Computing the solution of the master equation
can be prohibitively time-consuming for large truncated state spaces ⌦⌧ . By approximat-
ing using the manipulated exponential distribution, only the expectation (approximately
calculated using ODEs) and the extinction probability need to be calculated.
A major shortcoming of the preceding analysis is that there are substantial time con-
straints when explicitly solving the master equation (Equation (4.30)). To model a state
space ⌦⌧ where ⌧ = 104 incurs a runtime of approximately 7 hours for a single matrix
exponential (using R function “expm” from the package “matrix”). While this is feasible
when exploring the behaviour of a species given a limited set of parameter values, it is not
conducive to parameter fitting, where the probability distributions from many parameter
sets in a potentially large parameter space must be compared to empirical data.
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Furthermore, a truncated state space of 104 will often not be biologically realistic. For
example, the DivE distribution algorithm conservatively predicts that a single HTLV-1+
T cell clone can reach a frequency of 1010 infected cells. This makes direct solution of the
master equation impossible, both in terms of runtime and memory. The transition matrix
of a mass-action birth-death process where ⌧ = 1010 will have (⌧+1)2 =
 
1010 + 1
 2 ⇡ 1020
entries. While only the minority of these entries (specifically 3⌧  1, as each state can only
move to its immediate neighbours, except state ⌧ which can only decrease and 0 which
is an absorbing state) will be non-zero, all terms in the matrix exponential except the first
column will be non-zero. Assuming that each non-zero entry is a single precision floating
point that uses 4 bytes, the matrix exponential would use 1020   1010 ⇥ 4 ⇡ 4 ⇥ 1020
bytes which is approximately 400,000 petabytes. Clearly this is not possible with current
computational power.
The finite state projection method (FSP) aims to address the di culty of an intractably
large state space [183, 191, 192]. The FSP truncates the state space in a di↵erent way
than we have. The FSP does not consider a pre-determined minimum and maximum
frequency, but instead iteratively expands a truncated state space until the probability
that the system takes values outside this state space is less than an arbitrary error level ✏
(runtime-permitting). The limits on the state space change as the system is propagated.
However, the FSP has disadvantages. P(X; t) has to be calculated at each time step, and
this cannot be expedited. For our purposes, repeated iterations of the FSP, while faster
than matrix exponential calculation, is much slower than simple matrix multiplication with
a single, pre-calculated matrix exponential. Like the Gillespie algorithm, the runtime of
the FSP increases markedly with simulation duration, whereas a matrix exponential does
not. Further, the truncated state space is likely to substantially increase as the system is
run.
While it has been argued that stochastic modelling is necessary even for large species [137],
it is generally accepted that deterministic modelling is acceptable for biological processes
that occur on a large scale. For systems with dynamics that occur on small and large
scales, a hybrid model of deterministic and stochastic systems can be employed. In the
next chapter, we discuss a hybrid model of the within-host dynamics of HTLV-1 infection
that examines mechanisms of viral persistence.
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5. Hybrid Model of HTLV-1 persistence
5.1. Introduction
Like all retroviruses, human T-Lymphotropic virus type-1 (HTLV-1) persists within host
via two mechanisms. Infectious spread (i.e. de novo infection) occurs through cell-cell
contact between infected and uninfected CD4+ T cells, whereupon the virus will integrate
in a di↵erent location of the target cell genome than its progenitor. In mitotic spread,
infected cells proliferate to produce identical sister cells with the same genomic site of
proviral integration. The interplay between infectious and mitotic spread results in mul-
tiple, distinct clones, where a clone is defined as a population of identically infected cells,
each with a common integration site [20, 22, 125].
The relative contributions of infectious spread and mitotic spread are unknown, and this
ratio will directly determine the e cacy of di↵erent drug regimens. Although no e↵ective
treatment for HTLV-1 infection has yet been identified [193], anti-retroviral therapy (ART)
is believed to reduce infectious spread [21] because of its ability to drastically reduce
reverse transcription in HIV infection [194, 195]. Similarly, immuno-suppressants such as
Ciclosporin will inhibit T cell proliferation and thus may be e↵ective in reducing mitotic
spread [196, p. 163].
It is not possible to directly observe ongoing within-host HTLV-1 persistence in real time,
and a number of factors make it di cult to estimate the ratio of infectious to mitotic
spread from existing data. Since infectious spread establishes new clones, the number of
clones is closely related to the rate of infectious spread. However, estimating the number
of clones in the host from blood samples is nontrivial (see Chapter 2). Further, even if the
number of clones is known, the frequency of each clone, which informs the rate of mitotic
spread, is unknown. Finally, even if a complete census of the number of clones and their
frequencies was available, this would not in itself determine the ratio, as the turnover rate
would be unknown.
Despite the di culties in directly observing or estimating quantitatively the ratio of infec-
tious to mitotic spread, the prevailing view is that mitotic spread accounts for the majority
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of HTLV-1 persistence [14, 20, 24, 197], and that infectious spread is thought to be neg-
ligible after the initial phase of infection [21, 24, 198]. This belief is supported by three
main observations. First, it was thought that there were relatively few HTLV-1 clones
in one host [20, 22, 23, 24, 25, 26, 113, 114]. Second, it has been reported that HTLV-1
has relatively little sequence variation when compared with other viruses including HIV,
Hepatitis C Virus (HCV) and influenza A [14, 15, 199, 200, 201, 202, 203]. Since the host
DNA-based DNA polymerase used in cell proliferation (mitotic spread) is substantially
less error-prone than the viral RNA-based DNA polymerase used in reverse transcription
(infectious spread), lack of sequence variation would imply that mitotic spread is the most
common form of spread. Third, many HTLV-1+ clones have been observed at multiple
time points separated by several years [22, 23], and it is all but impossible that repeated
proviral integration (infectious spread) at the same integration site would occur frequently
enough to maintain a long-lived clone.
However, the preceding three observations do not necessarily imply that infectious spread is
negligible [14], particularly when we consider the number of clones. First, estimates of the
number of clones have increased over time [20, 22, 23, 24, 25, 26], and DivE estimates that
there are approximately 104 clones in ACs and HAM/TSP patients [11, 125, 204]. Second,
a relatively small amount of sequence variation is unsurprising if only a few clones are
observed, and this is compounded if multiple cells of the same clone are sampled. Finally,
the repeated observation of several clones over many years implies the presence of mitotic
spread, but not an absence of infectious spread. Indeed, many new clones are detected in
subsequent samples, and so it is not necessary to surmise that all clones were established
during initial infection. Further, the observation of a temporary but dramatic reduction in
PVL upon treating HAM/TSP patients with the reverse transcriptase inhibitor lamivudine
[21] strongly implies that infectious spread remains important in HTLV-1 persistence.
There has been renewed interest in the role that infectious spread may play in HTLV-1
associated disease. Melamed et al [124] compared the clonality of HTLV-1 to HTLV-2 and
found that the oligoclonality index (OCI) of HTLV-2 clones was higher that of HTLV-1,
implying a higher relative contribution of mitotic spread in HTLV-2 persistence. Since
HTLV-2 is not known to cause disease, it is conceivable that infectious spread may be a
driving determinant of disease. In addition, as we have seen in Section 3.3, there are fewer
clones in asymptomatic carriers, which is consistent with the hypothesis that infectious
spread plays a role in progression to inflammatory disease.
Even when taking recent estimates of clonal diversity into account, there is still good
reason to believe that mitotic spread is predominant, as 104 clones (created by infectious
spread) must be compared to approximately 1011 infected cells (maintained by mitotic
spread). However, this does not consider clones that are continuously created and killed
98
by the immune response and natural death. In this chapter, we develop a deterministic and
stochastic hybrid model of HTLV-1 dynamics to directly model the relative contributions
of infectious spread and mitotic spread.
5.2. Hybrid model
We first outline a model that does not consider runtime and memory constraints. We then
discuss approximations that reduce the complexity of the model such that it can be run
in an acceptably short time frame.
5.2.1. Deterministic Model of HTLV-1 Dynamics
We consider a system with S(t) ⇢ N clones at time t, where each clone is indexed by
a natural number i 2 N. In a given instant, an infected cell will either express some or
all viral proteins (we term this state expressing) or it will not express viral proteins (we
term this state latent). Proliferation and death rates will be di↵erent between expressing
and latent cells, and so we consider the expressing and latent compartments of the clone
separately. By expressing viral proteins or by silencing the expression of viral proteins,
the cell can switch between expressing and latent compartments.
We have the following system of ODEs for each clone (Figure 5.1).
x˙i =
⇡xi
K +N(t)
   xi + "iyi   sixi (5.1a)
y˙i =
pyi
K +N(t)
  dyi   "iyi + sixi (5.1b)
where N(t) =
PS(t)
j=1 xj(t) + yj(t) is the total number of infected cells summed over all
clones alive at time t; ⇡ and p are the proliferation rates of expressing and latent cells
respectively,   and d are the death rates of expressing and latent cells respectively, and
"i and si are the respective clone-specific rates of viral expression and silencing, and K is
the density dependency parameter (see Section 5.2.8).
The above ODEs model the dynamics within a clone, but do not incorporate infectious
spread or describe the number of clones. The number of clones S(t) at time t is given by
S(t) = S(0) +
Z t
0
rI
24 X
i2S(s)
xi(s)
35 ds  Z t
0
X
i2S(s)
Di(s)ds (5.2)
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Figure 5.1.: Schematic of single clone dynamics. A single HLTV-1 clone of infected cells is
divided into expressing (blue) and latent (red) compartments. Expressing and latent
cells can proliferate and die, or switch between compartments. Density-dependent
proliferation rates ⇡0(t) and p0(t) are defined in Equation (5.4).
where rI is the rate of infectious spread. It is assumed that only expressing cells can infect
uninfected cells. Di(t) is the extinction probability of clone i at time t, although it does
not have a simple functional form. We discuss Di(t) in Section 5.2.5.
In Chapter 4, we explored situations where deterministic modelling is inappropriate. First,
deterministic models do not account for random e↵ects [156]. Second, they are continuous
(i.e. not discrete) [153]. Third, their values approximately correspond to the expectation
of a system [175, 205]. Finally, if an attempt is made to estimate uncertainty, it is often as-
sumed that deviations from the expectation are normally distributed [158, 159]. However,
for species that are low in copy number (in our case small HTLV-1+ T cell clones), random
e↵ects need to be considered [154, 155, 157], rounding to integers will present a greater
error than for large clones, the expected value is unlikely to satisfactorily encompass the
behaviour of the clone over time, and the assumption of normality is frequently violated.
This is particularly true when clone extinction is likely (see Section 4.4.4). Because small
clones contain the majority of information on infectious spread, we must reformulate our
deterministic model to a discrete stochastic model of clone dynamics. Instead of mod-
elling a single state (expected value) of the clone at a given time, we must model many
potential states of the clone and their corresponding probabilities. Crucially, we must do
this without restricting the shape that the probability distribution may take over time by
specifying a particular analytical form.
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5.2.2. Stochastic Model of Within-Host HTLV-1 Dynamics
Under a stochastic framework, we describe within host HTLV-1 dynamics with a set of
reactions and their corresponding propensities, at a time when the entire system of clones
(but not necessarily each individual clone) has reached steady state. The dynamics of
an individual clone can be summarised via the following seven reactions: latent cells can
proliferate, die, or express viral proteins; expressing cells can proliferate, die, be silenced,
or infect uninfected cells (Figures 5.1 and 1.1). Thus the total number of possible reactions
R at time t is R = 7S(t). Let X(t) =
 
(Xi(t), Yi(t))i2S(t)
 T
be the state vector at time
t of the expressing and latent compartments of all clones. X(t) is a random variable in
NS(t)0 that consists of the random variables Xi, Yi 2 N0 of the frequencies xi(t) and yi(t) of
“species” Xi and Yi. X(t) is the set of expressing and latent cells of clone i, (i = 1, ..., S(t)),
and is of length 2S(t).
For a single clone i, we have the following reactions:
R7(i 1)+1 : Xi ⇡
0(t) ! 2Xi (5.3a)
R7(i 1)+2 : Xi   ! ⇤ (5.3b)
R7(i 1)+3 : Xi s ! Yi (5.3c)
R7(i 1)+4 : Yi p(t) ! 2Yi (5.3d)
R7(i 1)+5 : Yi d ! ⇤ (5.3e)
R7(i 1)+6 : Yi "i ! Xi (5.3f)
R7(i 1)+7 : Xi rI ! Xi + XS(t)+1 (5.3g)
where
⇡0(t) =
⇡
K +N(t)
(5.4a)
p0(t) =
p
K +N(t)
(5.4b)
In our model, the above reactions are monomolecular (that is, the reactions do not depend
on contact between species or clones). This is an approximation, but an acceptable one
since HTLV-1 proviral load remains stable over many years [206], and so the number of
uninfected cells stays more or less constant. Therefore, using Equation (4.3), the reactions
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have the following propensities.
↵7(i 1)+1(X(t)) =
⇡xi
K +N(t)
(5.5a)
↵7(i 1)+2(X(t)) =  xi (5.5b)
↵7(i 1)+3(X(t)) = sxi (5.5c)
↵7(i 1)+4(X(t)) =
pyi
K +N(t)
(5.5d)
↵7(i 1)+5(X(t)) = dyi (5.5e)
↵7(i 1)+6(X(t)) = "iyi (5.5f)
↵7(i 1)+7(X(t)) = rIxj (5.5g)
with the following stoichiometric vectors:
⌫7(i 1)+1 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1 1
2i 0
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
, ⌫7(i 1)+2 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1  1
2i 0
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
, ⌫7(i 1)+3 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1  1
2i 1
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
,
⌫7(i 1)+4 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1 0
2i 1
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
, ⌫7(i 1)+5 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1 0
2i  1
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
, ⌫7(i 1)+6 =
0BBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1 1
2i  1
...
...
2S(t)  1 0
2S(t) 0
1CCCCCCCCCCCCCCCCCCA
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and
⌫7(i 1)+7 =
0BBBBBBBBBBBBBBBBBBBBBBBBB@
1 0
2 0
...
...
2i  1 0
2i 0
...
...
2S(t)  1 0
2S(t) 0
2S(t) + 1 0
2S(t) + 2 1
1CCCCCCCCCCCCCCCCCCCCCCCCCA
5.2.3. Clone State Space and Interactions
The “curse of dimensionality” [174, 205] refers to the exponentially increasing number of
states that must be modelled as more species of the system are introduced. As we have
seen in Chapter 4, for a single clone Z(t) 2 N0 that is not divided into expressing and
latent states, the state space (i.e. the set of all states the system can take) is given by
⌦ = {z : z 2 {0, ..., ⌧}}, where ⌧ is the maximum frequency of the clone and number of
states is given by |⌦| = ⌧ +1. If we divide the clone into expressing and latent cells, where
each can reach a frequency of ⌧ , the state space becomes ⌦ = {(x, y) : x, y 2 {0, ..., ⌧}},
and |⌦| = (⌧ + 1)2.
If all clones interact and are modelled using a single master equation, assuming all clones
have the same frequency range, the size of the state space will increase to (⌧ + 1)2S(t).
Thus the complexity and runtime of the model increases exponentially with the number of
clones. In contrast, when each clone is modelled in isolation, the number of clones a↵ects
complexity and runtime linearly. Therefore to make the model computationally tractable,
we model each clone individually, which involves further approximations.
With the exception of infectious spread, each reaction in Equation (5.3) occurs within a
clone and does not a↵ect other clones, and infectious spread does not a↵ect any pre-existing
clones. However, the proliferation propensities (equations (5.5a) and (5.5d)) of a clone
depend on the combined frequencies of all other clones, which would seem to necessitate
modelling all clones in a single state space. There are two approximations we can make
to avoid this problem. First, we could “linearise” proliferation rates such that Equations
(5.5a) and (5.5d) become ↵7(i 1)+1(X(t)) = ⇡0(t)xi, and ↵7(i 1)+4(X(t)) = p0(t)yi, where
⇡0(t) =
⇡
K +N(btc) (5.6)
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Figure 5.2.: Example clone state space and interactions for upper bound ⌧ = 4. Mappings
between states are described by mass action terms. Here ⇡0 and p0 are “aggregate”
proliferation rates that are constant within a time step. See Section 5.2.3 for further
details.
and
p0(t) =
p
K +N(btc) (5.7)
are step-functions that remain constant within a time step and are updated between time
steps (btc is the “floor” function that returns the integer smaller than t). Since the number
of infected cells N(t) =
PS(t)
j=1 xj+yj is unlikely to change substantially within time steps,
this is an acceptable approximation. An example state space of a clone where ⌧ = 4, and
the interactions between possible clone states is given in Figure 5.2.
However, changing proliferation values between time steps requires the the matrix expo-
nential be recalculated at every time step, and thus this will not reduce runtime to a
su cient extent. The second approximation then is to assume that N(t) is constant. This
will not be valid in early infection, but is acceptable during chronic infection when the
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system is at equilibrium, as the HTLV-1 proviral load (PVL) remains stable for many
years [22, 206]. Assuming the number of infected cells is constant, the propensities (5.5a)
and (5.5d) become
↵7(i 1)+1(X(t)) =
⇡xi
H + xi + yi
(5.8)
and
↵7(i 1)+4(X(t)) =
pyi
H + xi + yi
(5.9)
and we can model each clone individually with H = K +N(t⇤).
Modelling each clone individually in this way incurs an error because the propensities for
proliferation are dependent only upon the initial state of the system, and do not change
with the growth or decay of the other clones. However, this approximation allows for a
single matrix exponential to be calculated for each clone, and for the evolution of the clone
probability distribution to be calculated using recursive property of the matrix exponential
(see Section 4.3.3). We discuss parameters H and K in Section 5.2.8.
5.2.4. Hybrid Model Propagation: Strang Splitting
We have seen previously that using the matrix exponential to calculate the solution to
the master equation requires the state space ⌦⌧ to be finite (Section 4.3.1). Here the
upper bound ⌧ refers to the maximum frequency that either the expressing or latent cells
can take, and thus the maximum frequency of a clone is 2⌧ (Figure 5.2). If A⌦⌧ is the
transition matrix of the state space ⌦⌧ = {(x, y) : x, y 2 {0, ..., ⌧}} then A⌦⌧ is a |⌦⌧ |
by |⌦⌧ | matrix and so the number of entries in A⌦⌧ is (⌧ + 1)4. The DivE distribution
generation algorithm (Section 2.2.11) estimates that the frequency of a given clone can
range up to size 1010, and so it is not possible to model all clones stochastically, even with
our simplifying approach that models each clone independently.
Fortunately, for clones above a given size F (see Section 5.2.9), the distorting e↵ects
of the extinction probability are negligible. Thus for large clones we can assume that
the probability distribution will be well described using only the expectation, variance,
and covariance of the expressing and latent compartments [176]. These quantities can
be modelled deterministically using a system of ODEs [207], which we discuss in Section
5.2.6.
We thus partition our system of the within-host dynamics of HTLV-1 infection into two
constituent systems: a deterministic system D(t) modelled by a system of ODEs, and a
stochastic system S(t) modelled by multiple master equations. We propagate these systems
concurrently as a hybrid model, using the method of “Strang splitting” [208] (Figure 5.3).
The Strang splitting method is as follows (formulation below taken from [173]):
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1. Choose Duration and length of time step h 
2. Initialize 
3. Run D(t) for half time step, keep S(t) constant 
4. Run S(t) for a whole time step, keep D(t) constant 
5. Run D(t) for next half time step, keep S(t) constant 
6. Repeat until duration reached 
…ti ti+(h/2) ti+1… 
S(t) 
D(t) 
S(t) 
D(t) 
S(t) 
D(t) 
Figure 5.3.: Schematic of strang splitting procedure. Dashed arrows indicate that
values from deterministic system are used as intitial conditions for stochastic
system and vice-versa.
1. For the duration of the simulation tend > 0, choose Nt 2 N. Let h = tend/Nt and
tn = nh 8n = 0, ..., Nt.
2. Set n = 0 and set initial conditions.
3. Half time step in deterministic D(t): Solve deterministic process in time interval
[tn , tn + h/2] and keep S(t) constant.
4. Full time step in stochastic S(t): Solve stochastic process (i.e. clone-specific master
equations) in time interval [tn , tn+1] and keep D(tn + h/2) constant.
5. Next half time step in deterministic system D(t): Solve deterministic process in time
interval [tn + h/2 , tn+1] and keep S(t) constant.
6. If n < Nt, set n n+ 1 and return to step 3.
In addition to the error incurred by modelling part of the stochastic system deterministi-
cally, there is an error associated in not propagating both systems exactly simultaneously,
and this error is a function of the length of the time step h [173]. Modelling the whole sys-
tem for a single time step consists of steps 3 to 5. In our system, between time steps, some
deterministically modelled clones become small enough to necessitate stochastic modelling,
whereas some stochastically modelled clones may grow to the extent that they need to be
modelled deterministically (see section 5.2.7). We choose our time step to be equal to one
day.
5.2.5. Infectious Spread rI
Equation (5.2) models the number of clones at time t. Though it is a continuous process,
we approximate the number of clones created in the interval at time [tn , tn + h/2] by
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Snew(tn + h/2) where
Snew(tn + h/2) = (h/2)⇥ rI
S(tn)X
i=1
xi(tn + h/2) (5.10)
New clones are assumed to start in state (xS(tn)+k , yS(tn)+k) = (0, 1), for k 2 {1, ..., Snew(tn+
h/2)}. Note that rI
PS(tn)
i=1 xi(tn + h/2) does not model the probability that a particular
integration site will be infected, i.e. that a particular, as yet un-established clone will go
from state (0, 0) to state (0, 1) . It is also assumed that all new clones are created at the
beginning of a time step. The error associated with this assumption is proportional to the
length of the time step h and inversely proportional to the lifetime of a clone. Because our
time step is equal to one day, this will not present a significant source of error. Equation
(5.10) is deterministic, which is reasonable since the mass action term
PS(tn)
i=1 xi(tn+h/2)
will always be large.
An interesting feature of our model is the ability to estimate the expected number of
clones at time t (see Equation (5.2)), which is not straightforward when using a purely
deterministic formulation. The birth of new clones is a simple mass-action term that is
easily described deterministically. Because death occurs at the level of the cell, and not
the clone, it is less straightforward to estimate the number of clones that will be killed
given a number of cells killed. For example, if we know that 103 cells are killed, this may
result in the death of 0 clones (i.e. if all dead cells are from one su ciently large clone) or
as many as 103 clones (i.e. where each clone was a singleton).
In contrast, our model allows the extinction probability of a single clone to be calculated
for any time step. Therefore, the expected number of clones that die in the interval
[t, t+ t] is given by Z t+ t
t
X
i2S(s)
1⇥Di(s)ds (5.11)
where Di(t) = P((Xi, Yi) = (0, 0) ; t) is the extinction probability of clone i at time t.
5.2.6. Variance and Covariance of Clones
Under a stochastic paradigm, the ODEs in equation (5.1) approximately correspond to
the expected frequencies of the expressing and latent compartments of a given clone i.
Because the propensities of our model (equation (5.5)) have degrees of at most 1, we can
derive another set of ODEs to model the variance and covariance [207] of a given species
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i. With our notation, the moments are given by
dmi
dt
=
RX
r=1
⌫ir
0@↵r(X(t)) +X
k,l
@2↵r(m)
@xk@xl
Ckl
2!
1A (5.12a)
dCij
dt
=
RX
r=1
 
⌫ir
X
k
@↵r(X(t))
@xk
Ckj
1!
+ ⌫jr
X
l
@↵r(X(t))
@xl
Cil
1!
!
+
RX
r=1
⌫[i,j]r
0@↵r(X(t)) +X
k,l
@2↵r(X(t))
@xk@xl
Ckl
2!
1A
(5.12b)
where mi is the expected value of species i, Cij is the covariance between species i and
species j, ⌫ir is the i
th component of ⌫r, the stoichiometric vector of reaction r, and
⌫ [i,j]r = ⌫ir⌫
j
r . Note that the subscripts i and j in the above equations refer to the ith
and jth entry of the state vector X(t). Because we divide clones into two compartments
(expressing and latent), X(t) has 2S(t) entries. Re-indexing so that the subscript i refers
to the ith clone (i 2 {1, ..., S(t)}), we introduce the following shorthand. Let
xi :=E[Xi] (5.13a)
yi :=E[Yi] (5.13b)
Vxi :=Var[Xi] (5.13c)
Vyi :=Var[Yi] (5.13d)
Cxi,yi :=Cov[Xi, Yi] (5.13e)
To relate this to Equation (5.12), we have Vxi = V2i 1 = C(2i 1),(2i 1) = Cov[Xi, Xi] =
Var[Xi], Vyi = V2i = C(2i),(2i) = Cov[Yi, Yi] = Var[Yi], and Cxi,yi = C(2i 1),(2i) =
Cov[Xi, Yi].
We approximate by assuming that the frequency of a given clone is independent of any
other clone, i.e. that for i 6= j, Cov[Xi, Xj ] = Cov[Yi, Yj ] = Cov[Xi, Yj ] = 0. This assump-
tion is valid at the level of the individual clone, in that Cov[Xi, Yj ] ⇡ 0 for i 6= j. HoweverPS(t)
k=1Cik may not be negligible. Nevertheless, to substantially reduce the dimension of the
system of ODEs, we must assume that clone frequencies are approximately independent
of each other. With these assumptions, it can be shown that we have the following system
of ordinary di↵erential equations to describe the expectations, variances of covariance of
the expressing and latent compartments xi and yi of clone i. See Appendix B for further
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details.
dxi
dt
=
⇡xi
K +N(t)
   xi + "iyi   sixi (5.14a)
dyi
dt
=
pyi
K +N(t)
  dyi   "iyi + sixi (5.14b)
dVxi
dt
=
✓
⇡(K +N(t))  ⇡xi
(K +N(t))2
      si
◆
2Vxi + 2"iCxi,yi
+
✓
⇡
(K +N(t))2
+   + si
◆
xi + "iyi
(5.14c)
dVyi
dt
=
✓
p(K +N(t))  pyi
(K +N(t))2
  d  "i
◆
2Vyi + 2siCxi,yi
+
✓
p
(K +N(t))2
+ d+ "i
◆
yi + sixi
(5.14d)
dCxi,yi
dt
=
✓
(⇡ + p)(K +N(t))  ⇡xi   pyi
(K +N(t))2
      si   d  "i
◆
Cxi,yi
+ siVxi + "iVyi   sixi   "iyi
(5.14e)
We also require the variance of xi + yi, and so we compute Vxi+yi = Vxi + Vyi + 2Cxi,yi .
5.2.7. Clone Movement Between Deterministic and Stochastic
Compartments
Recall that F is the frequency above which we can safely approximate the stochastic
behaviour of a clone as a deterministic process. See Section 5.2.9 for a discussion on how
F is determined. When the expected value of the size of a deterministically modelled
clone xi(t) + yi(t) clone drops below F , it is modelled stochastically and values xi(t) and
yi(t) are rounded to the nearest integer. If the state (xi(t) , yi(t)) 2 ⌦⌧ is indexed by ,
then the initial distribution P0 is given by the Kronecker delta  x,, as in Equation (4.31).
Note this requires F < ⌧ .
We “promote” a stochastically modelled clone to a deterministically modelled clone at
time t if either:
P(Xi + Yi = 2⌧ ; t)  P(Xi + Yi = (2⌧   1) ; t) > ✏ (5.15a)
P(Xi = ⌧ ; t)  P(Xi = (⌧   1) ; t) > ✏ (5.15b)
P(Yi = ⌧ ; t)  P(Yi = (⌧   1) ; t) > ✏ (5.15c)
where ✏ > 0. These conditions guard against the upper limit ⌧ distorting the probability
distribution. If the state space is unconstrained and the distribution is unimodal, then we
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would ordinarily expect for a > b > E[Xi + Yi],
P(Xi + Yi = a ; t) < P(Xi + Yi = b ; t) (5.16)
However, using a truncated state space ⌦⌧ causes probability mass to build up at Xi +
Yi = 2⌧ (Section 4.4.2). To prevent a distortion of the expectation, we promote when
P(Xi + Yi = 2⌧ ; t)   P(Xi + Yi = (2⌧   1) ; t) > ✏. In practice ✏ must be greater than
zero as extremely small build ups of probability mass happen before extinction probability
nears P(Ext)⇤. We set ✏ = 1/1000, as this value allows for feasibly small values of ⌧ that
do not overly distort the probability distribution, and that allows P(Ext; t) to get close to
its asymptote.
When a clone is promoted, we again make use of the conditional distribution PN (X(t) ; t)
(Section 4.4.4). This is defined for the two-dimensional case as it is for the one-dimensional
case, i.e.
PN (X(t) = ! ; t) = '(t)⇥ P(X(t) = ! ; t) (5.17)
for (0, 0) 6= ! 2 ⌦⌧ , and where
'(t) =
1
1  P ((Xi + Yi) = 0 ; t) =
1
1  P (X(t) = (0, 0) ; t) (5.18)
“Inflated moments” E[PN (X(t) ; t)] and Var[PN (X(t) ; t)] can be calculated from PN (X(t) ; t)
in the usual way, and it is these quantities that are entered into the system of ODEs given
in Equation (5.14) (Figure 5.4).
This allows us to deterministically model clones with an expectation of a su cient size,
even if their extinction probability is non-negligible. However, the extinction probability
of each clone must be recorded. We do this in the following way. When the duration
of simulation tend is reached, the extinction probability must be reinstated. Thus the
distribution that is modelled around the expectation and variance of the clone must be
scaled down accordingly.
5.2.8. Choice of Density Dependency Parameters H and K
Due to competition for resources and lymphocyte capacity, per-capita rates of cell prolif-
eration vary with the total number of cells in the population. Cells will be comparatively
free to proliferate when there are fewer cells with which to compete. Proliferation rates
for expressing and latent of HTLV-1+ cells have been estimated previously [209]. In our
model, these rates correspond to ⇡0(t) and p0(t) (Equation (5.4)), and so values of K, ⇡
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Figure 5.4.: Schematic of clone promotion and demotion. An example P(X(t) ; t)
is shown (purple), along with its corresponding conditional distribution
PN (X(t) ; t). Moments of PN (X(t) ; t) are then modelled deterministically
using Equation (5.14).
and p must be estimated. Since we are modelling the system at an equilibrium state, we
set the death rates of expressing and latent cells to be equal to the proliferation rates.
To determine the carrying capacity parameter K and the proliferation rates ⇡ and p, we
consider a simple model of cell proliferation. Let x be the number of circulating CD4+
cells, and let z be the number of HTLV-1 infected cells (note here we do not divide infected
cells into clones, or into expressing and latent compartments). We assume proliferation
rates of latently infected cells are equal to proliferation rates of uninfected cells. The
functions f(x) and g(z) of the proliferation rates of latent and expressing HTLV-1+ cells
are given by
f(x) =
p
K + x
(5.19a)
g(z) =
⇡
K + z
(5.19b)
where K determines the extent to which the rate of proliferation changes with population
size. K > 0 is the frequency at which the proliferation rate is halved. Between them,
functions f(x) and g(z) have three parameters (K, ⇡ and p). To determine K and p, we
need two data points, for which we use published estimates of proliferation rates [209, 210]
(values of f(x)), together with population size estimates (values of x). Estimates of K and
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p will be more accurate if data points cover a wide range of CD4+ T cell population sizes.
Therefore, we use data from ART-untreated HIV patients who are lymphopenic [210] as
well as data from HTLV-1 infection [209]. The number NCD4 of CD4+ T cells in the body
of a non-lymphopenic patient is estimated as 1012 (see Section 2.2.9). We estimate the
corresponding number in lymphopenic patients Nlymph using the average ratio ⇢ of normal
CD4 counts per µL to CD4 counts in HIV-infected, ART-untreated patients, where data
is again taken from [210]. Therefore Nlymph is given by
Nlymph = ⇢⇥NCD4 = 6.6⇥ 1011 (5.20)
Let Nbody be the number of HTLV-1-infected cells in the body. Let rlymph be the CD4+ T
cell proliferation rate in lymphopenic patients. Let rCD4 be the CD4+ T cell proliferation
rate in healthy patients (we will use this value as a proxy for the proliferation rate of
HTLV-1 latently infected cells). Finally, let rHTLV-1 be the proliferation rate of HTLV-1
infected cells that express viral proteins. Then we solve the following system of equations
for p, ⇡ and K.
rlymph =
p
K +Nlymph
(5.21a)
rCD4 =
p
K +NCD4
(5.21b)
rHTLV-1 =
⇡
K +Nbody
(5.21c)
5.2.9. Choice of State Space Upper Limit ⌧ and Frequency F
As we have seen in Section 4.4.2, the need to set a value of ⌧ that is low enough to
be computationally feasible must be balanced against the need to not infringe upon the
trajectory of a growing clone. Here we outline a general procedure for calculating ⌧ , as
well as the frequency F above which it is appropriate to model a species deterministically,
where parameters are unknown.
Calculate F
Let ⇥ be our parameter space. Choose the parameter set ✓D 2 ⇥ that most favours death
of individuals (in our case this would be the maximum possible values for   and d, and
the lowest possible values of ⇡ and p). For an extinction probability ✏1 > 0, choose F 2 N
to be the highest value such that
P (X = 0 ; t = h | ✓D , x0 = F ) > ✏1 (5.22)
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(where P (X = 0 ; t) = P (X(t) = (0, 0) ; t) in the case of an HTLV-1+ clone that is divided
into expressing and latent compartments). This definition states that deterministically-
modelled clones must be modelled stochastically as soon as their frequency is low enough
for extinction to be probable in the next time step of length h. This will be valid for any
parameter set ✓k 2 ⇥ because of the choice of ✓D.
Calculate ⌧
Choose the parameter set ✓G 2 ⇥ that most favours growth of individuals. Let text be the
minimum value such that time taken such that✓ |P(Ext; text)  P(Ext; text   h)|
P(Ext; text   h)
◆
< ✏2 (5.23)
i.e. text is the time taken for the extinction probability to change by less than ✏2 > 0 and
thus be near its asymptote. We choose ⌧ to be the smallest value such that
(P (X + Y = 2⌧ ; text | ✓G , (x0, y0) = (a, b))   P (X + Y = 2⌧   1 ; text | ✓G , (x0, y0) = (a, b))) < ✏3
(5.24)
for ✏3 > 0, for all a, b such that a+ b  F . Note that the choice of time step h contributes
to the definitions of ⌧ and F . Having shorter and more numerous time steps takes less time
than having longer and fewer time steps, because runtime scales linearly with the number
of time steps, but exponentially with the size of the state space. Choosing ✏1 = 1/1000,
✏2 = 0.05, and ✏3 = 1/100, we obtain ⌧ = 21 and F = 4 infected cells.
5.2.10. Modelling the Proportion of Expressing Cells
Our HTLV-1 data provide the abundance of clones, but not their respective proportions
of expressing and latent cells. We now estimate the proportion of infected cells ⇢i(t) that
express viral proteins at time t for each clone i, given the clone rates of proviral expression
and silencing. We will apply these proportions to our data to create initial conditions for
the expressing and latent compartment of each clone. The following derivation was made
by Vikram Sunkara. Let
⇢i(t) =
xi(t)
xi(t) + yi(t)
(5.25)
By the product rule we have
d⇢i(t)
dt
=
dxi(t)
dt
1
xi(t) + yi(t)
+ xi(t)
1
(xi(t) + yi(t))2
✓
dxi(t)
dt
+
dyi(t)
dt
◆
. (5.26)
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We examine each term of the above equation separately. Using Equation (5.1a) we have
dxi(t)
dt
1
xi(t) + yi(t)
=
⇡xi(t)
(xi(t) + yi(t))(K +
PS(t)
j=1 xj(t) + yj(t))
   xi(t)
xi(t) + yi(t)
+
"yi(t)
xi(t) + yi(t)
  sixi(t)
xi(t) + yi(t)
=
⇡⇢i(t)
K +
PS(t)
j=1 xj(t) + yj(t)
   ⇢i(t) + "i(1  ⇢i(t))  si⇢i(t). (5.27)
We derive an expression for
⇣
dxi(t)
dt +
dyi(t)
dt
⌘
by adding Equations (5.1a) and (5.1b) to
obtain ✓
dxi(t)
dt
+
dyi(t)
dt
◆
=
⇡xi(t)
K +
PS(t)
j=1 xj(t) + yj(t)
   x(t) + piy(t)
K +
PS(t)
j=1 xj(t) + yj(t)
  dyi(t). (5.28)
We rewrite xi(t)
1
(xi(t)+yi(t))2
⇣
dxi(t)
dt +
dyi(t)
dt
⌘
as,
⇢i
1
xi(t) + yi(t)
✓
dxi(t)
dt
+
dyi(t)
dt
◆
.
By substituting equation (5.28) into the equation above we get the expression
⇢i(t)
1
xi(t) + yi(t)
✓
dxi(t)
dt
+
dyi(t)
dt
◆
=
⇢i(t)2⇡
K +
PS(t)
j=1 xj(t) + yj(t)
  ⇢i(t)2+ ⇢i(t)(1  ⇢i(t))p
K +
PS(t)
j=1 xj(t) + yj(t)
 ⇢i(t)(1 ⇢i(t))d.
(5.29)
We now have an ODE for ⇢i(t). Substituting Equations (5.29) and (5.27) into (5.26) gives
d⇢i(t)
dt
= (⇢i(t)  ⇢i(t)2)
 
⇡   p
K +
PS(t)
j=1 xj(t) + yj(t)
+ (d+  )
!
  ⇢i(t)("i + si) + "i (5.30)
For a given parameter set, we can predict the evolution the expected proportion of ex-
pressing cells over time.
We use Equation (5.30) to estimate initial proportions of the expressing and latent com-
partments of a clone. Combining all clones together and defining " =
PS(t)
i=1 "i we obtain
⇢(t) =
PS(t)
i=1 ⇢i(t). Our numerical simulations show that Equation (5.30) converges to a
steady state ⇢⇤ (Figure 5.5), and we calculate
xi(0) = ⇢
⇤ ⇥ (xi(0) + yi(0)) , yi(0) = (1  ⇢⇤)⇥ (xi(0) + yi(0)) (5.31)
5.3. Parameter Inference
We first discuss how to fit the parameters of a hybrid model in an ideal case where there
are no unseen clones.
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Figure 5.5.: Proportion of expressing cells over time. ⇢(t) is modelled for four pa-
rameter sets, with four initial conditions (⇢(0) 2 {0, 0.33, 0.67, 1}) each. In all
cases, ⇢(t) reaches a steady state ⇢⇤.
Let Dt0 , Dt1 , ...DtM be data from timepoints t0, ..., tM , where each Dtj = {d1,tj , ..., dSj ,tj}.
is a collection of clone frequencies. Then, if Y (t) = ((Xi(t) + Yi(t))i2S(t))T is the state
vector of each clone’s total frequency (expressing plus latent cells), then the likelihood
L(✓k) of a set of parameters ✓k = {rI ,⇡, p,  , d, s, ("i)i2S(t),K} is
L(✓k) =
MY
j=1
P(Y (t) = Dtj ; tj | ✓k) (5.32)
Assuming independence of clone frequencies and timepoints, this becomes
L(✓k) =
MY
j=1
SjY
i=1
P
 
(Xi + Yi) = di,tj ; tj | ✓k
 
(5.33)
where Sj is the number of clones at time tj . The parameter choice kmax such that L(✓k)
is maximal will be our final parameter estimate. We will optimize using the R package
FME [98].
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5.3.1. Parameter Inference with Unseen Clones
For simplicity, assume that there are only two data points D1 and D2 from timepoints t1
and t2. There are two categories of clone data to which we will fit our hybrid model:
1. Clones observed in both D1 and D2. Let A denote the set of all clones in this
category.
2. Clones observed at one timepoint but not the other, and clones not observed at either
timepoint. Unobserved clones may be new (i.e. established by infectious spread
between time t0 and t1) or old. Let B denote the set of all clones in this category.
Note that A [ B is the set of all modelled clones. We construct the likelihood function
di↵erently for each set, so that
L(✓k) = L(A)⇥ L(B) (5.34)
The first category is calculated in exactly the same way as the ideal case above. Since
clones in this category are observed at both time points, we can order one of the data sets
so that clone i at timepoint 1 has the same integration site as clone i at timepoint 2, we
have
L(A) =
|A|Y
i=1
P
 
(Xi + Yi) = di,tj ; tj | ✓k
 
(5.35)
Constructing the likelihood L(B) of the second category is less straightforward. Because
these are unseen clones in both timepoints, we cannot order the data sets so that clones
with identical indices have identical integration sites (and are in fact the same clone).
Instead, we ask how probable it is that any of the clones in B modelled from timepoint 1
produced any of the clones in B observed in timepoint 2.
Suppose that there are h clones in B modelled from time t1 and s clones in B observed
at t2. We first assume that there are more modelled clones than observed clones that fall
into the second category (i.e. h > s). This is very likely to be true for realistic values of
infectious spread rI . This is because, strictly speaking, stochastically modelled clones do
not die, but instead have increasingly high probabilities of extinction. If (dj)sj=1 are the
frequencies of clones in B observed at t2, then define ds+1, ..., dh = 0. If h < s, then we
can create random variables Xh+1, Yh+1, ..., Xs, Ys that take frequency 0 with probability
1 and all other frequencies with probability 0 (i.e. each Xj , Yj =  x,0. We define, for
d = max{s, h},
L(B) =
X
 2P
dY
i=1
P
 
(Xi + Yi) = D (i)|✓k
 
(5.36)
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where P is the set of all permutations on {1, ..., d}. Note that if h < s, L(B) = 0, because
P((Xh+l + Yh+l) = dj) = 0 8j, 8l 2 {1, ..., (s   h)}. In practice, this rules out values
of infectious spread rI that are impossibly low. If h < s, then there are more clones at
timepoint 2 than clones have been created and killed from timepoint 1.
5.3.2. Hybrid Model Propagation
The presence of unseen clones in our data requires that the clone frequencies to which we
fit our hybrid model must be estimated, and so we use the DivE distribution generation
algorithm (Section 2.2.11). We model the dynamics of clones in the body, and not the
blood, because this allows us to model extinction. If zero cells of a particular clone are
observed (or estimated using the algorithm) in the blood, this does not necessarily imply
that the clone is extinct, as cells from the clone could be in the solid lymphoid tissue. We
model clones in the body to avoid this di culty.
The system described in Equation (5.14) has 5S(t) ordinary di↵erential equations, where
S(t) is the number of clones at time t. Since the S(t) can exceed 105, having five equations
(values of xi, yi, Vxi , Vyi and Cxi,yi) per clone is not feasible. Instead we group clones into
categories based on the order of magnitude of their abundance. We group stochastic clones
based on their starting frequency. In addition, we allow new clones to have di↵erent rates
of proviral expression to reflect the heterogeneity of the behaviour of clones with di↵erent
integration sites.
5.4. Preliminary Results
We now present preliminary results of our hybrid model. Our two outcomes of interest are
the total number of infected cells, and the expected number of clones over time (Section
5.2.5). We investigate the behaviour of the hybrid when applied to distributions as esti-
mated by the DivE distribution generation algorithm. Parameters were chosen to explore
the validity of the model.
5.4.1. System Death with Zero Proliferation
Unsurprisingly, the system dies when proliferation rates in expressing and latent compart-
ments are set equal to zero (Figure 5.6). What is more interesting is that the expected
number of cells decreases far more quickly than does the expected number of clones. This
is consistent with our knowledge of the HTLV-1 clonal population structure: large clones
constitute the bulk of proviral load; the majority of clones are of low abundance.
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Figure 5.6.: Example: expected number of cells and clones over time with zero
proliferation. [✓k = {⇡ = p = 0,   = 0.1, d = 0.01, " = 0.1, s = 0.03, K =
2.2⇥ 103, rI = 10 6}] For example patient A, both the number of clones S(t)
and the number of cells N(t) decrease to zero, but N(t) decreases far more
sharply than S(t).
5.4.2. E↵ect of Proviral Expression on Clone
The extent of proviral expression can dictate the fate of a clone. Figures 5.7 and 5.8 show
clone probability distributions where with " > s and " < s respectively. Between each
figure, ⇡, p,   are d are unchanged, with ⇡ >   and p < d. Hence the only factor in
determining the growth or death of a clone is are the ratio between " and s. Although
these are parameters that we have chosen and that are not inferred from empirical data,
it is reassuring that in principle the model can account for the reported e↵ects of proviral
expression on clonal abundance [22, 42].
5.4.3. “Equilibrium” in Hybrid Model
Figure 5.9 shows the number of clones and the number of cells given a set of parameters ✓ =
{⇡ = p = 2.8 ⇥ 1010,   = d = 0.2, K = 1000} (resulting in ⇡0(t) = p0(t) =   = d = 0.2),
and with rI = 0. Under a purely deterministic formulation of our model, these parameters
would would result in zero change to the system over time. However, as we have seen in
Section 4.4.3, the combination of equal proliferation and death rates with the absorbing
state (0, 0) results instead in the slow attrition of the clone, due to the lack of source
inflow and due to the strictly increasing extinction probability. The increased probability
of extinction feeds into both the expected number of clones S(t) and the number of infected
cells N(t). Because rI = 0, no new clones are born, and so both S(t) and N(t) decrease
over time, although N(t) decreases by only a relatively small amount.
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Figure 5.7.: Proviral expression can drive proliferation. P(X; t) is plotted for multiple
values of t (circles). Later timepoints are represented by lighter colours. The expec-
tation E[P(X; t)] is shown in dashed vertical lines. In the expressing compartment
⇡ >  , and in the latent compartment, p < d. For " > s, the expectation increases
over time.
Figure 5.8.: Silencing can e↵ect clone death. As for Figure 5.7, but with " < s. Here the
higher silencing rate than expression rate results in clone shrinking.
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Figure 5.9.: Number of cells N(t) and clones S(t) at equilibrium, no new infec-
tion. While the system is at “equilibrium” (⇡0(t) =   and p0(t) = d) the
expected number of clones falls as the stochastic clones die away due to the
strictly increasing extinction probability and because rI = 0. Thus the num-
ber of infected falls too by a relatively small amount.
5.4.4. E↵ect of Infectious Spread Parameter rI
Figure 5.10 the evolution of the system for example patient C with parameters rI = 10 6,
and where net proliferation rates ⇡0(t) and p0(t) are initially greater than death rates
  = d = 0.1 (with ⇡0(0) = p0(0) = 0.2). Consistent with intuitive expectation, the density
dependency of the system confines the existing population of cells to reach a steady state.
At very early timepoints, there is a slight but perceptible decrease in the expected number
of cells. This is due to the fact that, at time t = 0, all clones (stochastically modelled or
otherwise) have an extinction probability of zero. Therefore, the instant that the system
is propagated, the expected number of clones decreases. Because rI > 0, the number of
clones increases over time, even where the number of infected cells reaches a steady state.
This is due to the use of a single matrix exponential, the justification for which being that
the number of infected cells, and thus the aggregate proliferation rates ⇡0(t) and p(t) does
not change substantially over time. However, in the above example, for large tl, ⇡0(tl) ⇡  
and p(tl) = d, but this is not reflected in the stochastically modelled clones. While this
problem does not arise when the system is propagated from equilibrium. the above results
highlight the importance of updating the matrix exponential between time steps when the
system is not at equilibrium.
The model behaves as we would expect, and can produce qualitatively di↵erent results
depending on the parameters given. Crucially, the model is responsive to the changing
the rate of infectious spread rI , which suggests that the model will be useful in inferring
rates of infectious spread with patient data.
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Figure 5.10.: Example: E↵ect of rate of infectious spread parameter rI . For
example patient C the system “grows” (⇡0(0) = p0(0) = 0.2,   = d = 0.1 ),
but the density dependency of the model stops unchecked growth. While the
system as a whole, the infectious spread parameter rI = 10 6 results in an
increasing expected number of clones S(t) over time.
5.4.5. E↵ect of Time Step Length
In the preceding sections, the time step length h was chosen to be one day. However,
because the deterministic and stochastic components of the hybrid model are not propa-
gated exactly simultaneously (see section 5.2.4), we incur a splitting error, which varies in
proportion to h. To ensure that the error is su ciently small, we run the model for mul-
tiple sets of parameters (representing “growth”, “equilibrium” and “death”) and multiple
time step lengths. In each instance, we record a number of observables, and h is chosen
such that decreasing the time step further does not a↵ect the observables. We choose as
our observables the number of clones at a given duration of the hybrid (400 days); and
the minimum number of clones over the model run.
In Figure 5.11, each observable is plotted as a function of the inverse of h. Each plot
saturates, and the growth parameters require the least stringent (i.e. the longest) time step
before saturation. The equilibrium and death parameters require shorter and a greater
number of time steps. Since the expected number of clones is a↵ected by h, the choice of
h will a↵ect the fitted value of the rate of infectious spread rI , and the plots suggest that
a value of h = 1/30 of a day will result in a su ciently small Strang splitting error.
121
Figure 5.11.: E↵ect of Time Step Length. The e↵ect of changing the length of time
step h is examined with reference to: the expected number of clones at a
given time (400 days) and the minimum number of clones throughout the
model run. Analysis performed for three parameter sets: ✓G = {rI = 2 ⇥
10 11,⇡0(0) = p0(0) = 0.2,   = d = 0.1} (left column - ”growth”); ✓E = {rI =
2 ⇥ 10 11,⇡0(0) = p0(0) =   = d = 0.2} (middle column - ”equilibrium”);
✓D = {rI = 2 ⇥ 10 11,⇡0(0) = p0(0) = 0.2,   = d = 0.4} (right column -
”death”).
5.5. Identifiability of Rate of Infectious Spread: Proof of
Principle
The following method was produced by Vikram Sunkara, with input from myself on HTLV-
1 biology and simplifying assumptions that can be made.
We now present a proof of principle that the rate of infectious spread rI can be identified
under idealised conditions. We assume that the population is at equilibrium, that the
proportion of infected cells that express viral proteins is content, and that there are there
are no unseen clones in any data points.
Jahnke et al [188] gave analytical solutions to the chemical master equation for systems
with a highly-restrictive set of monomolecular reactions. These reactions include: i) con-
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stant source inflow and ii) mass-action death. Importantly, the analytical solutions do not
allow mass-action birth.
We cannot use this analytical solution to describe probability distribution associated with
the birth and death of infected cells within a clone, because here both birth and death are
mass-action reactions, and because there is no source inflow from 0 to 1 .
However, we can make approximations such that the two types of reactions listed above
describe the birth and death of infected clones. If the number of expressing cells x =PS(t)
j=1 xi is constant, then the rate of birth of new clones is given by   = rI ⇥ x, which is
also constant.
Clone death will not usually be a mass-action reaction. That is, there is not a constant
death rate per clone, since di↵erent clones are of di↵erent sizes and thus will take di↵ering
times to die. For this reason, we require that the system is at equilibrium. At equilibrium,
we can more safely assume all clones that die have only recently been born. This enables
us to surmise that the only clones that die start from a frequency of one. If we further
assume that per-cell rates of viral expression and death do not di↵er between clones, then
all clones have the same death rate  . We now define a stochastic process Z(t) that
approximates the number of new clones at time t. We have
Z(t) := P( )  P
✓Z t
0
 Z(s)ds
◆
(5.37)
The clone death rate   is estimated as the reciprocal of the estimated time to die, given
that clones are new and thus started from state (xi, yi) = (0, 1). We have
  =
1
E(T : (x = 0, y = 1)! (x = 0, y = 0) | ✓k = {⇡k,  k, pk, dk, "k, sk,Kk}, N⇤) (5.38)
where N⇤ = N(t⇤) is the total number of infected cells at time t⇤ when the system has
reached a steady state. The expected time to die is calculated from results given in [211].
Equation (5.37) is the master equation that has the following corresponding probability
distribution. Using results from [188], it can be shown that the probability of observing
S 2 N0 new clones at time t is given by
P(Z(t) = S |Z(0) = 0) =
 
 (t)Se  (t)
S!
!
(5.39)
where
 (t) :=
 (1  e t)
 
(5.40)
Since   = rI , we can estimate rI using this probability distribution, together with a
maximum likelihood approach so long as the following hold: i) the total number of infected
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cells is known; and ii) if the number of new clones S at time t is known. It is the latter
condition that requires us to have a complete census. Knowing the number of clones (as
estimated by DivE or any other method) is insu cient: we must know which clones are
new. We will use the following procedure to determine whether the rate of infectious
spread is identifiable.
1. Choose parameters ✓ = {⇡,  , p, d, ", s,K} and infectious spread rate rI .
2. Choose initial clone frequencies.
3. Run the stochastic simulation algorithm [153] with parameters ✓ and rI .
4. Take M “samples” from the stochastic simulation algorithm. In each sample Dj ,
record the time tj the sample was taken, the total number of infected cells Nj , and
the number of new clones Zj .
5. Using sampled data, estimate via least squares regression parameters ✓ˆ.
6. Using ✓ˆ, calculate  ˆ.
7. Estimate parameters  ˆ and thus rˆI by maximizing the likelihood function L(rˆI , ✓ˆ)
given below and assessing the accuracy of  ˆ as an estimate of  .
The likelihood of L(rˆI , ✓ˆ) is given by
L(rˆI , ✓ˆ) = L( ˆ,  ˆ) =
MY
j=1
P(Z(t) = Zj |  ˆ ,  ˆ) (5.41)
The  ˆmax that maximizes L(rˆI , ✓ˆ) = L( ˆ,  ˆ) is our final estimate of  . rˆI is then calculated
as
rˆI =
 
x
where x is estimated as x = ⇢⇤Nj . Thus the estimate of rI will only be constant if the
population is at equilibrium where Nj constant.
Figure 5.12 shows the likelihood of di↵erent rˆI values for a given set of inferred parameters
✓ˆ. The value of rˆI that maximizes the likelihood is remarkably close to the parameter on
which the Gillespie realisation were based.
While the assumptions on which this method is based are unrealistic (we will not have
access to as many data points, nor a full clone census at any data point), the preceding
analysis demonstrates that the rate of infectious spread is at least identifiable given perfect
data, and so serves as an important proof of principle. We are developing the method to
account for unseen clones.
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Figure 5.12.: Example Likelihood Function without unseen clones. L(rˆI , ✓k) is
shown for di↵erent values of rˆI using the procedure outlined in Section 5.5.
The value of rI used to create the in silico data from which L(rˆI , ✓k) is
calculated is shown in red. Value of rˆI which maximizes L(rˆI , ✓k) close to
original rI .
5.6. Discussion
In this chapter, we developed a model of the dynamics of within-host HTLV-1 persistence.
The model divides the total population of HTLV-1-infected cells first into clones, and
second into expressing and latent compartments of each clone. We first gave a purely
deterministic formulation of the model, described by a series of ordinary di↵erential equa-
tions (ODEs). Because the ODEs are both continuous and deterministic, we presented
the model under a stochastic formulation to capture the uncertainty in the fate of a given
clone. However, because of the large number of clones and the very high frequencies some
clones can take, it is not feasible to model the entire system stochastically, even when the
system is substantially simplified by modelling each clone individually.
We therefore explored how to model the system of HTLV-1 clones in a hybrid model of
deterministic and stochastic parts that influence each other and are modelled concurrently.
Any deterministic modelling here is an approximation of the “true” stochastic process, but
in our system, the error incurred in modelling a clone deterministically varies inversely
with its frequency. That is, the larger the clone, the more acceptable it is to model the
clone deterministically.
Using results from Engblom et al [207], our deterministic approximations of the stochastic
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system employ a system of ODEs that describe the first and second moments of the
probability distribution of each clone. The set of ODEs that describe the expectation of
each clone correspond to the original deterministic model.
Clones can radically change in size [11], most notably when small clones invade the popu-
lation after undergoing malignant transformation. Thus our model has to allow for clones
moving between the stochastic and deterministic compartments, and we defined conditions
for this movement that were based on the probability of extinction of a given clone.
Preliminary results of the model are encouraging. The model can replicate known features
of HTLV-1 infection, as well as more general features of stochastic processes that we
explored in Chapter 4. The most important feature of the model is that di↵erent values of
infectious spread rI produce noticeably di↵erent outcomes. This means that it is highly
likely that patient data can be used to infer the rate of infectious spread.
We also outlined an alternative model that aims to show that the rate of infectious spread
is at least identifiable in principle, given a complete census of clones and their frequencies
at every time point for which we have data. We are investigating extensions to the model
that will allow us to infer rI under less restrictive conditions, for example to allow clones
to have di↵erent expression rates or where a complete census is unavailable. It will be
more di cult to extend the model so that the assumption of equilibrium is not required,
as this would imply that the birth rate of clones is no longer constant.
5.6.1. Improvements to Hybrid Model
The ability to model the entire system of all HTLV-1 clones using a single master equation
would alleviate many of the di culties encountered in modelling within-host dynamics of
HTLV-1. It would nullify concerns regarding: when it is acceptable to model a clone
deterministically; what value of ⌧ would be an acceptable upper bound for a single clone;
how to approximate density-dependency in the stochastically modelled clones, and how the
extinction probability of a given clone should be incorporated in a hybrid model. However,
it is extremely unlikely that computational power will increase to the extent that the use
of a single stochastic system would be feasible in the near future.
A more realistic goal is to have a larger value of ⌧ . This would allow us to better estimate
the extinction probability and thus achieve more accurate estimates of rI , and would
further make the conditions for promoting a stochastically modelled clone more stringent
(Section 5.2.7). Thus a smaller error associated with hybrid modelling would be incurred.
It may also be possible to update proliferation rates between time-steps, and this would
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more accurately capture density dependency, at the cost of requiring the calculation of the
matrix exponential at each time step. Additionally, it would be interesting to investigate
whether the assumption of independence of clone frequencies (i.e. that Cov[Xi, Yj ] = 0, i 6=
j) is valid, and this could be investigated by including additional covariance terms in the
system of ODEs given in Equations (5.14).
Rather than use the per-capita death rate of infected cells   as a fixed parameter, in-
cluding   as a free parameter would help the model to better explain the wide variation
between individuals in their proviral load. It would further capture the heterogeneity of
an individuals CD8+ T cell response to the virus [43]. The reason that we have not done
so is because we are keen to reduce the parameter space by as much as possible in pursuit
of the rate of infectious spread, although this remains a priority for our future work.
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6. Concluding remarks
There is extensive, though incomplete, knowledge of the qualitative behaviour of viral
persistence. However, a quantitative understanding is still in its infancy. Indeed it can
be argued that it is only relatively recently that a realistic attempt at quantitative un-
derstanding has been possible, and this is primarily due to the increased availability and
precision of high-throughput sequencing data.
Without good data, perhaps the most that could be said for mathematical models (be-
sides their elegance) is their ability to explicitly and precisely explore the consequences
of assumptions. With better data, however, comes the ability to truly compare theory
with observation, and so refine it with empirical underpinning. Further, in the absence of
perfect or complete data, it is uncontroversial to say that mathematical modelling is and
will continue to be an integral part of biology.
In HTLV-1 infection, it has long been known that the virus persists in many distinct
clones, which are the aggregate of many years of de novo viral replication and infected
cell proliferation. The primary motivation for estimating clonal diversity or rates of viral
persistence more quantitatively is of course to inform drug development. Another reason
though, is that when the idiosyncrasies of each problem are stripped away, they are at
their core quite general.
Estimating the number of HTLV-1 clones is at least in principle the same problem as
estimating biodiversity, or any problem where the number of classes contains important
information about a population or process of interest and must be estimated. Estimating
rates of HTLV-1 infectious and mitotic spread in the presence of an immune response is
similar to estimating rates of “creation”, “copying” and “death”. Therefore, in addition
to the problems themselves, the tools and techniques required to adequately address them
are also valuable.
Our first aim was to estimate the number of HTLV-1 clones in a single host. Because
of the problem’s similarity to the “unseen species problem” in population ecology, we
first assessed the suitability of widely-used non-parametric estimators of species richness.
We found that each estimator rose systematically with sample size when applied to in
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silico subsamples, much as estimates of clonal diversity have risen over time as method
sensitivity has improved. This provided scant assurance that the diversity estimate from
a full data set, which is in essence a subsample of the infected cells in the whole body,
would not also increase if the data set was larger. That is, a larger volume of blood would
falsely imply a higher diversity.
Perhaps one reason for these methods’ widespread use in disciplines outside of their original
setting is their apparent simplicity. Each method is straightforward to use, but this belies
a complex derivation that makes it di cult to critique on theoretical grounds. Further,
given the nature of the problem (we do not know how many species there are) estimator
accuracy is di cult to measure, and so it is unsurprising that within immunology and
microbiology, adoption of these estimators has been fairly uncritical.
In response to the estimators’ poor performance with HTLV-1 data, we developed our own
diversity estimator, DivE. The essential idea of this method is to incorporate a failsafe
against the systematic bias with sample size that we observed with the previous estimators.
DivE fits simple mathematical models to rarefaction data (which plots the estimated
diversity against the number of individuals). Importantly, DivE also fits each model to
subsamples of that data in order to assess which model is most able to produce consistent
estimates while still describing the data to which is was fitted (a constant function would
be consistent, but wrong). We found that DivE did not systematically increase with
sample size. Furthermore, because DivE requires an input of population size, we were
able to assess its accuracy as well as its consistency, and here too it performed well.
DivE can be applied beyond HTLV-1 clonality. We used data provided by our collabora-
tors on T cell receptor repertoires and human microbiota to compare DivE to the ecological
estimators. While DivE performed well, the ecological estimators displayed the same bias
with sample size that we had observed earlier in the HTLV-1 data, with an interesting
exception. When observed rarefaction curves reached a plateau, ecological estimates were
largely consistent. However in this case, the saturating curve suggests that further sam-
pling would not yield significantly greater diversity. Thus our analysis suggests that the
ecological estimators are consistent only when they are redundant.
A key limitation of DivE became apparent using the TCR data: DivE cannot produce
accurate estimates for severely undersampled data. Though this is arguably no di↵erent
than the principle of “garbage in, garbage out”, we attempted to better define under-
sampling with the curvature parameter. Our analysis provided guidelines for when it is
permissible to use DivE. The requirement of a population size input can be viewed either
as a positive or a negative attribute. While we argue such an input should be an essential
component of any diversity estimator, it is often non-trivial to estimate and so it would
be convenient not to have to estimate this quantity.
129
Our second aim was to produce a mathematical model of the within-host dynamics of
HTLV-1 that describes both infectious and mitotic spread. We aimed to model the evo-
lution of clones at vastly di↵erent scale, without ignoring indispensable features of the
virus’ behaviour. Random e↵ects, a discrete state space, and extinction are all impor-
tant features when modelling small clones. Because small clones contain the majority of
information on infectious spread, we must employ stochastic modelling.
Stochastic processes are a large field and there are many ways in which to model the
uncertainty of a particular population. Some of these methods are based on the under-
lying deterministic process (the signal) but incorporate a noise term. Another method,
the Gillespie’s Stochastic Simulation Algorithm, randomly chooses the timing of changes
(“reactions”) of the system, and which change occurs.
While each of these processes might capture the inherent uncertainty we require of our
HTLV-1 clones, they have a drawback in that, for identical parameters, di↵erent results
may be achieved between successive simulations (or realisations). We therefore elected
to use the chemical master equation (CME), which describes the rate of change of the
probability distribution associated with state of a given system. This is a description of a
stochastic process that is not itself susceptible to stochasticity.
We considered birth-death process where extinction, and not merely the possibility that
a species temporarily takes a frequency of zero, is possible. In our analyses of such birth-
death process, we found that extinction fundamentally changes the nature of the proba-
bility distribution. Because numerically solving the CME is time-consuming, we explored
approximations that can be made.
When the starting frequency of a species is low, we found that manipulations of the expo-
nential distribution gave excellent representations of the evolving probability distribution,
to such a high extent that is worth investigating how this approximation holds when in-
vestigated with proper mathematical rigour, most immediately in the case of multiple
interacting species. We further found the less surprising result that the Gaussian distri-
bution approximates the probability distribution when starting frequencies are su ciently
high. It will be important to more precisely quantify the conditions under which either
approximation is appropriate.
We applied the techniques described above to build a deterministic and stochastic hybrid
model. While it is simple to assert that large clones can be modelled deterministically and
small clones stochastically, it is di cult in practice to specify how large is large enough.
Further, defining how parts of the system (in our case species) can move between the
deterministic and stochastic compartments is non-trivial. Ultimately, the solution to both
problems is subjective, and we chose to address each problem in terms of the extinction
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probability, because our previous analysis had shown this to be the fundamental factor
preventing a normal approximation to the evolving probability distribution. Thus “large”
clones are those that have a negligible probability of extinction within a given time step,
and stochastic clones are moved to the deterministic compartment when there is no change
to the extinction probability.
An appealing quality of our hybrid model is that it is not susceptible to distortion by
sampling variation, and thus the relationship between assumption and consequence is
preserved. Preliminary results suggest that the model captures fundamental dynamics of
HTLV-1 infection. If proliferation values are zero, then unsurprisingly the system dies
away. Interestingly though, the expected number of clones decreases far more slowly than
the expected number of cells, consistent with experimental observation whereby most
clones contain few cells, and a few clones contain most cells.
The hybrid model also displays markedly di↵erent patterns in the expected number of
clones over time for di↵erent values of the rate of infectious spread, strongly implying that
it will be possible to infer this rate from empirical patient data. If so, this would represent
a substantial advance in our knowledge of HTLV-1 persistence.
We are investigating how our hybrid model could be applied to investigate early HTLV-1
infection, and the amendments that this would require. For example, the assumption of
equilibrium would no longer be appropriate, and this would mean that rates of proliferation
would no longer be constant, as we have assumed for stochastic clones.
Outside of HTLV-1, there are several potential applications of our work, in particular
modelling the human T cell receptor (TCR) repertoire. The mechanisms by which the
immune system is reconstituted after immune suppression or transplantation are poorly
understood. Drawing parallels between this system and HTLV-1 infectious and mitotic
spread, we would like to investigate the extent to which re-constitution occurs through
the generation of new TCR clonotypes, or through the increased expansion of existing
clonotypes.
In population genetics, our model could be employed to estimate the rates of mutation
and copying of genes throughout generations, and could be used to model invasion and
eventual fixation of a particular gene. A very interesting application would be to measure
the extent of PCR error [212]. One can argue that PCR is essentially a birth-death
process with the presence of errors, each of which create a new “species” of amplicon or
PCR product. Quantifying the error-rate would perhaps facilitate correction of it. Finally,
HIV-1 also exhibits proviral integration, and so one would expect that the system of HIV
clones would behave in a similar manner to HTLV-1 clones, raising implications for HIV-1
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latency. We would expect then that the ratio of infectious to mitotic spread in HTLV-1
would be reversed in HIV-1.
It is important to stress that even if the analogy of copying, creating and death can only
be extended so far, and if the biological processes and models of these process are very
di↵erent, then it is still possible that the machinery of our hybrid, whereby deterministic
compartments interact with stochastic compartments, will be of use. For example, the
movement of species between deterministic and stochastic compartments is defined in
terms of the probability distribution and its interaction with the upper limits of the state
space, not the model itself. This means that our analysis of interacting compartments is
potentially as applicable as the actual model.
This work was only possible thanks to frequent collaboration between ourselves and many
experimentalists, who generously shared their data and their time. I hope that the trans-
action has not been zero-sum. According to Blaise Pascal, “As we speak of poetical beauty,
so ought we to speak of mathematical beauty and medical beauty” [213]. I cannot argue
with the great man, although it is probably wise not to invite judgement on whether the
preceding pages warrant such description.
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A. Appendix A: DivE supporting
information
Table A.1.: Subsamples used in analysis of relationship between sample size and estimated
diversity, and in comparison of DivE with AICc
Data Source Patient Population Subsample Sizes Subsample Percentages
HTLV-1 H1 NA 500, 1000, 2000, 3000, 4596 10.9, 21.8, 43.5, 65.3, 100
HTLV-1 H2 NA 500, 1000, 2000, 3000, 4210 11.9, 23.8, 47.5, 71.3, 100
HTLV-1 H3 NA 500, 1000, 2000, 4000, 4967 10.1, 20.1, 40.3, 80.5, 100
HTLV-1 H4 NA 500, 1000, 2000, 3000, 3992 12.5, 25.1, 50.1, 75.2, 100
HTLV-1 H5 NA 500, 1000, 1623 30.8, 61.6, 100
HTLV-1 H6 NA 500, 1000, 2000, 2002 25, 50, 99.9, 100
HTLV-1 H7 NA 500, 1000, 2000, 3000, 3406 14.7, 29.4, 58.7, 88.1, 100
HTLV-1 H8 NA 500, 1000, 1693 29.5, 59.1, 100
HTLV-1 H9 NA 500, 1000, 1127 44.4, 88.7, 100
HTLV-1 H10 NA 500, 1000, 5000, 9000, 12962 3.86, 7.71, 38.6, 69.4, 100
HTLV-1 H11 NA 500, 1000, 2000, 4000, 5388 9.28, 18.6, 37.1, 74.2, 100
HTLV-1 H12 NA 500, 1000, 2000, 4000, 5007 9.99, 20, 39.9, 79.9, 100
HTLV-1 H13 NA 500, 1000, 2000, 3000, 3716 13.5, 26.9, 53.8, 80.7, 100
HTLV-1 H14 NA 500, 1000, 2000, 3000, 3907 12.8, 25.6, 51.2, 76.8, 100
TCRs T1 CD4 Total 166667, 333333, 5e+05, 666667, 833333, 1e+06 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD4 Total 333333, 666667, 1e+06, 1333333, 1666667, 2e+06 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD8 Total 116667, 233333, 350000, 466667, 583333, 7e+05 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD8 Total 166667, 333333, 5e+05, 666667, 833333, 1e+06 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD4 Na¨ıve 83333, 166667, 250000, 333333, 416667, 5e+05 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD4 CM 83333, 166667, 250000, 333333, 416667, 5e+05 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD4 EM 21667, 43333, 65000, 86667, 108333, 130000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD8 Na¨ıve 8167, 16333, 24500, 32667, 40833, 49000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD8 CM 12667, 25333, 38000, 50667, 63333, 76000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T1 CD8 EM 2833, 5667, 8500, 11333, 14167, 17000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD4 Na¨ıve 107833, 215667, 323500, 431333, 539167, 647000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD4 EM 35000, 70000, 105000, 140000, 175000, 210000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD4 CM 85500, 171000, 256500, 342000, 427500, 513000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD8 Na¨ıve 42667, 85333, 128000, 170667, 213333, 256000 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD8 EM 6783, 13567, 20350, 27133, 33917, 40700 16.7, 33.3, 50, 66.7, 83.3, 100
TCRs T2 CD8 CM 5667, 11333, 17000, 22667, 28333, 34000 16.7, 33.3, 50, 66.7, 83.3, 100
Microbes M1 bP1 427, 640, 853, 1067, 1280 33.4, 50, 66.6, 83.4, 100
Microbes M2 bP10 689, 1034, 1378, 1722, 2067 33.3, 50, 66.7, 83.3, 100
Microbes M3 bP2 685, 1028, 1371, 1713, 2056 33.3, 50, 66.7, 83.3, 100
Microbes M4 bP3 720, 1080, 1439, 1799, 2159 33.3, 50, 66.7, 83.3, 100
Microbes M5 bP4 679, 1018, 1358, 1698, 2037 33.3, 50, 66.7, 83.4, 100
Microbes M6 bP5 687, 1031, 1375, 1718, 2062 33.3, 50, 66.7, 83.3, 100
Microbes M7 bP6 820, 1230, 1639, 2049, 2459 33.3, 50, 66.7, 83.3, 100
Microbes M8 bP7 774, 1161, 1548, 1935, 2322 33.3, 50, 66.7, 83.3, 100
Microbes M9 bP8 786, 1178, 1571, 1964, 2357 33.3, 50, 66.7, 83.3, 100
Microbes M10 bP9 789, 1184, 1579, 1973, 2368 33.3, 50, 66.7, 83.3, 100
Microbes M1 uP1 381, 571, 761, 952, 1142 33.4, 50, 66.6, 83.4, 100
Microbes M2 uP10 522, 782, 1043, 1304, 1565 33.4, 50, 66.6, 83.3, 100
Microbes M3 uP2 567, 850, 1133, 1417, 1700 33.4, 50, 66.6, 83.4, 100
Microbes M4 uP3 503, 755, 1007, 1258, 1510 33.3, 50, 66.7, 83.3, 100
Microbes M5 uP4 568, 852, 1135, 1419, 1703 33.4, 50, 66.6, 83.3, 100
Microbes M6 uP5 640, 960, 1281, 1601, 1921 33.3, 50, 66.7, 83.3, 100
Microbes M7 uP6 698, 1046, 1395, 1744, 2093 33.3, 50, 66.7, 83.3, 100
Microbes M8 uP7 589, 884, 1179, 1473, 1768 33.3, 50, 66.7, 83.3, 100
Microbes M9 uP8 531, 797, 1063, 1328, 1594 33.3, 50, 66.7, 83.3, 100
Microbes M10 uP9 605, 907, 1209, 1512, 1814 33.4, 50, 66.6, 83.4, 100
Table A.2.: DivE species richness estimates for HTLV-1 data
Patient Timepoint DivE DivE lower bound DivE upper bound
1 1 2.50E+04 3.20E+03 1.70E+06
1 1 2.70E+04 3.50E+03 2.00E+06
153
1 1 2.40E+04 3.10E+03 1.60E+06
1 2 2.50E+04 3.40E+03 1.30E+06
1 2 2.60E+04 3.70E+03 1.20E+06
1 2 1.80E+04 3.00E+03 6.30E+05
1 3 2.40E+04 3.50E+03 1.10E+06
1 4 1.80E+04 3.20E+03 5.00E+05
1 4 2.50E+04 3.00E+03 2.00E+06
1 4 2.00E+04 3.00E+03 7.50E+05
2 1 1.00E+04 2.00E+03 1.90E+05
2 1 8.80E+03 1.80E+03 1.50E+05
2 1 1.10E+04 1.80E+03 3.00E+05
2 2 1.10E+04 1.80E+03 3.40E+05
2 2 9.50E+03 2.00E+03 1.50E+05
2 2 1.20E+04 2.00E+03 3.30E+05
2 3 6.40E+03 1.60E+03 1.20E+05
2 3 9.00E+03 1.60E+03 2.50E+05
2 3 9.00E+03 1.60E+03 2.30E+05
3 1 2.60E+04 3.40E+03 1.30E+06
3 1 3.30E+04 3.60E+03 2.00E+06
3 1 3.20E+04 3.80E+03 1.50E+06
3 2 3.10E+04 3.90E+03 1.50E+06
3 2 2.80E+04 3.80E+03 1.10E+06
3 2 2.50E+04 3.30E+03 1.50E+06
3 3 1.90E+04 2.70E+03 9.70E+05
3 3 2.40E+04 3.00E+03 1.20E+06
3 3 2.10E+04 2.80E+03 9.80E+05
4 1 2.00E+04 3.60E+03 3.90E+05
4 1 1.90E+04 3.50E+03 3.70E+05
4 1 1.70E+04 3.50E+03 2.50E+05
4 2 2.00E+04 3.80E+03 3.70E+05
4 2 1.90E+04 4.30E+03 2.30E+05
4 2 2.40E+04 4.10E+03 5.50E+05
4 3 2.10E+04 3.90E+03 4.40E+05
4 3 1.70E+04 3.60E+03 2.20E+05
4 3 2.30E+04 4.00E+03 5.60E+05
5 1 8.90E+03 1.60E+03 2.10E+05
5 1 1.10E+04 1.90E+03 2.70E+05
5 1 9.80E+03 1.80E+03 2.20E+05
5 2 7.30E+03 1.60E+03 1.10E+05
5 2 8.20E+03 1.70E+03 1.40E+05
5 2 7.40E+03 1.60E+03 1.70E+05
5 3 8.70E+03 1.60E+03 2.60E+05
5 3 8.10E+03 1.50E+03 2.00E+05
5 3 7.20E+03 1.50E+03 1.70E+05
6 1 1.10E+04 2.10E+03 2.20E+05
6 1 8.80E+03 1.80E+03 1.40E+05
6 1 1.10E+04 2.10E+03 1.90E+05
6 2 7.40E+03 1.80E+03 6.70E+04
6 2 1.10E+04 2.00E+03 1.80E+05
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6 2 8.60E+03 1.70E+03 1.10E+05
6 3 5.70E+03 1.50E+03 4.70E+04
6 3 9.00E+03 1.70E+03 1.90E+05
6 3 5.50E+03 1.50E+03 3.80E+04
7 1 7.70E+04 9.70E+03 4.70E+06
7 1 7.70E+04 9.20E+03 5.10E+06
7 1 8.10E+04 1.00E+04 5.10E+06
7 2 7.10E+04 9.90E+03 3.20E+06
7 2 6.70E+04 9.90E+03 1.90E+06
7 2 7.40E+04 9.00E+03 4.50E+06
7 3 6.80E+04 1.00E+04 2.30E+06
7 3 6.50E+04 1.00E+04 2.30E+06
7 3 7.80E+04 9.70E+03 4.70E+06
8 1 3.50E+04 5.00E+03 1.40E+06
8 1 3.00E+04 5.20E+03 7.40E+05
8 1 3.00E+04 5.80E+03 5.20E+05
8 2 2.70E+04 5.20E+03 5.30E+05
8 2 2.30E+04 5.50E+03 2.40E+05
8 2 2.30E+04 5.80E+03 2.10E+05
8 3 2.80E+04 4.70E+03 7.20E+05
8 3 3.10E+04 4.50E+03 1.30E+06
8 3 2.60E+04 4.60E+03 6.80E+05
9 1 5.70E+04 4.80E+03 1.30E+07
9 1 5.90E+04 6.30E+03 5.30E+06
9 1 5.50E+04 6.20E+03 4.70E+06
9 2 6.80E+04 6.10E+03 9.90E+06
9 2 4.90E+04 7.30E+03 1.90E+06
9 2 6.70E+04 6.40E+03 7.70E+06
9 3 6.60E+04 4.50E+03 2.70E+07
9 3 5.30E+04 4.30E+03 1.00E+07
9 3 5.50E+04 4.60E+03 1.00E+07
10 1 3.30E+04 4.50E+03 1.80E+06
10 1 3.90E+04 4.80E+03 2.50E+06
10 1 3.80E+04 4.70E+03 2.50E+06
10 2 3.00E+04 5.00E+03 8.80E+05
10 2 3.20E+04 5.30E+03 8.20E+05
10 2 3.30E+04 4.90E+03 1.20E+06
10 3 3.00E+04 4.00E+03 1.60E+06
10 3 3.20E+04 4.80E+03 1.20E+06
10 3 2.80E+04 4.20E+03 9.90E+05
11 1 2.20E+04 3.70E+03 6.90E+05
11 1 3.10E+04 4.30E+03 1.40E+06
11 1 3.60E+04 5.10E+03 1.60E+06
11 2 2.70E+04 4.70E+03 7.20E+05
11 2 2.60E+04 5.30E+03 4.00E+05
11 2 3.40E+04 4.80E+03 1.50E+06
11 3 2.80E+04 4.90E+03 6.00E+05
11 3 3.20E+04 5.10E+03 9.80E+05
11 3 2.80E+04 5.10E+03 5.60E+05
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12 1 1.00E+05 9.80E+03 8.30E+06
13 1 2.00E+04 2.90E+03 6.80E+05
13 2 1.60E+04 3.50E+03 1.90E+05
14 1 3.70E+04 3.70E+03 4.60E+06
14 2 2.60E+04 4.30E+03 8.10E+05
A.1. List of DivE Candidate Models
1. Logistic
y =
a1
a2 + x a3
2. Negative exponential
y =
a1
a2
 
1  e a2x 
3. Logarithmic
y = a1 log(a2x+ 1)
4. Quadratic Logarithmic
y = a1 log(a3x+ 1) + a2 log(a3x+ 1)
2
5. Quartic Logarithmic
y = a1 log(a5x+ 1) + a2 log(a5x+ 1)
2 + a3 log(a5x+ 1)
3 + a4 log(a5x+ 1)
4
6. Quintic Logarithmic
y = a1 log(a6x+1)+a2 log(a6x+1)
2+a3 log(a6x+1)
3+a4 log(a6x+1)
4+a5 log(a6x+1)
5
7. NIST Kirby
y =
a1 + a2x+ a3x2
x2 + a2x
8. NIST MGH09
y =
a1(x2 + a2x)
x2 + a3x+ a4
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9. Hyperbolic G
y =
a1x
a2 + x
+
a3x
a4 + x
10. Cubic Logarithmic
y = a1 log(a4x+ 1) + a2 log(a4x+ 1)
2 + a3 log(a4x+ 1)
3
11. Gunary
y =
x
a1 + a2 + a3x0.5
12. Cellular Conductance
y =
a1
1 + e
x a2
a3
+
a4
1 + e
x 45
a5
13. NIST Thurber
y =
a1 + a2x+ a3x2 + a4x3
1 + a5x+ a6x2 + a7x3
14. Lorentzian Modified Peak F
y =
a1
a2 +
⇣
x a3
a4
⌘a5
15. Pseudo Voight peak modified
y = a1
"
a4
 
1
1 + x a2a3
!a5
+ (1  a4)e 0.5
⇣
x a2
a3
⌘a6#
16. Five-parameter logistic with o↵set
y = a1 +
a2   a1⇣
1 +
⇣
x
a3
⌘a4⌘a5
17. Triple exponential
y = a1e
a2x + a3e
a4x + a5e
a6x + a7
18. NIST Bennett 5
y = a1 (a2 + x)
 1
a3 + a4
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19. BioScience B
y = a1
 
1 
✓
1 +
✓
x
a2
◆a3◆ a4!
+ a5
20. High-low a nity double
y =
a1a2x
1 + a2x
+
a3a4x
1 + a4x
21. Logistic B with o↵set
y =
a1
1 +
⇣
x
a2
⌘a3 + a4
22. Hyperbolic logistic
y =
a1xa2
a3 + xa2
23. Hill
y =
a1xa2
aa23 + x
a2
24. Log-normal peak with o↵set
y = a1 exp
 
 0.5
✓
log(x+ 1)  a2
a3
◆2!
+ a4
25. Inverse Bleasdale
y =
x⇣
(a1 + a2x)
 1
a3
⌘
26. Double exponential
y = a1e
a2x + a3e
a4x + a5
27. Polytrope transform with o↵set
y =
a1
(a3x+ a4)a2
+ a5
28. Generalized product accumulation
y =
a1(a2   x)
(a3 + (a2   x)) + a4(a2   x) + a5
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29. Generalized substrate depletion
y =
a1x
a2 + x
  a3x  a4
30. Weibull peak
y = a1 exp
0B@ 0.5
0@ log
⇣
x
a2
⌘
a3
1A2
1CA
31. Gaussian peak modified with o↵set
y = a1 exp
✓
 0.5
✓
x  a2
a3
◆a4◆
+ a5
32. Morgan-Mercer-Flodin (MMF) with o↵set
y =
a1a2 + a3xa4
a2 + xa4
+ a5
33. Log-normal peak modified with o↵set
y = a1 exp
✓
 0.5
✓
(log(x+ 1)  a2)
a3
◆a4◆
+ a5
34. Weibull
y = a1   a2 exp( a3xa4)
35. Weibull peak modified with o↵set
y = a1   a2 exp
0@ 0.5
0@ log
⇣
x
a2
⌘
a3
1Aa41A+ a5
36. General polyfunctional 2 logs
y = a1x
a2 + a3x
a4 + a5 log(x+ 1)
a6 + a7 log(x+ 1)x
a8
37. General polyfunctional
y = a1x
a2 + a3x
a4 + a5x
a6 + a7x
a8
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38. General polyfunctional log
y = a1x
a2 + a3x
a4 + a5x
a6 + a7 log(x+ 1)x
a8
39. Bradley transform
y = a1 log ( a2 log(a3x+ a4))
40. Lorentzian modified peak C
y =
a1
a2 + (x  a3)a4
41. Janoschek growth modified
y = a1(a1   a4) (1  exp( a2xa3))
42. General polyfunctional atan
y = a1x
a2 + a3x
a4 + a5x
a6 + a7atan(x)
a8
43. Simple equation 16
y = a1x
(a2+a3 log(x))
44. Simple equation 30
y = a1x
a2xa3
45. Simple equation 26 with o↵set
y =
a1
(1 + a2xa3)2
+ a4
46. Simple equation 40 with o↵set
y = a1 log(x+ a2)
a3 + a4
47. Harris
y =
1
(a1 + a2xa3)
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48. General polyModelal tanh
y = a1x
a2 + a3x
a4 + a5x
a6 + a7tanh(x)
a8
49. General polyfunctional negative exponential
y = a1x
a2 + a3x
a4 + a5x
a6 + a7e
 a8x
50. General polyfunctional sin
y = a1x
a2 + a3x
a4 + a5x
a6 + a7sin(x)
a8
51. General polyfunctional log negative exponential
y = a1x
a2 + a3x
a4 + a5e
 a6x + a7 log(x+ 1)xa8
52. General polyfunctional log tanh
y = a1x
a2 + a3x
a4 + a5tanh(x)
a6 + a7 log(x+ 1)x
a8
53. General polyfunctional log atan
y = a1x
a2 + a3x
a4 + a5atan(x)
a6 + a7 log(x+ 1)x
a8
54. Arrhenius law stretched
y = a1 exp
⇣
 a2
x
⌘a3
55. Quadratic logarithmic variable shape
y = a1 log(a3x+ 1) + a2 log(a4x+ 1)
2
56. Cubic logarithmic variable shape
y = a1 log(a4x+ 1) + a2 log(a5x+ 1)
2 + a3 log(a6x+ 1)
3
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57. Quartic logarithmic variable shape
y = a1 log(a5x+ 1) + a2 log(a6x+ 1)
2 + a3 log(a7x+ 1)
3 + a4 log(a8x+ 1)
4
58. Quintic logarithmic variable shape
y = a1 log(a6x+1)+a2 log(a7x+1)
2+a3 log(a8x+1)
3+a4 log(a9x+1)
4+a5 log(a10x+1)
5
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B. Appendix B: Derivation of
Expectation, Variance, and
Covariance Clone ODEs
Under a stochastic paradigm, the ODEs in equation (5.1) approximately correspond to
the expected frequencies of the expressing and latent compartments of a given clone i.
Because the propensities of our model (equation (5.5)) have degrees of at most 1, we can
derive another set of ODEs to model the variance and covariance [207] of a given species
i. With our notation, the moments are given by
dmi
dt
=
RX
r=1
⌫ir
0@↵r(X(t)) +X
k,l
@2↵r(m)
@xk@xl
Ckl
2!
1A (B.1a)
dCij
dt
=
RX
r=1
 
⌫ir
X
k
@↵r(X(t))
@xk
Ckj
1!
+ ⌫jr
X
l
@↵r(X(t))
@xl
Cil
1!
!
+
RX
r=1
⌫[i,j]r
0@↵r(X(t)) +X
k,l
@2↵r(X(t))
@xk@xl
Ckl
2!
1A
(B.1b)
where mi is the expected value of species i, Cij is the covariance between species i and
species j, ⌫ir is the i
th component of ⌫r, the stoichiometric vector of reaction r, and
⌫ [i,j]r = ⌫ir⌫
j
r . Note that the subscripts i and j in the above equations refer to the ith
and jth entry of the state vector X(t). Because we divide clones into two compartments
(expressing and latent), X(t) has 2S(t) entries. Re-indexing so that the subscript i refers
to the ith clone (i 2 {1, ..., S(t)}), we introduce the following shorthand. Let
xi :=E[Xi] (B.2a)
yi :=E[Yi] (B.2b)
Vxi :=Var[Xi] (B.2c)
Vyi :=Var[Yi] (B.2d)
Cxi,yi :=Cov[Xi, Yi] (B.2e)
To relate this to Equation (B.1), we have Vxi = V2i 1 = C(2i 1),(2i 1) = Cov[Xi, Xi] =
Var[Xi], Vyi = V2i = C(2i),(2i) = Cov[Yi, Yi] = Var[Yi], and Cxi,yi = C(2i 1),(2i) =
Cov[Xi, Yi].
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We approximate by assuming that the frequency of a given clone is independent of any
other clone, i.e. that for i 6= j, Cov[Xi, Xj ] = Cov[Yi, Yj ] = Cov[Xi, Yj ] = 0. This assump-
tion is valid at the level of the individual clone, in that Cov[Xi, Yj ] ⇡ 0 for i 6= j. HoweverPS(t)
k=1Cik may not be negligible. Nevertheless, to substantially reduce the dimension of the
system of ODEs, we must assume that clone frequencies are approximately independent
of each other. With these assumptions, it can be shown that we have the following system
of ordinary di↵erential equations to describe the expectations, variances of covariance of
the expressing and latent compartments xi and yi of clone i. See Appendix B for further
details.
We now list all partial derivatives of our system. We have the following first order partial
derivatives
@↵7(i 1)+1(m)
@xi
=
⇡(K +N(t))  ⇡xi
(K +N(t))2
,
@↵7(i 1)+2(m)
@xi
=  ,
@↵7(i 1)+3(m)
@xi
= si,
and
@↵7(i 1)+4(m)
@yi
=
p(K +N(t))  pyi
(K +N(t))2
,
@↵7(i 1)+5(m)
@yi
= d,
@↵7(i 1)+6(m)
@yi
= "i
For second order partial derivatives, we have
@2↵7(i 1)+a(m)
@xk@yl
= 0 8i, k, l, for a 2 {2, 3, 5, 6}
i.e. for all non-proliferation propensities. We can ignore the second order partial derivatives
of the proliferation propensity functions ↵7(i 1)+1(m) and ↵7(i 1)+4(m), as
@2↵7(i 1)+b(m)
@xk@yl
= O( 3) ⇡ 0 8i, k, l, for b 2 {1, 4}
and
@2↵7(i 1)+1(m)
@x2i
⇡ @
2↵7(i 1)+4(m)
@y2i
= O( 3) ⇡ 0
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Thus we have
dxi
dt
=
⇡xi
K +N(t)
   xi + "iyi   sixi (B.3a)
dyi
dt
=
pyi
K +N(t)
  dyi   "iyi + sixi (B.3b)
dVxi
dt
=
✓
⇡(K +N(t))  ⇡xi
(K +N(t))2
      si
◆
2Vxi + 2"iCxi,yi
+
✓
⇡
(K +N(t))2
+   + si
◆
xi + "iyi
(B.3c)
dVyi
dt
=
✓
p(K +N(t))  pyi
(K +N(t))2
  d  "i
◆
2Vyi + 2siCxi,yi
+
✓
p
(K +N(t))2
+ d+ "i
◆
yi + sixi
(B.3d)
dCxi,yi
dt
=
✓
(⇡ + p)(K +N(t))  ⇡xi   pyi
(K +N(t))2
      si   d  "i
◆
Cxi,yi
+ siVxi + "iVyi   sixi   "iyi
(B.3e)
We also require the variance of xi + yi, and so we compute Vxi+yi = Vxi + Vyi + 2Cxi,yi .
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